<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">gastro-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гастроэнтерологии, гепатологии, колопроктологии</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Gastroenterology, Hepatology, Coloproctology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1382-4376</issn><issn pub-type="epub">2658-6673</issn><publisher><publisher-name>«Gastro» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22416/1382-4376-2026-36-1-70-146</article-id><article-id custom-type="elpub" pub-id-type="custom">gastro-j-2058</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES</subject></subj-group></article-categories><title-group><article-title>Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российского научного медицинского общества терапевтов, Российского общества профилактики неинфекционных заболеваний, Российского научного медицинского общества терапевтов, Российского общества клинической онкологии, Научного сообщества по изучению микробиома человека по лекарственным поражениям печени</article-title><trans-title-group xml:lang="en"><trans-title>Clinical Guidelines of the Russian Society for the Study of the Liver, Russian  Gastroenterological Association, Russian Society for the Prevention  of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Drug-Induced Liver Injury</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6815-6015</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивашкин</surname><given-names>В. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashkin</surname><given-names>V. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ивашкин Владимир Трофимович — доктор медицинских наук, профессор, академик РАН, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского</p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1</p></bio><bio xml:lang="en"><p>Vladimir T. Ivashkin — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">ivashkin_v_t@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>О. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна — доктор медицинских наук, академик РАН, профессор, директор </p><p>101000, г. Москва, Петроверигский пер., 10, стр. 3</p></bio><bio xml:lang="en"><p>Оksana M. Drapkina — Dr. Sci. (Med.), Academician of the Russian Academy of Sciences, Director</p><p>101000, Moscow, Petroverginskiy lane, 10, build. 3</p></bio><email xlink:type="simple">drapkina@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8821-6142</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Райхельсон</surname><given-names>К. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Raikhelson</surname><given-names>K. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Райхельсон Карина Леонидовна — доктор медицинских наук, профессор Научно-клинического и образовательного центра гастроэнтерологии и гепатологии медицинского института; профессор кафедры общей врачебной практики (семейной медицины)</p><p>199034, г. Санкт-Петербург, Университетская наб., 7/9</p></bio><bio xml:lang="en"><p>Karina L. Raikhelson — Dr. Sci. (Med.), Professor of the Scientific, Clinical and Educational Centre of Gastroenterology and Hepatology, Institute of High Technologies; Professor of the Department of General Medical Practice (Family Medicine)</p><p>199034, Saint Petersburg, Universitetskaya embankment, 7/9</p></bio><email xlink:type="simple">kraikhelson@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4294-5531</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Оковитый</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Okovityi</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оковитый Сергей Владимирович — доктор медицинских наук, профессор, профессор Научно-клинического и образовательного центра гастроэнтерологии и гепатологии медицинского института; заведующий кафедрой фармакологии и клинической фармакологии</p><p>197022, г. Санкт-Петербург, ул. Профессора Попова, 14а</p></bio><bio xml:lang="en"><p>Sergey V. Okovityi — Dr. Sci. (Med.), Professor, Professor of the Scientific, Clinical and Educational Centre of Gastroenterology and Hepatology, Institute of High Technologies; Head of the Department of Pharmacology and Clinical Pharmacology</p><p>197022, Saint Petersburg, Professora Popova str., 14А</p></bio><email xlink:type="simple">sergey.okovity@pharminnotech.com</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8913-140X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маевская</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maevskaya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маевская Марина Викторовна — доктор медицинских наук, профессор</p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1</p></bio><bio xml:lang="en"><p>Marina V. Maevskaya — Dr. Sci. (Med.), Professor</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">maevskaya_m_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3851-626X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гречишникова</surname><given-names>В. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Grechishnikova</surname><given-names>V. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гречишникова Василиса Романовна* — аспирант, ассистент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского</p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1</p></bio><bio xml:lang="en"><p>Vasilisa R. Grechishnikova* — Postgraduate, Teaching Assistant of the Department of Internal Disease Propaedeutics, Gastroenterology and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">korneeva_v_r@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5939-1032</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жаркова</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zharkova</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жаркова Мария Сергеевна — кандидат медицинских наук, заведующая отделением гепатологии Клиники пропедевтики внутренних болезней, гастроэнтерологии, гепатологии им. В.Х. Василенко</p><p>119048, г. Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>Maria S. Zharkova — Cand. Sci. (Med.), Head of the Hepatology Department, V.Kh. Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">zharkova_m_s@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4860-0112</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хлынова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlynova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хлынова Ольга Витальевна — доктор медицинских наук, член-корреспондент РАН, профессор, заведующая кафедрой госпитальной терапии и кардиологии</p><p>614000, г. Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>Olga V. Khlynova — Dr. Sci. (Med.), Corresponding Member of Russian Academy of Sciences, Professor, Head of the Department of Hospital Therapy and Cardiology</p><p>614000, Perm, Petropavlovskaya str., 26</p></bio><email xlink:type="simple">olgakhlynova@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1367-2079</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гладков</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gladkov</surname><given-names>O. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гладков Олег Александрович — доктор медицинских наук, профессор, директор </p><p>454048, г. Челябинск, ул. Блюхера, 9В</p></bio><bio xml:lang="en"><p>Oleg A. Gladkov — Dr. Sci. (Med.), Professor, Director; Chief Specialist in Chemotherapy in the Cheyabinsk Region</p><p>454048, Chelyabinsk, Blukhera str., 9V</p></bio><email xlink:type="simple">gladkovoa@gmail.com</email><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3126-141X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Деева</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Deeva</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Деева Татьяна Андреевна — кандидат медицинских наук, доцент кафедры биологической химии Института цифрового биодизайна и моделирования живых систем</p><p>119048, г. Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>Tatiana A. Deeva —Cand. Sci. (Med.), Associate Professor in the Department of Biological Chemistry, Institute of Digital Biodesign and Modeling of Living Systems</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">deeva_t_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1724-9980</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеенко</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseenko</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексеенко Сергей Алексеевич — доктор медицинских наук, профессор, заведующий кафедрой госпитальной терапии</p><p>680000, г. Хабаровск, ул. Муравьева-Амурского, 35</p></bio><bio xml:lang="en"><p>Sergei A. Alekseenko — Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy</p><p>680000, Khabarovsk, Muravyova-Amurskogo str., 35</p></bio><email xlink:type="simple">sa.alexeenko@gmail.com</email><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7603-8481</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахмедов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhmedov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ахмедов Вадим Адильевич — доктор медицинских наук, профессор, заведующий кафедрой медицинской реабилитации дополнительного профессионального образования</p><p>644043, г. Омск, ул. Ленина, 12</p></bio><bio xml:lang="en"><p>Vadim A. Akhmedov — Dr. Sci. (Med.), Professor, Head of the Department of Medical Rehabilitation of Continuing Professional Education</p><p>644043, Omsk, Lenina str., 12</p></bio><email xlink:type="simple">v_akhmedov@mail.ru</email><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6151-2021</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бакулин</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakulin</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бакулин Игорь Геннадьевич — доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса</p><p>191015, г. Санкт-Петербург, ул. Кирочная, 41</p></bio><bio xml:lang="en"><p>Igor G. Bakulin — Dr. Sci. (Med.), Professor, Head of the De- partment of Propaedeutics of Internal Medicine, Gastroenterology and Dietetics named after S.M. Ryss</p><p>191015, Saint Petersburg, Kirochnaya str., 41</p></bio><email xlink:type="simple">igbakulin@yandex.ru</email><xref ref-type="aff" rid="aff-9"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4075-4096</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бакулина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakulina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бакулина Наталья Валерьевна — доктор медицинских наук, профессор, проректор по науке и инновационной деятельности, заведующая кафедрой внутренних болезней, клинической фармакологии и нефрологии</p><p>191015, г. Санкт-Петербург, ул. Кирочная, 41</p></bio><bio xml:lang="en"><p>Natalia V. Bakulina — Dr. Sci. (Med.), Head of the Department of Internal Medicine, Nephrology, General and Clinical Pharmacology with a course in Pharmacy</p><p>191015, Saint Petersburg, Kirochnaya str., 41</p></bio><email xlink:type="simple">natalya.bakulina@szgmu.ru</email><xref ref-type="aff" rid="aff-10"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9134-931X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барановский</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Baranovsky</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Барановский Андрей Юрьевич — доктор медицинских наук, руководитель Научно-клинического и образовательного центра гастроэнтерологии и гепатологии медицинского института</p><p>199034, г. Санкт-Петербург, Университетская наб., 7/9</p></bio><bio xml:lang="en"><p>Andrey Yu. Baranovsky — Dr. Sci. (Med.), Head of the Scientific, Clinical and Educational Centre of Gastroenterology and Hepatology, Institute of High Technologies</p><p>199034, Saint Petersburg, Universitetskaya embankment, 7/9</p></bio><email xlink:type="simple">baranovsky46@mail.ru</email><xref ref-type="aff" rid="aff-11"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3105-4645</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вологжанина</surname><given-names>Л. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Vologzhanina</surname><given-names>L. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вологжанина Людмила Георгиевна — кандидат медицинских наук, доцент кафедры факультетской терапии № 1</p><p>614000, г. Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>Lyudmila G. Vologzhanina — Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy N 1</p><p>614000, Perm, Petropavlovskaya str., 26</p><p> </p></bio><email xlink:type="simple">ludovica@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7554-5433</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голованова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Golovanova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голованова Елена Владимировна — доктор медицинских наук, профессор кафедры терапии и профилактической медицины</p><p>127473, г. Москва, ул. Делегатская, 20, стр. 1</p></bio><bio xml:lang="en"><p>Elena V. Golovanova — Dr. Sci. (Med.), Professor of the De- partment of Therapy and Preventive Medicine</p><p>127473, Moscow, Delegatskaya str., 20, build. 1</p></bio><email xlink:type="simple">golovanovaev@mail.ru</email><xref ref-type="aff" rid="aff-12"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глушенков</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Glushenkov</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Глушенков Дмитрий Владимирович — врач-терапевт, заведующий лечебно-диагностическим отделением № 3 с функциями приемного отделения университетской клинической больницы № 2</p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1</p></bio><bio xml:lang="en"><p>.mitry V. Glushenkov —Physician, Head of the Treatment and Diagnostic Department No. 3 with the functions of the Admissions Department of University Clinical Hospital No. 2</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">Dr.glushenkov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2569-1699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долгушина</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolgushina</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Долгушина Анастасия Ильинична — доктор медицинских наук, заведующая кафедрой госпитальной терапии</p><p>454092, Chelyabinsk, Vorovskogo str., 64</p></bio><bio xml:lang="en"><p>Anastasia I. Dolgushina — Dr. Sci. (Med.), Head of the Depart- ment of Hospital Therapy</p><p>454092, Chelyabinsk, Vorovskogo str., 64</p></bio><email xlink:type="simple">dolgushinaai@yandex.ru</email><xref ref-type="aff" rid="aff-13"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9870-7132</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Игумнова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Igumnova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Игумнова Оксана Александровна — кандидат медицинских наук, ассистент кафедры факультетской терапии № 1</p><p>614000, г. Пермь, ул. Петропавловская, 26</p></bio><bio xml:lang="en"><p>Oxana A. Igumnova — Cand. Sci. (Med.), Assosistant Professor at the Department of Faculty Therapy No. 1.</p><p>614000, Perm, Petropavlovskaya str., 26</p></bio><email xlink:type="simple">samsonchik88@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5699-541X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивашкин</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashkin</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ивашкин Константин Владимирович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского</p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1</p></bio><bio xml:lang="en"><p>Konstantin V. Ivashkin — Dr. Sci. (Med.), Professor, Department of Propaedeutics of Internal Medicine, Gastroenterology, and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">ivashkin_k_v_1@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5056-4504</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козлова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Козлова Ирина Вадимовна — доктор медицинских наук, профессор</p><p>410012, г. Саратов, ул. Большая Казачья, 112</p></bio><bio xml:lang="en"><p>Irina V. Kozlova — Dr. Sci. (Med.), Professor</p><p>410012, Saratov, Bolshaya Kazachya str., 112</p></bio><email xlink:type="simple">kozlova@inbox.ru</email><xref ref-type="aff" rid="aff-14"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0142-0264</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кондрашина</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kondrashina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кондрашина Элина Александровна — кандидат медицинских наук, доцент Научно-клинического и образовательного центра гастроэнтерологии и гепатологии медицинского института</p><p>199034, г. Санкт-Петербург, Университетская наб., 7/9</p></bio><bio xml:lang="en"><p>Elina A. Kondrashina — Cand. Sci. (Med.), Associate Professor at the Scientific, Clinical, and Educational Center for Gastroenterology and Hepatology of the Medical Institute</p><p>199034, Saint Petersburg, Universitetskaya embankment, 7/9</p></bio><email xlink:type="simple">elalkon@rambler.ru</email><xref ref-type="aff" rid="aff-11"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8736-5851</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лазебник</surname><given-names>Л. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Lazebnik</surname><given-names>L. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лазебник Леонид Борисович — доктор медицинских наук, профессор кафедры поликлинической терапии лечебного факультета</p><p>127473, г. Москва, ул. Делегатская, 20, стр. 1</p></bio><bio xml:lang="en"><p>Leonid B. Lazebnik — Dr. Sci. (Med.), Professor of the Depar- tment of Outpatient Therapy, Faculty of General Medicine</p><p>127473, Moscow, Delegatskaya str., 20, build. 1</p></bio><email xlink:type="simple">ecgarticle@gmail.com</email><xref ref-type="aff" rid="aff-12"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6114-564X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маев</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maev</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маев Игорь Вениаминович — доктор медицинских наук, академик РАН, профессор</p><p>127473, г. Москва, ул. Делегатская, 20, стр. 1</p></bio><bio xml:lang="en"><p>Igor V. Maev — Dr. Sci. (Med.), Academician of the Russian Academy of Sciences, Professor</p><p>127473, Moscow, Delegatskaya str., 20, build. 1</p></bio><email xlink:type="simple">igormaev@rambler.ru</email><xref ref-type="aff" rid="aff-12"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6738-6417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марченко</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Marchenko</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марченко Наталья Валерьевна — кандидат медицинских наук, доцент Научно-клинического и образовательного центра гастроэнтерологии и гепатологии медицинского института; врач-гастроэнтеролог</p><p>199034, г. Санкт-Петербург, Университетская наб., 7/9</p></bio><bio xml:lang="en"><p>Natalia V. Marchenko — Cand. Sci. (Med.), Associate Professor at the Scientific, Clinical, and Educational Center for Gastroenterology and Hepatology, Medical Institute;т Gastroenterologist</p><p>199034, Saint Petersburg, Universitetskaya embankment, 7/9</p><p> </p></bio><email xlink:type="simple">dr.marchenko@gmail.com</email><xref ref-type="aff" rid="aff-15"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1210-2528</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Надинская</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Nadinskaia</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Надинская Мария Юрьевна — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии</p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1</p></bio><bio xml:lang="en"><p>Maria Yu. Nadinskaia — Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Medicine, Gastroenterology, and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">nadinskaya_m_yu@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2430-4709</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новик</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Novik</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новик Алексей Викторович — доктор медицинских наук, ведущий научный сотрудник, врач-онколог</p><p>197758, г. Санкт-Петербург, пос. Песочный,  ул. Ленинградская, 68</p></bio><bio xml:lang="en"><p>Aleksei V. Novik — Dr. Sci. (Med.), Leading Researcher, Oncologist</p><p>197758, Saint Petersburg, Pesochny settlement, Leningradskaya str., 68</p></bio><email xlink:type="simple">anovik@list.ru</email><xref ref-type="aff" rid="aff-16"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5156-2842</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осипенко</surname><given-names>М. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Osipenko</surname><given-names>M. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Осипенко Марина Федоровна — доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней</p><p>630091, г. Новосибирск, Красный просп., 52</p></bio><bio xml:lang="en"><p>Marina F. Osipenko — Dr. Sci. (Med.), Professor, Head of the Department of Internal Diseases Propedeutics</p><p>630091, Novosibirsk, Krasnyi ave., 52</p></bio><email xlink:type="simple">ngma@bk.ru</email><xref ref-type="aff" rid="aff-17"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7590-8932</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пазенко</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pazenko</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пазенко Екатерина Владимировна — кандидат медицинских наук, младший научный сотрудник научно-клинического и образовательного центра гастроэнтерологии и гепатологии медицинского института; врач-гастроэнтеролог</p><p>199034, г. Санкт-Петербург, Университетская наб., 7/9</p></bio><bio xml:lang="en"><p>Ekaterina V. Pazenko — Cand. Sci. (Med.), Junior Researcher at the Scientific, Clinical and Educational Center for Gastroenterology and Hepatology of the Medical Institute; Gastroenterologist</p><p>199034, Saint Petersburg, Universitetskaya embankment, 7/9</p></bio><email xlink:type="simple">kaboi@rambler.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1278-3746</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пирогова</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Pirogova</surname><given-names>I. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пирогова Ирина Юрьевна — доктор медицинских наук, профессор кафедры общей врачебной практики</p><p>117198, г. Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Irina Yu. Pirogova — Dr. Sci. (Med.), Professor of the Department of General Medical Practice</p><p>117198, Moscow, Miklukho-Maklaya str., 6</p></bio><email xlink:type="simple">irina_pirogova@inbox.ru</email><xref ref-type="aff" rid="aff-18"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5402-8266</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Прашнова</surname><given-names>М. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Prashnova</surname><given-names>M. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Прашнова Мария Константиновна — кандидат медицинских наук, доцент Научно-клинического и образовательного центра гастроэнтерологии и гепатологии</p><p>199034, г. Санкт-Петербург, Университетская наб., 7/9 </p><p> </p></bio><bio xml:lang="en"><p>Mariya K. Prashnova — Cand. Sci. (Med.), Assosiate Professor of the Scientific, Clinical, and Educational Center for Gastroenterology and Hepatology</p><p>199034, Saint Petersburg, Universitetskaya embankment, 7/9</p></bio><email xlink:type="simple">prashnova@mail.ru</email><xref ref-type="aff" rid="aff-11"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4690-1811</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Приходько</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Prikhodko</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Приходько Вероника Александровна — кандидат биологических наук, доцент кафедры фармакологии и клинической фармакологии</p><p>197022, г. Санкт-Петербург, ул. Профессора Попова, 14а</p></bio><bio xml:lang="en"><p>Veronika A. Prikhodko — Cand. Sci. (Med.), Associate Professor of the Department of Pharmacology and Clinical Pharmacology</p><p>197022, Saint Petersburg, Professora Popova str., 14А</p></bio><email xlink:type="simple">vaprikhodko@rambler.ru</email><xref ref-type="aff" rid="aff-19"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3481-8092</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саенко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Saenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Саенко Анна Алексеевна — кандидат медицинских наук, доцент кафедры госпитальной терапии</p><p>454092, г. Челябинск, ул. Воровского, 64</p></bio><bio xml:lang="en"><p>Anna A. Saenko — Cand. Sci. (Med.), Associate Professor of the Department of Hospital Therapy</p><p>454092, Chelyabinsk, Vorovskogo str., 64</p></bio><email xlink:type="simple">anna-selyanina@mail.ru</email><xref ref-type="aff" rid="aff-13"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1496-0689</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тарасова Лариса Владимировна — доктор медицинских наук, профессор, заведующая кафедрой госпитальной терапии</p><p>428015, г. Чебоксары, Московский просп., 15</p></bio><bio xml:lang="en"><p>Larisa V. Tarasova — Dr. Sci. (Med.), Professor, Head of the De- partment of Hospital Therapy</p><p>428015, Cheboksary, Moskovsky ave., 15</p></bio><email xlink:type="simple">Tlarisagast18@mail.ru</email><xref ref-type="aff" rid="aff-20"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0981-1083</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тихонова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tikhonova</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тихонова Татьяна Андреевна — кандидат медицинских наук, доцент кафедры терапии, гастроэнтерологии и пульмонологии</p><p>410012, г. Саратов, ул. Большая Казачья, 112</p></bio><bio xml:lang="en"><p>Tatiana A. Tikhonova — Cand. Sci. (Med.), Associate Professor of the Department of Therapy, Gastroenterology, and Pulmonology</p><p>410012, Saratov, Bolshaya Kazachya str., 112</p></bio><email xlink:type="simple">jdipisma@mail.ru</email><xref ref-type="aff" rid="aff-14"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6829-1241</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткаченко</surname><given-names>П. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Tkachenko</surname><given-names>P. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ткаченко Петр Евгеньевич — кандидат медицинских наук, ассистент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского</p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1</p></bio><bio xml:lang="en"><p>Petr E. Tkachenko — Cand. Sci. (Med.), Assistant Professor of the Department of Propaedeutics of Internal Medicine, Gastroenterology, and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine</p><p>119435, Moscow, Pogodinskaya str., 1, build. 1</p></bio><email xlink:type="simple">evgeniytkach@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0944-9811</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хлынов</surname><given-names>И. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlynov</surname><given-names>I. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хлынов Игорь Борисович — доктор медицинских наук, доцент кафедры факультетской терапии и гериатрии</p><p>620028, г. Екатеринбург, ул. Репина, 3</p></bio><bio xml:lang="en"><p>Igor B. Khlynov — Dr. Sci. (Med.), Associate Professor of the Department of Faculty Therapy and Geriatrics</p><p>620028, Ekaterinburg, Repina str., 3</p></bio><email xlink:type="simple">hlinov.doc@yandex.ru</email><xref ref-type="aff" rid="aff-21"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8339-9496</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыганова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsyganova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цыганова Юлия Вадимовна — кандидат медицинских наук, доцент</p><p>428015, г. Чебоксары, Московский просп., 15</p></bio><bio xml:lang="en"><p>Yulia V. Tsyganova — Cand. Sci. (Med.), Docent</p><p>428015, Cheboksary, Moskovsky ave., 15</p></bio><email xlink:type="simple">aj_00001@mail.ru</email><xref ref-type="aff" rid="aff-20"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины»  Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный университет»; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University; Academician I.P. Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный университет»; ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University; Saint Petersburg State Chemical-Pharmaceutical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФГБОУ ВО «Пермский государственный медицинский университет им. академика Е.А. Вагнера» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm State Medical University named after Academician E.A. Wagner</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>Медицинский центр «Эвимед»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Evimed Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ФГБОУ ВО «Дальневосточный государственный медицинский университет» Министерства здравоохранения</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Far Eastern State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-8"><aff xml:lang="ru"><institution>ФГБОУ ВО «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Omsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-9"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>NorthWestern State Medical University named after I.I. Mechnikov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-10"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I.I. Mechnikov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-11"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-12"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский университет медицины» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-13"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-14"><aff xml:lang="ru"><institution>ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saratov State Medical University named after V.I. Razumovsky</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-15"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный университет»; ФГБУ «Российский научный центр радиологии и хирургических технологий им. академика А.М. Гранова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University; Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-16"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Oncology named after N.N. Petrov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-17"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-18"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Peoples’ Friendship University of Russia named after Patrice Lumumba</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-19"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State Chemical-Pharmaceutical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-20"><aff xml:lang="ru"><institution>ФГБОУ ВО «Чувашский государственный университет им. И.Н. Ульянова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.N. Ulyanov Chuvash State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-21"><aff xml:lang="ru"><institution>ФГБОУ ВО «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>01</day><month>04</month><year>2026</year></pub-date><volume>36</volume><issue>1</issue><fpage>70</fpage><lpage>146</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ивашкин В.Т., Драпкина О.М., Райхельсон К.Л., Оковитый С.В., Маевская М.В., Гречишникова В.Р., Жаркова М.С., Хлынова О.В., Гладков О.А., Деева Т.А., Алексеенко С.А., Ахмедов В.А., Бакулин И.Г., Бакулина Н.В., Барановский А.Ю., Вологжанина Л.Г., Голованова Е.В., Глушенков Д.В., Долгушина А.И., Игумнова О.А., Ивашкин К.В., Козлова И.В., Кондрашина Э.А., Лазебник Л.Б., Маев И.В., Марченко Н.В., Надинская М.Ю., Новик А.В., Осипенко М.Ф., Пазенко Е.В., Пирогова И.Ю., Прашнова М.К., Приходько В.А., Саенко А.А., Тарасова Л.В., Тихонова Т.А., Ткаченко П.Е., Хлынов И.Б., Цыганова Ю.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Ивашкин В.Т., Драпкина О.М., Райхельсон К.Л., Оковитый С.В., Маевская М.В., Гречишникова В.Р., Жаркова М.С., Хлынова О.В., Гладков О.А., Деева Т.А., Алексеенко С.А., Ахмедов В.А., Бакулин И.Г., Бакулина Н.В., Барановский А.Ю., Вологжанина Л.Г., Голованова Е.В., Глушенков Д.В., Долгушина А.И., Игумнова О.А., Ивашкин К.В., Козлова И.В., Кондрашина Э.А., Лазебник Л.Б., Маев И.В., Марченко Н.В., Надинская М.Ю., Новик А.В., Осипенко М.Ф., Пазенко Е.В., Пирогова И.Ю., Прашнова М.К., Приходько В.А., Саенко А.А., Тарасова Л.В., Тихонова Т.А., Ткаченко П.Е., Хлынов И.Б., Цыганова Ю.В.</copyright-holder><copyright-holder xml:lang="en">Ivashkin V.T., Drapkina О.M., Raikhelson K.L., Okovityi S.V., Maevskaya M.V., Grechishnikova V.R., Zharkova M.S., Khlynova O.V., Gladkov O.А., Deeva T.A., Alekseenko S.A., Akhmedov V.A., Bakulin I.G., Bakulina N.V., Baranovsky A.Y., Vologzhanina L.G., Golovanova E.V., Glushenkov D.V., Dolgushina A.I., Igumnova O.A., Ivashkin K.V., Kozlova I.V., Kondrashina E.A., Lazebnik L.B., Maev I.V., Marchenko N.V., Nadinskaia M.Y., Novik A.V., Osipenko M.F., Pazenko E.V., Pirogova I.Y., Prashnova M.K., Prikhodko V.A., Saenko A.A., Tarasova L.V., Tikhonova T.A., Tkachenko P.E., Khlynov I.B., Tsyganova Y.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gastro-j.ru/jour/article/view/2058">https://www.gastro-j.ru/jour/article/view/2058</self-uri><abstract><sec><title>Цель представления</title><p>Цель представления: клинических рекомендаций заключается в обеспечении информационной поддержки для принятия врачами-гастроэнтерологами, врачами общей практики и врачами-терапевтами решений, способствующих повышению качества оказания медицинской помощи пациенту с лекарственными поражениями печени, с учетом новейших клинических данных и принципов доказательной медицины.</p></sec><sec><title>Основное содержание</title><p>Основное содержание. Клинические рекомендации содержат информацию о современных представлениях об этиологии, факторах риска и патогенезе лекарственных поражений печени, особенностях их клинического течения. Также в рекомендациях представлена информация об актуальных методах лабораторной и инструментальной, инвазивной и неинвазивной диагностики лекарственных поражений печени и их клинических фенотипов, подходах к их лечению с учетом наличия коморбидностей, особенностей диспансерного наблюдения и профилактики. Приведенная информация проиллюстрирована алгоритмами дифференциального диагноза, действий врача. Помимо этого, присутствует информация для пациента и критерии оценки качества оказания медицинской помощи.</p></sec><sec><title>Заключение</title><p>Заключение. Осведомленность специалистов в вопросах диагностики, лечения и наблюдения пациентов с лекарственными поражениями печени способствует своевременной постановке диагноза и инициации лечения, что в отдаленной перспективе будет существенно влиять на их прогноз и качество жизни.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with drug-induced liver injury, taking into account the latest clinical data and principles of evidence-based medicine.</p></sec><sec><title>Key points</title><p>Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of drug-induced liver injury, peculiarities of its clinical course. Also, the recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for drug-induced liver injury disease and its clinical phenotypes assessment; approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician’s actions. In addition, there is information for the patient and criteria for assessing the quality of medical care.</p></sec><sec><title>Conclusion</title><p>Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with drug- induced liver injury contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гепатотоксичность</kwd><kwd>лекарственно-индуцированный аутоиммуноподобный гепатит</kwd><kwd>поражение печени</kwd><kwd>острая печеночная недостаточность</kwd><kwd>печеночная энцефалопатия</kwd><kwd>печеночная панель</kwd><kwd>стеатоз печени</kwd><kwd>стеатогепатит</kwd><kwd>дислипидемии</kwd><kwd>жировая болезнь печени</kwd><kwd>кардиометаболические факторы риска</kwd><kwd>неалкогольный стеатогепатит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hepatotoxicity</kwd><kwd>drug-induced autoimmune-like hepatitis</kwd><kwd>liver injury</kwd><kwd>acute liver failure</kwd><kwd>hepatic encephalopathy</kwd><kwd>liver panel</kwd><kwd>iver steatosis</kwd><kwd>steatohepatitis</kwd><kwd>dyslipidemia</kwd><kwd>fatty liver disease</kwd><kwd>cardiometabolic risk factors</kwd><kwd>nonalcoholic steatohepatitis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–61. DOI: 10.1016/j.jhep.2019.02.014</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–61. DOI: 10.1016/j.jhep.2019.02.014</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fontana R.J., Liou I., Reuben A., Suzuki A., Fiel M.I., Lee W., et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77(3):1036–65. DOI: 10.1002/hep.32689</mixed-citation><mixed-citation xml:lang="en">Fontana R.J., Liou I., Reuben A., Suzuki A., Fiel M.I., Lee W., et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77(3):1036–65. DOI: 10.1002/hep.32689</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chen M., Suzuki A., Borlak J., Andrade R.J., Lucena M.I. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14. DOI: 10.1016/j.jhep.2015.04.016</mixed-citation><mixed-citation xml:lang="en">Chen M., Suzuki A., Borlak J., Andrade R.J., Lucena M.I. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14. DOI: 10.1016/j.jhep.2015.04.016</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Council for International Organizations of Medical Sciences (CIOMS). Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting. Geneva, 2020. URL: https://cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun2020.pdf</mixed-citation><mixed-citation xml:lang="en">Council for International Organizations of Medical Sciences (CIOMS). Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting. Geneva, 2020. URL: https://cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun2020.pdf</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hoofnagle J.H., Björnsson E.S. Drug-induced liver injury — types and phenotypes. N Engl J Med. 2019;381(3):264–73. DOI: 10.1056/NEJMra1816149</mixed-citation><mixed-citation xml:lang="en">Hoofnagle J.H., Björnsson E.S. Drug-induced liver injury — types and phenotypes. N Engl J Med. 2019;381(3):264–73. DOI: 10.1056/NEJMra1816149</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Li M., Wang Y., Lv T.T., Liu J.M., Kong Y.Y., Jia J.D., et al. Mapping the incidence of drug-induced liver injury: A systematic review and meta-analysis. J Dig Dis. 2023;24(5):332–9. DOI: 10.1111/1751-2980.13205</mixed-citation><mixed-citation xml:lang="en">Li M., Wang Y., Lv T.T., Liu J.M., Kong Y.Y., Jia J.D., et al. Mapping the incidence of drug-induced liver injury: A systematic review and meta-analysis. J Dig Dis. 2023;24(5):332–9. DOI: 10.1111/1751-2980.13205</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lucena M.I., Sanabria J., García-Cortes M., Stephens C., Andrade R.J. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020;5(9):862–74. DOI: 10.1016/S2468-1253(20)30006-6</mixed-citation><mixed-citation xml:lang="en">Lucena M.I., Sanabria J., García-Cortes M., Stephens C., Andrade R.J. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020;5(9):862–74. DOI: 10.1016/S2468-1253(20)30006-6</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yu S., Li J., He T., Zheng H., Wang S., Sun Y., et al. Age-related differences in drug-induced liver injury: A retrospective single-center study from a large liver disease specialty hospital in China, 2002–2022. Hepatol Int. 2024;18(4):1202–13. DOI: 10.1007/s12072-024-10679-1</mixed-citation><mixed-citation xml:lang="en">Yu S., Li J., He T., Zheng H., Wang S., Sun Y., et al. Age-related differences in drug-induced liver injury: A retrospective single-center study from a large liver disease specialty hospital in China, 2002–2022. Hepatol Int. 2024;18(4):1202–13. DOI: 10.1007/s12072-024-10679-1</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lucena M.I., Andrade R.J., Kaplowitz N., GarcíaCortes M., Fernández M.C., Romero-Gomez M., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology. 2009;49(6):2001–9. DOI: 10.1002/hep.22895</mixed-citation><mixed-citation xml:lang="en">Lucena M.I., Andrade R.J., Kaplowitz N., GarcíaCortes M., Fernández M.C., Romero-Gomez M., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology. 2009;49(6):2001–9. DOI: 10.1002/hep.22895</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chalasani N., Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–59. DOI: 10.1053/j.gastro.2010.04.001</mixed-citation><mixed-citation xml:lang="en">Chalasani N., Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–59. DOI: 10.1053/j.gastro.2010.04.001</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., achkoria K., García-Ruiz E., et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21. DOI: 10.1016/j.gastro.2005.05.006</mixed-citation><mixed-citation xml:lang="en">Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., achkoria K., García-Ruiz E., et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21. DOI: 10.1016/j.gastro.2005.05.006</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Reuben A., Koch D.G., Lee W.M.; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–76. DOI: 10.1002/hep.23937</mixed-citation><mixed-citation xml:lang="en">Reuben A., Koch D.G., Lee W.M.; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–76. DOI: 10.1002/hep.23937</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chalasani N.P., Maddur H., Russo M.W., Wong R.J., Reddy K.R.; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878–98. DOI: 10.14309/ajg.0000000000001259</mixed-citation><mixed-citation xml:lang="en">Chalasani N.P., Maddur H., Russo M.W., Wong R.J., Reddy K.R.; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878–98. DOI: 10.14309/ajg.0000000000001259</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Барановский А.Ю., Райхельсон К.Л., Пальгова Л.К., Маевская М.В., Кондрашина Э.А. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):85–115. DOI: 10.22416/1382-4376-2019-29-1-101-131</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Baranovsky A.Yu., Raikhelson K.L., Palgova L.K., Maevskaya M.V., Kondrashina E.A., et al. Drug-induced liver injuries (clinical guidelines for physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):85–115. (In Russ.). DOI: 10.22416/1382-4376-2019-29-1-101-131</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Daly A.K. Genetics of drug-induced liver injury: Current knowledge and future prospects. Clin Transl Sci. 2023;16(1):37–42. DOI: 10.1111/cts.13424</mixed-citation><mixed-citation xml:lang="en">Daly A.K. Genetics of drug-induced liver injury: Current knowledge and future prospects. Clin Transl Sci. 2023;16(1):37–42. DOI: 10.1111/cts.13424</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cirulli E.T., Nicoletti P., Abramson K., Andrade R.J., Bjornsson E.S., Chalasani N., et al.; Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC). A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology. 2019;156(6):1707–16.e2. DOI: 10.1053/j.gastro.2019.01.034</mixed-citation><mixed-citation xml:lang="en">Cirulli E.T., Nicoletti P., Abramson K., Andrade R.J., Bjornsson E.S., Chalasani N., et al.; Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC). A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology. 2019;156(6):1707–16.e2. DOI: 10.1053/j.gastro.2019.01.034</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hautekeete M.L., Horsmans Y., Van Waeyenberge C., Demanet C., Henrion J., Verbist L., et al. HLA association of amoxicillin-clavulanate — induced hepatitis. Gastroenterology. 1999;117(5):1181–6. DOI: 10.1016/s0016-5085(99)70404-x</mixed-citation><mixed-citation xml:lang="en">Hautekeete M.L., Horsmans Y., Van Waeyenberge C., Demanet C., Henrion J., Verbist L., et al. HLA association of amoxicillin-clavulanate — induced hepatitis. Gastroenterology. 1999;117(5):1181–6. DOI: 10.1016/s0016-5085(99)70404-x</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4):883–9. DOI: 10.1053/jhep.2002.32102</mixed-citation><mixed-citation xml:lang="en">Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4):883–9. DOI: 10.1053/jhep.2002.32102</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Nicoletti P., Devarbhavi H., Goel A., Venkatesan R., Eapen C.E., Grove J.I., et al. Genetic risk factors in drug-induced liver injury due to isoniazid-containing antituberculosis drug regimens. Clin Pharmacol Ther. 2021;109(4):1125–35. DOI: 10.1002/cpt.2100</mixed-citation><mixed-citation xml:lang="en">Nicoletti P., Devarbhavi H., Goel A., Venkatesan R., Eapen C.E., Grove J.I., et al. Genetic risk factors in drug-induced liver injury due to isoniazid-containing antituberculosis drug regimens. Clin Pharmacol Ther. 2021;109(4):1125–35. DOI: 10.1002/cpt.2100</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashi P.H., Rockey D.C., Fontana R.J., Tillmann H.L., Kaplowitz N., Barnhart H.X., et al.; Drug-Induced Liver Injury Network (DILIN) Investigators. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017;66(4):1275–85. DOI: 10.1002/hep.29283</mixed-citation><mixed-citation xml:lang="en">Hayashi P.H., Rockey D.C., Fontana R.J., Tillmann H.L., Kaplowitz N., Barnhart H.X., et al.; Drug-Induced Liver Injury Network (DILIN) Investigators. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017;66(4):1275–85. DOI: 10.1002/hep.29283</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade R.J., López-Ortega S., López-Vega M.C., Robles M., Cueto I., Lucena M.I. Idiosyncratic drug hepatotoxicity: A 2008 update. Expert Rev Clin Pharmacol. 2008;1(2):261–76. DOI: 10.1586/17512433.1.2.261</mixed-citation><mixed-citation xml:lang="en">Andrade R.J., López-Ortega S., López-Vega M.C., Robles M., Cueto I., Lucena M.I. Idiosyncratic drug hepatotoxicity: A 2008 update. Expert Rev Clin Pharmacol. 2008;1(2):261–76. DOI: 10.1586/17512433.1.2.261</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dakhoul L., Ghabril M., Gu J., Navarro V., Chalasani N., Serrano J.; United States Drug Induced Liver Injury Network. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16(5):722–9.e2. DOI: 10.1016/j.cgh.2017.12.036</mixed-citation><mixed-citation xml:lang="en">Dakhoul L., Ghabril M., Gu J., Navarro V., Chalasani N., Serrano J.; United States Drug Induced Liver Injury Network. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16(5):722–9.e2. DOI: 10.1016/j.cgh.2017.12.036</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Van Roey G., Goos W., Claessens C., Hoorens A., Verlinden W., Schouten J. Acute grade IV toxic hepatitis due to the e-cigarette. Acta Gastroenterol Belg. 2024;87(1):44–7. DOI: 10.51821/87.1.11378</mixed-citation><mixed-citation xml:lang="en">Van Roey G., Goos W., Claessens C., Hoorens A., Verlinden W., Schouten J. Acute grade IV toxic hepatitis due to the e-cigarette. Acta Gastroenterol Belg. 2024;87(1):44–7. DOI: 10.51821/87.1.11378</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Liu A., Walter M., Wright P., Bartosik A., Dolciami D., Elbasir A., et al. Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure. Biol Direct. 2021;16(1):6. DOI: 10.1186/s13062-020-00285-0</mixed-citation><mixed-citation xml:lang="en">Liu A., Walter M., Wright P., Bartosik A., Dolciami D., Elbasir A., et al. Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure. Biol Direct. 2021;16(1):6. DOI: 10.1186/s13062-020-00285-0</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H., Ding L., Zou Y., Hu S.Q., Huang H.G., Kong W.B., et al. Predicting drug-induced liver injury in human with Naïve Bayes classifier approach. J Comput Aided Mol Des. 2016;30(10):889–98. DOI: 10.1007/s10822-016-9972-6</mixed-citation><mixed-citation xml:lang="en">Zhang H., Ding L., Zou Y., Hu S.Q., Huang H.G., Kong W.B., et al. Predicting drug-induced liver injury in human with Naïve Bayes classifier approach. J Comput Aided Mol Des. 2016;30(10):889–98. DOI: 10.1007/s10822-016-9972-6</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Pessayre D., Fromenty B., Berson A., Robin M.A., Lettéron P., Moreau R., et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44(1):34–87. DOI: 10.3109/03602532.2011.604086</mixed-citation><mixed-citation xml:lang="en">Pessayre D., Fromenty B., Berson A., Robin M.A., Lettéron P., Moreau R., et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44(1):34–87. DOI: 10.3109/03602532.2011.604086</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Albrecht W., Kappenberg F., Brecklinghaus T., Stoeber R., Marchan R., Zhang M., et al. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations. Arch Toxicol. 2019;93(6):1609–37. DOI: 10.1007/s00204-019-02492-9</mixed-citation><mixed-citation xml:lang="en">Albrecht W., Kappenberg F., Brecklinghaus T., Stoeber R., Marchan R., Zhang M., et al. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations. Arch Toxicol. 2019;93(6):1609–37. DOI: 10.1007/s00204-019-02492-9</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sandhu N., Navarro V. Drug-induced liver injury in GI practice. Hepatol Commun. 2020;4(5):631–45. DOI: 10.1002/hep4.1503</mixed-citation><mixed-citation xml:lang="en">Sandhu N., Navarro V. Drug-induced liver injury in GI practice. Hepatol Commun. 2020;4(5):631–45. DOI: 10.1002/hep4.1503</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lin J., Li M., Mak W., Shi Y., Zhu X., Tang Z., et al. Applications of in silico models to predict drug-induced liver injury. Toxics. 2022;10(12):788. DOI: 10.3390/toxics10120788</mixed-citation><mixed-citation xml:lang="en">Lin J., Li M., Mak W., Shi Y., Zhu X., Tang Z., et al. Applications of in silico models to predict drug-induced liver injury. Toxics. 2022;10(12):788. DOI: 10.3390/toxics10120788</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lee K.S., Oh S.J., Kim H.M., Lee K.H., Kim S.K. Assessment of reactive metabolites in drug-induced liver injury. Arch Pharm Res. 2011;34(11):1879–86. DOI: 10.1007/s12272-011-1108-x</mixed-citation><mixed-citation xml:lang="en">Lee K.S., Oh S.J., Kim H.M., Lee K.H., Kim S.K. Assessment of reactive metabolites in drug-induced liver injury. Arch Pharm Res. 2011;34(11):1879–86. DOI: 10.1007/s12272-011-1108-x</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Onfiani G., Nascimbeni F., Carubbi F. A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? J Basic Clin Physiol Pharmacol. 2021;32(6):1151–5. DOI: 10.1515/jbcpp-2021-0013</mixed-citation><mixed-citation xml:lang="en">Onfiani G., Nascimbeni F., Carubbi F. A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? J Basic Clin Physiol Pharmacol. 2021;32(6):1151–5. DOI: 10.1515/jbcpp-2021-0013</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">De Abajo F.J., Montero D., Madurga M., García Rodríguez L.A. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br J Clin Pharmacol. 2004;58(1):71–80. DOI: 10.1111/j.1365-2125.2004.02133.x</mixed-citation><mixed-citation xml:lang="en">De Abajo F.J., Montero D., Madurga M., García Rodríguez L.A. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br J Clin Pharmacol. 2004;58(1):71–80. DOI: 10.1111/j.1365-2125.2004.02133.x</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson E.S., Bergmann O.M., Björnsson H.K., Kvaran R.B., Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25. DOI: 10.1053/j.gastro.2013.02.006</mixed-citation><mixed-citation xml:lang="en">Björnsson E.S., Bergmann O.M., Björnsson H.K., Kvaran R.B., Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25. DOI: 10.1053/j.gastro.2013.02.006</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145–55. DOI: 10.1055/s-2002-30105</mixed-citation><mixed-citation xml:lang="en">Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145–55. DOI: 10.1055/s-2002-30105</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Low E.X.S., Zheng Q., Chan E., Lim S.G. Drug induced liver injury: East versus West — a systematic review and meta-analysis. Clin Mol Hepatol. 2020;26(2):142–54. DOI: 10.3350/cmh.2019.1003</mixed-citation><mixed-citation xml:lang="en">Low E.X.S., Zheng Q., Chan E., Lim S.G. Drug induced liver injury: East versus West — a systematic review and meta-analysis. Clin Mol Hepatol. 2020;26(2):142–54. DOI: 10.3350/cmh.2019.1003</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Meier Y., Cavallaro M., Roos M., Pauli-Magnus C., Folkers G., Meier P.J., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005;61(2):135–43. DOI: 10.1007/s00228-004-0888-z</mixed-citation><mixed-citation xml:lang="en">Meier Y., Cavallaro M., Roos M., Pauli-Magnus C., Folkers G., Meier P.J., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005;61(2):135–43. DOI: 10.1007/s00228-004-0888-z</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Idilman R., Bektas M., Cinar K., Toruner M., Cerit E.T., Doganay B., et al. The characteristics and clinical outcome of drug-induced liver injury: A single-center experience. J Clin Gastroenterol. 2010;44(6):e128–32. DOI: 10.1097/MCG.0b013e3181c5e9cc</mixed-citation><mixed-citation xml:lang="en">Idilman R., Bektas M., Cinar K., Toruner M., Cerit E.T., Doganay B., et al. The characteristics and clinical outcome of drug-induced liver injury: A single-center experience. J Clin Gastroenterol. 2010;44(6):e128–32. DOI: 10.1097/MCG.0b013e3181c5e9cc</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Licata A. Adverse drug reactions and organ damage: The liver. Eur J Intern Med. 2016;28:9–16. DOI: 10.1016/j.ejim.2015.12.017</mixed-citation><mixed-citation xml:lang="en">Licata A. Adverse drug reactions and organ damage: The liver. Eur J Intern Med. 2016;28:9–16. DOI: 10.1016/j.ejim.2015.12.017</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Byeon J.H., Kil J.H., Ahn Y.C., Son C.G. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019;233:190–6. DOI: 10.1016/j.jep.2019.01.006</mixed-citation><mixed-citation xml:lang="en">Byeon J.H., Kil J.H., Ahn Y.C., Son C.G. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019;233:190–6. DOI: 10.1016/j.jep.2019.01.006</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J., Ma Z., Niu M., Zhu Y., Liang Q., Zhao Y., et al. Evidence chain-based causality identification in herb-induced liver injury: Exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med. 2015;9(4):457–67. DOI: 10.1007/s11684-015-0417-8</mixed-citation><mixed-citation xml:lang="en">Wang J., Ma Z., Niu M., Zhu Y., Liang Q., Zhao Y., et al. Evidence chain-based causality identification in herb-induced liver injury: Exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med. 2015;9(4):457–67. DOI: 10.1007/s11684-015-0417-8</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Byeon J.H., Kil J.H., Ahn Y.C., Son C.G. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019;233:190–6. DOI: 10.1016/j.jep.2019.01.006</mixed-citation><mixed-citation xml:lang="en">Byeon J.H., Kil J.H., Ahn Y.C., Son C.G. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019;233:190–6. DOI: 10.1016/j.jep.2019.01.006</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Райхельсон К.Л., Пальгова Л.К., Кондрашина Э.А., Марченко Н.В., Барановский А.Ю. Лекарственные поражения печени: клинические рекомендации для врачей. СПб., 2017.</mixed-citation><mixed-citation xml:lang="en">Raikhelson K.L., Palgova L.K., Kondrashina E.A., Marchenko N.V., Baranovsky A.Yu. Drug-induced liver injury: Clinical guidelines for physicians. St. Petersburg, 2017. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Brennan P.N., Cartlidge P., Manship T., Dillon J.F. Guideline review: EASL clinical practice guidelines: Drug-induced liver injury (DILI). Frontline Gastroenterol. 2021;13(4):332–6. DOI: 10.1136/flgastro-2021-101886</mixed-citation><mixed-citation xml:lang="en">Brennan P.N., Cartlidge P., Manship T., Dillon J.F. Guideline review: EASL clinical practice guidelines: Drug-induced liver injury (DILI). Frontline Gastroenterol. 2021;13(4):332–6. DOI: 10.1136/flgastro-2021-101886</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Маев И.В., Ахмедов В.А., Вологжанина Л.Г., Долгушина А.И., Игумнова О.А. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2024;12:5–48. DOI: 10.31146/1682-8658-ecg-232-12-5-48</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Maev I.V., Akhmedov V.A., Vologzhanina L.G., Dolgushina A.I., Igumnova O.A., et al. Clinical guidelines. Drug-induced liver injury (DILI) in adults. Experimental and Clinical Gastroenterology. 2024;12:5–48. (In Russ.). DOI: 10.31146/1682-8658-ecg-232-12-5-48</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Mao Y., Ma S., Liu C., Liu X., Su M., Li D., et al.; Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: An update. Hepatol Int. 2024;18(2):384–419. DOI: 10.1007/s12072-023-10633-7</mixed-citation><mixed-citation xml:lang="en">Mao Y., Ma S., Liu C., Liu X., Su M., Li D., et al.; Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: An update. Hepatol Int. 2024;18(2):384–419. DOI: 10.1007/s12072-023-10633-7</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Kleiner D.E. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(4):364–72. DOI: 10.1055/s-0029-1240005</mixed-citation><mixed-citation xml:lang="en">Kleiner D.E. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(4):364–72. DOI: 10.1055/s-0029-1240005</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Kleiner D.E., Chalasani N.P., Lee W.M., Fontana R.J., Bonkovsky H.L., Watkins P.B., et al.; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology. 2014;59(2):661–70. DOI: 10.1002/hep.26709</mixed-citation><mixed-citation xml:lang="en">Kleiner D.E., Chalasani N.P., Lee W.M., Fontana R.J., Bonkovsky H.L., Watkins P.B., et al.; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology. 2014;59(2):661–70. DOI: 10.1002/hep.26709</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X., Ouyang J., Thung S.N. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis. 2013;17(4):547–64. DOI: 10.1016/j.cld.2013.07.004</mixed-citation><mixed-citation xml:lang="en">Zhang X., Ouyang J., Thung S.N. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis. 2013;17(4):547–64. DOI: 10.1016/j.cld.2013.07.004</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Bonkovsky H.L., Kleiner D.E., Gu J., Odin J.A., Russo M.W., Navarro V.M., et al.; U.S. Drug Induced Liver Injury Network Investigators. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65(4):1267– 77. DOI: 10.1002/hep.28967</mixed-citation><mixed-citation xml:lang="en">Bonkovsky H.L., Kleiner D.E., Gu J., Odin J.A., Russo M.W., Navarro V.M., et al.; U.S. Drug Induced Liver Injury Network Investigators. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65(4):1267– 77. DOI: 10.1002/hep.28967</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Rabinowich L., Shibolet O. Drug induced steatohepatitis: An uncommon culprit of a common disease. Biomed Res Int. 2015;2015:168905. DOI: 10.1155/2015/168905</mixed-citation><mixed-citation xml:lang="en">Rabinowich L., Shibolet O. Drug induced steatohepatitis: An uncommon culprit of a common disease. Biomed Res Int. 2015;2015:168905. DOI: 10.1155/2015/168905</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Goodman Z.D. Drug hepatotoxicity. Clin Liver Dis. 2002;6(2):381–97. DOI: 10.1016/s1089-3261(02)00011-9</mixed-citation><mixed-citation xml:lang="en">Goodman Z.D. Drug hepatotoxicity. Clin Liver Dis. 2002;6(2):381–97. DOI: 10.1016/s1089-3261(02)00011-9</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Lu H.C., González I.A., Byrnes K. Ground-glass hepatocellular inclusions are associated with polypharmacy. Ann Diagn Pathol. 2021;52:151740. DOI: 10.1016/j.anndiagpath.2021.151740</mixed-citation><mixed-citation xml:lang="en">Lu H.C., González I.A., Byrnes K. Ground-glass hepatocellular inclusions are associated with polypharmacy. Ann Diagn Pathol. 2021;52:151740. DOI: 10.1016/j.anndiagpath.2021.151740</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Bessone F., Dirchwolf M., Rodil M.A., Razori M.V., Roma M.G. Review article: Drug-induced liver injury in the context of nonalcoholic fatty liver disease — a physiopathological and clinical integrated view. Aliment Pharmacol Ther. 2018;48(9):892–913. DOI: 10.1111/apt.14952</mixed-citation><mixed-citation xml:lang="en">Bessone F., Dirchwolf M., Rodil M.A., Razori M.V., Roma M.G. Review article: Drug-induced liver injury in the context of nonalcoholic fatty liver disease — a physiopathological and clinical integrated view. Aliment Pharmacol Ther. 2018;48(9):892–913. DOI: 10.1111/apt.14952</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Kleiner D.E. Liver histology in the diagnosis and prognosis of drug-induced liver injury. Clin Liver Dis (Hoboken). 2014;4(1):12–6. DOI: 10.1002/cld.371</mixed-citation><mixed-citation xml:lang="en">Kleiner D.E. Liver histology in the diagnosis and prognosis of drug-induced liver injury. Clin Liver Dis (Hoboken). 2014;4(1):12–6. DOI: 10.1002/cld.371</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson E., Kalaitzakis E., Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25(12):1411–21. DOI: 10.1111/j.1365-2036.2007.03330.x</mixed-citation><mixed-citation xml:lang="en">Björnsson E., Kalaitzakis E., Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25(12):1411–21. DOI: 10.1111/j.1365-2036.2007.03330.x</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. DOI: 10.1038/clpt.2011.58</mixed-citation><mixed-citation xml:lang="en">Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. DOI: 10.1038/clpt.2011.58</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Fontana R.J., Seeff L.B., Andrade R.J., Björnsson E., Day C.P., Serrano J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop. Hepatology. 2010;52(2):730–42. DOI: 10.1002/hep.23696</mixed-citation><mixed-citation xml:lang="en">Fontana R.J., Seeff L.B., Andrade R.J., Björnsson E., Day C.P., Serrano J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop. Hepatology. 2010;52(2):730–42. DOI: 10.1002/hep.23696</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade R.J., Aithal G.P., de Boer Y.S., Liberal R., Gerbes A., Regev A., et al.; IAIHG and EASL DHI- LI Consortium. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. J Hepatol. 2023;79(3):853–66. DOI: 10.1016/j.jhep.2023.04.033</mixed-citation><mixed-citation xml:lang="en">Andrade R.J., Aithal G.P., de Boer Y.S., Liberal R., Gerbes A., Regev A., et al.; IAIHG and EASL DHI- LI Consortium. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. J Hepatol. 2023;79(3):853–66. DOI: 10.1016/j.jhep.2023.04.033</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">García-Cortés M., Ortega-Alonso A., Matilla-Cabello G., Medina-Cáliz I., Castiella A., Conde I., et al. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver Int. 2023;43(8):1749–60. DOI: 10.1111/liv.15623</mixed-citation><mixed-citation xml:lang="en">García-Cortés M., Ortega-Alonso A., Matilla-Cabello G., Medina-Cáliz I., Castiella A., Conde I., et al. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver Int. 2023;43(8):1749–60. DOI: 10.1111/liv.15623</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–8. DOI: 10.1002/hep.23588</mixed-citation><mixed-citation xml:lang="en">Björnsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–8. DOI: 10.1002/hep.23588</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">De Boer Y.S., Kosinski A.S., Urban T.J., Zhao Z., Long N., Chalasani N., et al.; Drug-Induced Liver Injury Network. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15(1):103–2.e2. DOI: 10.1016/j.cgh.2016.05.043</mixed-citation><mixed-citation xml:lang="en">De Boer Y.S., Kosinski A.S., Urban T.J., Zhao Z., Long N., Chalasani N., et al.; Drug-Induced Liver Injury Network. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15(1):103–2.e2. DOI: 10.1016/j.cgh.2016.05.043</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Licata A., Maida M., Cabibi D., Butera G., Macaluso F.S., Alessi N., et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. Dig Liver Dis. 2014;46(12):1116–20. DOI: 10.1016/j.dld.2014.08.040</mixed-citation><mixed-citation xml:lang="en">Licata A., Maida M., Cabibi D., Butera G., Macaluso F.S., Alessi N., et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. Dig Liver Dis. 2014;46(12):1116–20. DOI: 10.1016/j.dld.2014.08.040</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Perdices E.V., Medina-Cáliz I., Hernando S., Ortega A., Martín-Ocaña F., Navarro J.M., et al. Hepatotoxicity associated with statin use: Analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig. 2014;106(4):246–54.</mixed-citation><mixed-citation xml:lang="en">Perdices E.V., Medina-Cáliz I., Hernando S., Ortega A., Martín-Ocaña F., Navarro J.M., et al. Hepatotoxicity associated with statin use: Analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig. 2014;106(4):246–54.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson E.S., Medina-Caliz I., Andrade R.J., Lucena M.I. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022;6(8):1895–909. DOI: 10.1002/hep4.1959</mixed-citation><mixed-citation xml:lang="en">Björnsson E.S., Medina-Caliz I., Andrade R.J., Lucena M.I. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022;6(8):1895–909. DOI: 10.1002/hep4.1959</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Codoni G., Kirchner T., Engel B., Villamil A.M., Efe C., Stattermayer A.F., et al. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 2023;5(1):100605. DOI: 10.1016/j.jhepr.2022.100605</mixed-citation><mixed-citation xml:lang="en">Codoni G., Kirchner T., Engel B., Villamil A.M., Efe C., Stattermayer A.F., et al. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 2023;5(1):100605. DOI: 10.1016/j.jhepr.2022.100605</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Z., Qi G., Liu X., Li Z., Zhang A., Ma J., et al. Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021. PLoS One. 2023;18(3):e0281983. DOI: 10.1371/journal.pone.0281983</mixed-citation><mixed-citation xml:lang="en">Xu Z., Qi G., Liu X., Li Z., Zhang A., Ma J., et al. Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021. PLoS One. 2023;18(3):e0281983. DOI: 10.1371/journal.pone.0281983</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Lohse A.W., Sebode M., Bhathal P.S., Clouston A.D., Dienes H.P., Jain D., et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the international AIH pathology group: Results of a workshop on AIH histology hosted by the European reference network on hepatological diseases and the European society of pathology: results of a workshop on AIH histology hosted by the European reference network on hepatological diseases and the European society of pathology. Liver Int. 2022;42(5):1058–69. DOI: 10.1111/liv.15217</mixed-citation><mixed-citation xml:lang="en">Lohse A.W., Sebode M., Bhathal P.S., Clouston A.D., Dienes H.P., Jain D., et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the international AIH pathology group: Results of a workshop on AIH histology hosted by the European reference network on hepatological diseases and the European society of pathology: results of a workshop on AIH histology hosted by the European reference network on hepatological diseases and the European society of pathology. Liver Int. 2022;42(5):1058–69. DOI: 10.1111/liv.15217</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">García-Cortés M., Pinazo-Bandera J.M., Lucena M.I., Andrade R.J. Drug-induced autoimmune-like hepatitis. Clin Liver Dis (Hoboken). 2024;23(1):e0172. DOI: 10.1097/CLD.0000000000000172</mixed-citation><mixed-citation xml:lang="en">García-Cortés M., Pinazo-Bandera J.M., Lucena M.I., Andrade R.J. Drug-induced autoimmune-like hepatitis. Clin Liver Dis (Hoboken). 2024;23(1):e0172. DOI: 10.1097/CLD.0000000000000172</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Calle A.M., Aguirre N., Ardila J.C., Cardona Villa R. DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J. 2023;16(3):100673. DOI: 10.1016/j.waojou.2022.100673</mixed-citation><mixed-citation xml:lang="en">Calle A.M., Aguirre N., Ardila J.C., Cardona Villa R. DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J. 2023;16(3):100673. DOI: 10.1016/j.waojou.2022.100673</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Kardaun S.H., Sekula P., Valeyrie-Allanore L., Liss Y., Chu C.Y., Creamer D., et al.; RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80. DOI: 10.1111/bjd.12501</mixed-citation><mixed-citation xml:lang="en">Kardaun S.H., Sekula P., Valeyrie-Allanore L., Liss Y., Chu C.Y., Creamer D., et al.; RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80. DOI: 10.1111/bjd.12501</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">De A., Rajagopalan M., Sarda A., Das S., Biswas P. Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature. Indian J Dermatol. 2018;63(1):30–40. DOI: 10.4103/ijd.IJD_582_17</mixed-citation><mixed-citation xml:lang="en">De A., Rajagopalan M., Sarda A., Das S., Biswas P. Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature. Indian J Dermatol. 2018;63(1):30–40. DOI: 10.4103/ijd.IJD_582_17</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Choudhary S., McLeod M., Torchia D., Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6(6):31–7.</mixed-citation><mixed-citation xml:lang="en">Choudhary S., McLeod M., Torchia D., Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6(6):31–7.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Alphonce B., Komanya F., Magitta N.F., Deodatus S., Sindato E. Amoxicillin-induced DRESS syndrome without eosinophilia. Clin Case Rep. 2024;12(8):e9333. DOI: 10.1002/ccr3.9333</mixed-citation><mixed-citation xml:lang="en">Alphonce B., Komanya F., Magitta N.F., Deodatus S., Sindato E. Amoxicillin-induced DRESS syndrome without eosinophilia. Clin Case Rep. 2024;12(8):e9333. DOI: 10.1002/ccr3.9333</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y.C., Chang C.Y., Cho Y.T., Chiu H.C., Chu C.Y. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: A retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68(3):459–65. DOI: 10.1016/j.jaad.2012.08.009</mixed-citation><mixed-citation xml:lang="en">Chen Y.C., Chang C.Y., Cho Y.T., Chiu H.C., Chu C.Y. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: A retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68(3):459–65. DOI: 10.1016/j.jaad.2012.08.009</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Takinami M., Ono A., Kawabata T., Mamesaya N., Kobayashi H., Omori S., et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021;39(6):1716–23. DOI: 10.1007/s10637-021-01136-z</mixed-citation><mixed-citation xml:lang="en">Takinami M., Ono A., Kawabata T., Mamesaya N., Kobayashi H., Omori S., et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021;39(6):1716–23. DOI: 10.1007/s10637-021-01136-z</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Tew A., Khoja L., Pallan L., Steven N. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. J Oncol Pharm Pract. 2023;29(5):1163– 71. DOI: 10.1177/10781552221103548</mixed-citation><mixed-citation xml:lang="en">Tew A., Khoja L., Pallan L., Steven N. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. J Oncol Pharm Pract. 2023;29(5):1163– 71. DOI: 10.1177/10781552221103548</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Onoyama T., Takeda Y., Yamashita T., Hamamoto W., Sakamoto Y., Koda H., et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol. 2020;26(3):353–65. DOI: 10.3748/wjg.v26.i3.353</mixed-citation><mixed-citation xml:lang="en">Onoyama T., Takeda Y., Yamashita T., Hamamoto W., Sakamoto Y., Koda H., et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol. 2020;26(3):353–65. DOI: 10.3748/wjg.v26.i3.353</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Sundaram V., Björnsson E.S. Drug-induced cholestasis. Hepatol Commun. 2017;1(8):726–35. DOI: 10.1002/hep4.1088</mixed-citation><mixed-citation xml:lang="en">Sundaram V., Björnsson E.S. Drug-induced cholestasis. Hepatol Commun. 2017;1(8):726–35. DOI: 10.1002/hep4.1088</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Gudnason H.O., Björnsson H.K., Gardarsdottir M., Thorisson H.M., Olafsson S., Bergmann O.M., et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig Liver Dis. 2015;47(6):502–7. DOI: 10.1016/j.dld.2015.03.002</mixed-citation><mixed-citation xml:lang="en">Gudnason H.O., Björnsson H.K., Gardarsdottir M., Thorisson H.M., Olafsson S., Bergmann O.M., et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig Liver Dis. 2015;47(6):502–7. DOI: 10.1016/j.dld.2015.03.002</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Bjornsson E.S., Devarbhavi H.C. Drug-induced cholestatic liver diseases. Hepatology. 2025;82(4):996–1015. DOI: 10.1097/HEP.0000000000001052</mixed-citation><mixed-citation xml:lang="en">Bjornsson E.S., Devarbhavi H.C. Drug-induced cholestatic liver diseases. Hepatology. 2025;82(4):996–1015. DOI: 10.1097/HEP.0000000000001052</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Bessone F., Hernández N., Tanno M., Roma M.G. Drug-induced vanishing bile duct syndrome: From pathogenesis to diagnosis and therapeutics. Semin Liver Dis. 2021;41(3):331–48. DOI: 10.1055/s-0041-1729972</mixed-citation><mixed-citation xml:lang="en">Bessone F., Hernández N., Tanno M., Roma M.G. Drug-induced vanishing bile duct syndrome: From pathogenesis to diagnosis and therapeutics. Semin Liver Dis. 2021;41(3):331–48. DOI: 10.1055/s-0041-1729972</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Visentin M., Lenggenhager D., Gai Z., Kullak-Ublick G.A. Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1498–506. DOI: 10.1016/j.bbadis.2017.08.033</mixed-citation><mixed-citation xml:lang="en">Visentin M., Lenggenhager D., Gai Z., Kullak-Ublick G.A. Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1498–506. DOI: 10.1016/j.bbadis.2017.08.033</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. URL: https://www.ncbi.nlm.nih.gov/books/NBK547852/</mixed-citation><mixed-citation xml:lang="en">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. URL: https://www.ncbi.nlm.nih.gov/books/NBK547852/</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Stevenson H.L., Prats M.M., Sasatomi E. Chemotherapy-induced Sinusoidal Injury (CSI) score: A novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis. BMC Cancer. 2017;17(1):35. DOI: 10.1186/s12885-016-2998-2</mixed-citation><mixed-citation xml:lang="en">Stevenson H.L., Prats M.M., Sasatomi E. Chemotherapy-induced Sinusoidal Injury (CSI) score: A novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis. BMC Cancer. 2017;17(1):35. DOI: 10.1186/s12885-016-2998-2</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Overman M.J., Maru D.M., Charnsangavej C., Loyer E.M., Wang H., Pathak P., et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28(15):2549–55. DOI: 10.1186/s12885-016-2998-2</mixed-citation><mixed-citation xml:lang="en">Overman M.J., Maru D.M., Charnsangavej C., Loyer E.M., Wang H., Pathak P., et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28(15):2549–55. DOI: 10.1186/s12885-016-2998-2</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Morioka D., Izumisawa Y., Yamaguchi K., Sato K., Komiyama S., Nakagawa K., et al. Surgical intervention for portal hypertension caused by oxaliplatin-based chemotherapy: A case report and a review of literature regarding radiological and/or surgical interventions for oxaliplatin-associated portal hypertension. Clin J Gastroenterol. 2020;13(5):799–805. DOI: 10.1007/s12328-020-01157-w</mixed-citation><mixed-citation xml:lang="en">Morioka D., Izumisawa Y., Yamaguchi K., Sato K., Komiyama S., Nakagawa K., et al. Surgical intervention for portal hypertension caused by oxaliplatin-based chemotherapy: A case report and a review of literature regarding radiological and/or surgical interventions for oxaliplatin-associated portal hypertension. Clin J Gastroenterol. 2020;13(5):799–805. DOI: 10.1007/s12328-020-01157-w</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Lee W.M. Drug-induced acute liver failure. Clin Liver Dis. 2013;17(4):575–86. DOI: 10.1016/j.cld.2013.07.001</mixed-citation><mixed-citation xml:lang="en">Lee W.M. Drug-induced acute liver failure. Clin Liver Dis. 2013;17(4):575–86. DOI: 10.1016/j.cld.2013.07.001</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Tujios S., Stravitz R.T., Lee W.M. Management of acute liver failure: Update 2022. Semin Liver Dis. 2022;42(3):362–78. DOI: 10.1055/s-0042-1755274</mixed-citation><mixed-citation xml:lang="en">Tujios S., Stravitz R.T., Lee W.M. Management of acute liver failure: Update 2022. Semin Liver Dis. 2022;42(3):362–78. DOI: 10.1055/s-0042-1755274</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Burt A.D., Ferrell L.D., Hübscher S.G., Portmann B.C. MacSween’s pathology of the liver. 6th ed. Churchill Livingstone, 2012:645–760.</mixed-citation><mixed-citation xml:lang="en">Burt A.D., Ferrell L.D., Hübscher S.G., Portmann B.C. MacSween’s pathology of the liver. 6th ed. Churchill Livingstone, 2012:645–760.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Лазебник Л.Б., Голованова Е.В., Хлынова О.В., Алексеенко С.А., Арямкина О.Л., Бакулин И.Г. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29–54. DOI: 10.31146/1682-8658-ecg-174-2-29-54</mixed-citation><mixed-citation xml:lang="en">Lazebnik L.B., Golovanova E.V., Hlynova O.V., Alekseenko S.A., Aryamkina O.I., Bakulin I.G., et al. Medicinal liver damage in adults. Experimental and Clinical Gastroenterology. 2020;174(2):29–54. (In Russ.). DOI: 10.31146/1682-8658-ecg-174-2-29-54</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Calderon R.M., Cubeddu L.X., Goldberg R.B., Schiff E.R. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: A therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349–56. DOI: 10.4065/mcp.2009.0365</mixed-citation><mixed-citation xml:lang="en">Calderon R.M., Cubeddu L.X., Goldberg R.B., Schiff E.R. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: A therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349–56. DOI: 10.4065/mcp.2009.0365</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Bessone F., Hernandez N., Tagle M., Arrese M., Parana R., Méndez-Sánchez N., et al. Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Ann Hepatol. 2021;24:100321. DOI: 10.1016/j.aohep.2021.100321</mixed-citation><mixed-citation xml:lang="en">Bessone F., Hernandez N., Tagle M., Arrese M., Parana R., Méndez-Sánchez N., et al. Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Ann Hepatol. 2021;24:100321. DOI: 10.1016/j.aohep.2021.100321</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Ghabril M., Vuppalanchi R., Chalasani N. Drug-induced liver injury in patients with chronic liver disease. Liver Int. 2025;45(3):e70019. DOI: 10.1111/liv.70019</mixed-citation><mixed-citation xml:lang="en">Ghabril M., Vuppalanchi R., Chalasani N. Drug-induced liver injury in patients with chronic liver disease. Liver Int. 2025;45(3):e70019. DOI: 10.1111/liv.70019</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Chalasani N., Bonkovsky H.L., Fontana R., Lee W., Stolz A., Talwalkar J., et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology. 2015;148(7):1340– 52.e7. DOI: 10.1053/j.gastro.2015.03.006</mixed-citation><mixed-citation xml:lang="en">Chalasani N., Bonkovsky H.L., Fontana R., Lee W., Stolz A., Talwalkar J., et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology. 2015;148(7):1340– 52.e7. DOI: 10.1053/j.gastro.2015.03.006</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Stephens C., Robles-Diaz M., Medina-Caliz I., Garcia-Cortes M., Ortega-Alonso A., Sanabria-Cabrera J., et al. Comprehensive analysis and insights gained from longterm experience of the Spanish DILI Registry. J Hepatol. 2021;75(1):86–97. DOI: 10.1016/j.jhep.2021.01.029</mixed-citation><mixed-citation xml:lang="en">Stephens C., Robles-Diaz M., Medina-Caliz I., Garcia-Cortes M., Ortega-Alonso A., Sanabria-Cabrera J., et al. Comprehensive analysis and insights gained from longterm experience of the Spanish DILI Registry. J Hepatol. 2021;75(1):86–97. DOI: 10.1016/j.jhep.2021.01.029</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Fontana R.J., Watkins P.B., Bonkovsky H.L., Chalasani N., Davern T., Serrano J., et al.; DILIN Study Group. Drug-induced liver injury network (DILIN) prospective study: Rationale, design and conduct. Drug Saf. 2009;32(1):55–68. DOI: 10.2165/00002018-200932010-00005</mixed-citation><mixed-citation xml:lang="en">Fontana R.J., Watkins P.B., Bonkovsky H.L., Chalasani N., Davern T., Serrano J., et al.; DILIN Study Group. Drug-induced liver injury network (DILIN) prospective study: Rationale, design and conduct. Drug Saf. 2009;32(1):55–68. DOI: 10.2165/00002018-200932010-00005</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">De La Guerra R., Daniel T., Adewuyi O., Babich M. Drug-induced liver injury (DILI): A practical review. Pract Gastroenterol. 2024;(17):16–25. URL: https://practicalgastro.com/wp-content/uploads/2025/01/Babich-December-2024.pdf</mixed-citation><mixed-citation xml:lang="en">De La Guerra R., Daniel T., Adewuyi O., Babich M. Drug-induced liver injury (DILI): A practical review. Pract Gastroenterol. 2024;(17):16–25. URL: https://practicalgastro.com/wp-content/uploads/2025/01/Babich-December-2024.pdf</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Crabb D.W., Bataller R., Chalasani N.P., Kamath P.S., Lucey M., Mathurin P., et al.; NIAAA Alcoholic Hepatitis Consortia. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150(4):785–90. DOI: 10.1053/j.gastro.2016.02.042</mixed-citation><mixed-citation xml:lang="en">Crabb D.W., Bataller R., Chalasani N.P., Kamath P.S., Lucey M., Mathurin P., et al.; NIAAA Alcoholic Hepatitis Consortia. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150(4):785–90. DOI: 10.1053/j.gastro.2016.02.042</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Лазебник Л.Б., Голованова Е.В., Деева Т.А., Драпкина О.М., Еремина Е.Ю. и др. Алкогольная болезнь печени: клинические рекомендации. М.; 2024. URL: https://cr.minzdrav.gov.ru/preview-cr/711_2</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Lazebnik L.B., Golovanova E.V., Deeva T.A., Drapkina O.M., Eremina E.Yu., et al. Alcoholic liver disease: Clinical recommendations. Moscow; 2024. (In Russ.). URL: https://cr.minzdrav.gov.ru/preview-cr/711_2</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashi P.H., Rockey D.C., Fontana R.J., Tillmann H.L., Kaplowitz N., Barnhart H.X., et al.; Drug-Induced Liver Injury Network (DILIN) Investigators. Death and liver transplantation within 2 years of onset of druginduced liver injury. Hepatology. 2017;66(4):1275–85. DOI: 10.1002/hep.29283</mixed-citation><mixed-citation xml:lang="en">Hayashi P.H., Rockey D.C., Fontana R.J., Tillmann H.L., Kaplowitz N., Barnhart H.X., et al.; Drug-Induced Liver Injury Network (DILIN) Investigators. Death and liver transplantation within 2 years of onset of druginduced liver injury. Hepatology. 2017;66(4):1275–85. DOI: 10.1002/hep.29283</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Cabriales S.A., Shear N.H., Gonzalez-More-no E.I. Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. World J Clin Cases. 2019;7(6):705–16. DOI: 10.12998/wjcc.v7.i6.705</mixed-citation><mixed-citation xml:lang="en">Martinez-Cabriales S.A., Shear N.H., Gonzalez-More-no E.I. Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. World J Clin Cases. 2019;7(6):705–16. DOI: 10.12998/wjcc.v7.i6.705</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Kroshinsky D., Cardones A.R.G., Blumenthal K.G. Drug reaction with eosinophilia and systemic symptoms. N Engl J Med. 2024;391(23):2242–54. DOI: 10.1056/NEJMra2204547</mixed-citation><mixed-citation xml:lang="en">Kroshinsky D., Cardones A.R.G., Blumenthal K.G. Drug reaction with eosinophilia and systemic symptoms. N Engl J Med. 2024;391(23):2242–54. DOI: 10.1056/NEJMra2204547</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Kano Y., Ishida T., Hirahara K., Shiohara T. Visceral involvements and long-term sequelae in druginduced hypersensitivity syndrome. Med Clin North Am. 2010;94(4):743–59. DOI: 10.1016/j.mcna.2010.03.004</mixed-citation><mixed-citation xml:lang="en">Kano Y., Ishida T., Hirahara K., Shiohara T. Visceral involvements and long-term sequelae in druginduced hypersensitivity syndrome. Med Clin North Am. 2010;94(4):743–59. DOI: 10.1016/j.mcna.2010.03.004</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Mockenhaupt M. Severe drug-induced skin reactions: Clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60. DOI: 10.1111/j.1610-0387.2008.06878.x</mixed-citation><mixed-citation xml:lang="en">Mockenhaupt M. Severe drug-induced skin reactions: Clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60. DOI: 10.1111/j.1610-0387.2008.06878.x</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Fu S., Wu D., Jiang W., Li J., Long J., Jia C., et al. Molecular biomarkers in drug-induced liver injury: Challenges and future perspectives. Front Pharmacol. 2020;10:1667. DOI: 10.3389/fphar.2019.01667</mixed-citation><mixed-citation xml:lang="en">Fu S., Wu D., Jiang W., Li J., Long J., Jia C., et al. Molecular biomarkers in drug-induced liver injury: Challenges and future perspectives. Front Pharmacol. 2020;10:1667. DOI: 10.3389/fphar.2019.01667</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Clarke J.I., Dear J.W., Antoine D.J. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety — false dawn or new horizon? Expert Opin Drug Saf. 2016;15(5):625–34. DOI: 10.1517/14740338.2016.1160057</mixed-citation><mixed-citation xml:lang="en">Clarke J.I., Dear J.W., Antoine D.J. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety — false dawn or new horizon? Expert Opin Drug Saf. 2016;15(5):625–34. DOI: 10.1517/14740338.2016.1160057</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Senior J.R. Can rechallenge be done safely after mild or moderate drug-induced liver injury? Hepatology. 2016;63(3):691–3. DOI: 10.1002/hep.28353</mixed-citation><mixed-citation xml:lang="en">Senior J.R. Can rechallenge be done safely after mild or moderate drug-induced liver injury? Hepatology. 2016;63(3):691–3. DOI: 10.1002/hep.28353</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Tajima S., Yamamoto N., Masuda S. Clinical prospects of biomarkers for the early detection and/or prediction of organ injury associated with pharmacotherapy. Biochem Pharmacol. 2019;170:113664. DOI: 10.1016/j.bcp.2019.113664</mixed-citation><mixed-citation xml:lang="en">Tajima S., Yamamoto N., Masuda S. Clinical prospects of biomarkers for the early detection and/or prediction of organ injury associated with pharmacotherapy. Biochem Pharmacol. 2019;170:113664. DOI: 10.1016/j.bcp.2019.113664</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Gazzin S., Masutti F., Vitek L., Tiribelli C. The molecular basis of jaundice: An old symptom revisited. Liver Int. 2017;37(8):1094–102. DOI: 10.1111/liv.13351</mixed-citation><mixed-citation xml:lang="en">Gazzin S., Masutti F., Vitek L., Tiribelli C. The molecular basis of jaundice: An old symptom revisited. Liver Int. 2017;37(8):1094–102. DOI: 10.1111/liv.13351</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Danan G., Benichou C. Causality assessment of adverse reactions to drugs. Part I: A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30. DOI: 10.1016/0895-4356(93)90101-6</mixed-citation><mixed-citation xml:lang="en">Danan G., Benichou C. Causality assessment of adverse reactions to drugs. Part I: A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30. DOI: 10.1016/0895-4356(93)90101-6</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272–6. DOI: 10.1016/0168-8278(90)90124-a</mixed-citation><mixed-citation xml:lang="en">Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272–6. DOI: 10.1016/0168-8278(90)90124-a</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs. Part II: An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–6. DOI: 10.1016/0895-4356(93)90102-7</mixed-citation><mixed-citation xml:lang="en">Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs. Part II: An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–6. DOI: 10.1016/0895-4356(93)90102-7</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal V.K., McHutchison J.G., Hoofnagle J.H.; Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8(5):463–70. DOI: 10.1016/j.cgh.2010.02.008</mixed-citation><mixed-citation xml:lang="en">Agarwal V.K., McHutchison J.G., Hoofnagle J.H.; Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8(5):463–70. DOI: 10.1016/j.cgh.2010.02.008</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Сандлер Ю.Г., Винницкая Е.В., Райхельсон К.Л., Ивашкин К.В., Бацких С.Н., Александрова Е.Н. и др. Диагностика и лечение пациентов с аутоиммунным гепатитом (соглашение специалистов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(6):100–19. DOI: 10.22416/1382-4376-2024-34-6-100-119</mixed-citation><mixed-citation xml:lang="en">Sandler Yu.G., Vinnitskaya E.V., Raikhelson K.L., Ivashkin K.V., Batskikh S.N., Aleksandrova E.N., et al. Diagnosis and treatment of patients with autoimmune hepatitis (Experts’ agreement). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(6):100–19. (In Russ.). DOI: 10.22416/1382-4376-2024-34-6-100-119</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Tan E.M., Feltkamp T.E., Smolen J.S., Butcher B., Dawkins R., Fritzler M.J., et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40(9):1601–11. DOI: 10.1002/art.1780400909</mixed-citation><mixed-citation xml:lang="en">Tan E.M., Feltkamp T.E., Smolen J.S., Butcher B., Dawkins R., Fritzler M.J., et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40(9):1601–11. DOI: 10.1002/art.1780400909</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Damoiseaux J., Andrade L.E.C., Carballo O.G., Conrad K., Francescantonio P.L.C., Fritzler M.J., et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879–89. DOI: 10.1136/annrheumdis-2018-214436</mixed-citation><mixed-citation xml:lang="en">Damoiseaux J., Andrade L.E.C., Carballo O.G., Conrad K., Francescantonio P.L.C., Fritzler M.J., et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879–89. DOI: 10.1136/annrheumdis-2018-214436</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Mittal V., Muralee S., Tampi R.R. Valproic acid-induced hyperammonemia in the elderly: A review of the literature. Case Rep Med. 2009;2009:802121. DOI: 10.1155/2009/802121</mixed-citation><mixed-citation xml:lang="en">Mittal V., Muralee S., Tampi R.R. Valproic acid-induced hyperammonemia in the elderly: A review of the literature. Case Rep Med. 2009;2009:802121. DOI: 10.1155/2009/802121</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Shakerdi L., Ryan A. Drug-induced hyperammonaemia. J Clin Pathol. 2023;76(8):501–9. DOI: 10.1136/jcp-2022-208644</mixed-citation><mixed-citation xml:lang="en">Shakerdi L., Ryan A. Drug-induced hyperammonaemia. J Clin Pathol. 2023;76(8):501–9. DOI: 10.1136/jcp-2022-208644</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad J., Reddy K.R., Tillmann H.L., Hayashi P.H., Chalasani N., Fontana R.J., et al. Importance of hepatitis C virus RNA testing in patients with suspected drug-induced liver injury. Dig Dis Sci. 2019;64(9):2645–52. DOI: 10.1007/s10620-019-05591-w</mixed-citation><mixed-citation xml:lang="en">Ahmad J., Reddy K.R., Tillmann H.L., Hayashi P.H., Chalasani N., Fontana R.J., et al. Importance of hepatitis C virus RNA testing in patients with suspected drug-induced liver injury. Dig Dis Sci. 2019;64(9):2645–52. DOI: 10.1007/s10620-019-05591-w</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Grewal P., Ahmad J. Beware of HCV and HEV in patients with suspected drug-induced liver injury. Curr Hepatol Rep. 2018;17(3):270–5. DOI: 10.1007/s11901018-0410-1</mixed-citation><mixed-citation xml:lang="en">Grewal P., Ahmad J. Beware of HCV and HEV in patients with suspected drug-induced liver injury. Curr Hepatol Rep. 2018;17(3):270–5. DOI: 10.1007/s11901018-0410-1</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Fontana R.J., Engle R.E., Hayashi P.H., Gu J., Kleiner D.E., Nguyen H., et al. Incidence of hepatitis E infection in American patients with suspected drug-induced liver injury is low and declining: The DILIN prospective study. Am J Gastroenterol. 2022;117(9):1462–70. DOI: 10.14309/ajg.0000000000001869</mixed-citation><mixed-citation xml:lang="en">Fontana R.J., Engle R.E., Hayashi P.H., Gu J., Kleiner D.E., Nguyen H., et al. Incidence of hepatitis E infection in American patients with suspected drug-induced liver injury is low and declining: The DILIN prospective study. Am J Gastroenterol. 2022;117(9):1462–70. DOI: 10.14309/ajg.0000000000001869</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Davern T.J., Chalasani N., Fontana R.J., Hayashi P.H., Protiva P., Kleiner D.E., et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141(5):1665– 72. DOI: 10.1053/j.gastro.2011.07.051</mixed-citation><mixed-citation xml:lang="en">Davern T.J., Chalasani N., Fontana R.J., Hayashi P.H., Protiva P., Kleiner D.E., et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141(5):1665– 72. DOI: 10.1053/j.gastro.2011.07.051</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson’s disease. J Hepatol. 2025;82(4):690–728. DOI: 10.1016/j.jhep.2024.11.007</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson’s disease. J Hepatol. 2025;82(4):690–728. DOI: 10.1016/j.jhep.2024.11.007</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479–502. DOI: 10.1016/j.jhep.2022.03.033</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479–502. DOI: 10.1016/j.jhep.2022.03.033</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. DOI: 10.1016/j.jhep.2017.03.022</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. DOI: 10.1016/j.jhep.2017.03.022</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Hu S., Zhao F., Wang Q., Chen W.X. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: A meta-analysis. Clin Chem Lab Med. 2014;52(11):1533–42. DOI: 10.1515/cclm-2013-0926</mixed-citation><mixed-citation xml:lang="en">Hu S., Zhao F., Wang Q., Chen W.X. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: A meta-analysis. Clin Chem Lab Med. 2014;52(11):1533–42. DOI: 10.1515/cclm-2013-0926</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Balcerac A., Bihan K., Lebrun-Vignes B., Thabut D., Salem J.E., Weiss N. Drug-associated hyperammonaemia: A Bayesian analysis of the WHO Pharmacovigilance Database. Ann Intensive Care. 2022;12(1):55. DOI: 10.1186/s13613-022-01026-4</mixed-citation><mixed-citation xml:lang="en">Balcerac A., Bihan K., Lebrun-Vignes B., Thabut D., Salem J.E., Weiss N. Drug-associated hyperammonaemia: A Bayesian analysis of the WHO Pharmacovigilance Database. Ann Intensive Care. 2022;12(1):55. DOI: 10.1186/s13613-022-01026-4</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Надинская М.Ю., Маевская М.В., Бакулин И.Г., Бессонова Е.Н., Буеверов А.О., Жаркова М.С. и др. Диагностическое и прогностическое значение гипераммониемии у пациентов с циррозом печени, печеночной энцефалопатией и саркопенией (соглашение специалистов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(1):85–100. DOI: 10.22416/13824376-2024-34-1-85-100</mixed-citation><mixed-citation xml:lang="en">Nadinskaia M.Yu., Maevskaya M.V., Bakulin I.G., Bessonova E.N., Bueverov A.O., Zharkova M.S., et al. Diagnostic and prognostic value of hyperammonemia in patients with liver cirrhosis, hepatic encephalopathy, and sarcopenia (Experts’ agreement). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(1):85–100. (In Russ.). DOI: 10.22416/13824376-2024-34-1-85-100</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Vakrinou A., Murphy E., Sisodiya S.M., Vivekananda U., Balestrini S. Risk factors and outcome of hyperammonaemia in people with epilepsy. J Neurol. 2022;269(12):6395–405. DOI: 10.1007/s00415-022-11304-7</mixed-citation><mixed-citation xml:lang="en">Vakrinou A., Murphy E., Sisodiya S.M., Vivekananda U., Balestrini S. Risk factors and outcome of hyperammonaemia in people with epilepsy. J Neurol. 2022;269(12):6395–405. DOI: 10.1007/s00415-022-11304-7</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Meier C., Burns K., Manolikos C., Fatovich D., Bell D.A. Hyperammonaemia: Review of the pathophysiology, aetiology and investigation. Pathology. 2024;56(6):763–72. DOI: 10.1016/j.pathol.2024.06.002</mixed-citation><mixed-citation xml:lang="en">Meier C., Burns K., Manolikos C., Fatovich D., Bell D.A. Hyperammonaemia: Review of the pathophysiology, aetiology and investigation. Pathology. 2024;56(6):763–72. DOI: 10.1016/j.pathol.2024.06.002</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Aitkenhead H. UK National audit of the measurement of ammonia. Ann Clin Biochem. 2023;60(2):117–25. DOI: 10.1177/00045632231152085</mixed-citation><mixed-citation xml:lang="en">Aitkenhead H. UK National audit of the measurement of ammonia. Ann Clin Biochem. 2023;60(2):117–25. DOI: 10.1177/00045632231152085</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">National Metabolic Biochemistry Network. Guidelines for the investigation of hyperammonaemia. 2023. URL: https://metbio.net/wp-content/uploads/MetBio-Guideline-PERE918546-10-12-2018.pdf</mixed-citation><mixed-citation xml:lang="en">National Metabolic Biochemistry Network. Guidelines for the investigation of hyperammonaemia. 2023. URL: https://metbio.net/wp-content/uploads/MetBio-Guideline-PERE918546-10-12-2018.pdf</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad J., Rossi S., Rodgers S.K., Ghabril M., Fontana R.J., Stolz A., et al. Sclerosing cholangitis-like changes on magnetic resonance cholangiography in patients with drug induced liver injury. Clin Gastroenterol Hepatol. 2019;17(4):789–90. DOI: 10.1016/j.cgh.2018.06.035</mixed-citation><mixed-citation xml:lang="en">Ahmad J., Rossi S., Rodgers S.K., Ghabril M., Fontana R.J., Stolz A., et al. Sclerosing cholangitis-like changes on magnetic resonance cholangiography in patients with drug induced liver injury. Clin Gastroenterol Hepatol. 2019;17(4):789–90. DOI: 10.1016/j.cgh.2018.06.035</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Grewal P., Ahmad J. Bile duct injury due to drug induced liver injury. Curr Hepatol Rep. 2019;18(3):269–73. DOI: 10.1007/s11901-019-00474-0</mixed-citation><mixed-citation xml:lang="en">Grewal P., Ahmad J. Bile duct injury due to drug induced liver injury. Curr Hepatol Rep. 2019;18(3):269–73. DOI: 10.1007/s11901-019-00474-0</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">De Castro V.L., Moura E.G., Chaves D.M., Bernardo W.M., Matuguma S.E., Artifon E.L. Endoscopic ultrasound versus magnetic resonance cholangiopancreatography in suspected choledocholithiasis: A systematic review. Endosc Ultrasound. 2016;5(2):118–28. DOI: 10.4103/23039027.180476</mixed-citation><mixed-citation xml:lang="en">De Castro V.L., Moura E.G., Chaves D.M., Bernardo W.M., Matuguma S.E., Artifon E.L. Endoscopic ultrasound versus magnetic resonance cholangiopancreatography in suspected choledocholithiasis: A systematic review. Endosc Ultrasound. 2016;5(2):118–28. DOI: 10.4103/23039027.180476</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed T., Ahmad J. Recent advances in the diagnosis of drug-induced liver injury. World J Hepatol. 2024;16(2):186–92. DOI: 10.4254/wjh.v16.i2.186</mixed-citation><mixed-citation xml:lang="en">Ahmed T., Ahmad J. Recent advances in the diagnosis of drug-induced liver injury. World J Hepatol. 2024;16(2):186–92. DOI: 10.4254/wjh.v16.i2.186</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Larrey D., Meunier L., Valla D., Hillaire S., Hernandez-Gea V., Dutheil D., et al. Drug induced liver injury and vascular liver disease. Clin Res Hepatol Gastroenterol. 2020;44(4):471–9. DOI: 10.1016/j.clinre.2020.03.020</mixed-citation><mixed-citation xml:lang="en">Larrey D., Meunier L., Valla D., Hillaire S., Hernandez-Gea V., Dutheil D., et al. Drug induced liver injury and vascular liver disease. Clin Res Hepatol Gastroenterol. 2020;44(4):471–9. DOI: 10.1016/j.clinre.2020.03.020</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Del Carmen Manzano-Robleda M., Barranco-Fragoso B., Uribe M., Méndez-Sánchez N. Portal vein thrombosis: what is new? Ann Hepatol. 2015;14(1):20–7.</mixed-citation><mixed-citation xml:lang="en">Del Carmen Manzano-Robleda M., Barranco-Fragoso B., Uribe M., Méndez-Sánchez N. Portal vein thrombosis: what is new? Ann Hepatol. 2015;14(1):20–7.</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Park S.H., Choe J.Y., Kim S.K. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine. 2010;77(6):588–92. DOI: 10.1016/j.jbspin.2010.02.024</mixed-citation><mixed-citation xml:lang="en">Park S.H., Choe J.Y., Kim S.K. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine. 2010;77(6):588–92. DOI: 10.1016/j.jbspin.2010.02.024</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">Berends M.A., Snoek J., de Jong E.M., Van Krieken J.H., de Knegt R.J., van Oijen M.G., et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int. 2007;27(5):639–45. DOI: 10.1111/j.1478-3231.2007.01489.x</mixed-citation><mixed-citation xml:lang="en">Berends M.A., Snoek J., de Jong E.M., Van Krieken J.H., de Knegt R.J., van Oijen M.G., et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int. 2007;27(5):639–45. DOI: 10.1111/j.1478-3231.2007.01489.x</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Crespo G., Fernández-Varo G., Mariño Z., Casals G., Miquel R., Martínez S.M., et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: A prospective study. J Hepatol. 2012;57(2):281–7. DOI: 10.1016/j.jhep.2012.03.016</mixed-citation><mixed-citation xml:lang="en">Crespo G., Fernández-Varo G., Mariño Z., Casals G., Miquel R., Martínez S.M., et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: A prospective study. J Hepatol. 2012;57(2):281–7. DOI: 10.1016/j.jhep.2012.03.016</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Atallah E., Grove J.I., Crooks C., Burden-Teh E., Abhishek A., Moreea S., et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol. 2023;78(5):989–97. DOI: 10.1016/j.jhep.2022.12.034</mixed-citation><mixed-citation xml:lang="en">Atallah E., Grove J.I., Crooks C., Burden-Teh E., Abhishek A., Moreea S., et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol. 2023;78(5):989–97. DOI: 10.1016/j.jhep.2022.12.034</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">Özkan S.G., Pata C., Şekuri A., Çınar Y., Özkan H.A. Transient elastography of liver: Could it be a guide for diagnosis and management strategy in hepatic veno-occlusive disease (sinusoidal obstruction syndrome)? Transfus Apher Sci. 2022;61(1):103370. DOI: 10.1016/j.transci.2022.103370</mixed-citation><mixed-citation xml:lang="en">Özkan S.G., Pata C., Şekuri A., Çınar Y., Özkan H.A. Transient elastography of liver: Could it be a guide for diagnosis and management strategy in hepatic veno-occlusive disease (sinusoidal obstruction syndrome)? Transfus Apher Sci. 2022;61(1):103370. DOI: 10.1016/j.transci.2022.103370</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad J., Barnhart H.X., Bonacini M., Ghabril M., Hayashi P.H., Odin J.A., et al.; Drug-Induced Liver Injury Network. Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol. 2022;76(5):1070– 8. DOI: 10.1016/j.jhep.2021.12.043</mixed-citation><mixed-citation xml:lang="en">Ahmad J., Barnhart H.X., Bonacini M., Ghabril M., Hayashi P.H., Odin J.A., et al.; Drug-Induced Liver Injury Network. Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol. 2022;76(5):1070– 8. DOI: 10.1016/j.jhep.2021.12.043</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">Chalasani N.P., Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J.; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66. DOI: 10.1038/ajg.2014.131</mixed-citation><mixed-citation xml:lang="en">Chalasani N.P., Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J.; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66. DOI: 10.1038/ajg.2014.131</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">Kleiner D.E. Role of liver biopsy in the management of idiosyncratic DILI. Liver Int. 2025;45(3):e16097. DOI: 10.1111/liv.16097</mixed-citation><mixed-citation xml:lang="en">Kleiner D.E. Role of liver biopsy in the management of idiosyncratic DILI. Liver Int. 2025;45(3):e16097. DOI: 10.1111/liv.16097</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">Danan G., Teschke R. RUCAM in drug and herb induced liver injury: The Update. Int J Mol Sci. 2015;17(1):14. DOI: 10.3390/ijms17010014</mixed-citation><mixed-citation xml:lang="en">Danan G., Teschke R. RUCAM in drug and herb induced liver injury: The Update. Int J Mol Sci. 2015;17(1):14. DOI: 10.3390/ijms17010014</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">García-Cortés M., Stephens C., Lucena M.I., Fernández-Castañer A., Andrade R.J. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J Hepatol. 2011;55(3):683–91. DOI: 10.1016/j.jhep.2011.02.007</mixed-citation><mixed-citation xml:lang="en">García-Cortés M., Stephens C., Lucena M.I., Fernández-Castañer A., Andrade R.J. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J Hepatol. 2011;55(3):683–91. DOI: 10.1016/j.jhep.2011.02.007</mixed-citation></citation-alternatives></ref><ref id="cit149"><label>149</label><citation-alternatives><mixed-citation xml:lang="ru">Teschke R., Wolff A., Frenzel C., Schwarzenboeck A., Schulze J., Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol. 2014;6(1):17–32. DOI: 10.4254/wjh.v6.i1.17</mixed-citation><mixed-citation xml:lang="en">Teschke R., Wolff A., Frenzel C., Schwarzenboeck A., Schulze J., Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol. 2014;6(1):17–32. DOI: 10.4254/wjh.v6.i1.17</mixed-citation></citation-alternatives></ref><ref id="cit150"><label>150</label><citation-alternatives><mixed-citation xml:lang="ru">Teschke R., Eickhoff A., Schulze J. Drug- and herb-induced liver injury in clinical and translational hepatology: Causality assessment methods, quo vadis? J Clin Transl Hepatol. 2013;1(1):59–74. DOI: 10.14218/JCTH.2013.D002X</mixed-citation><mixed-citation xml:lang="en">Teschke R., Eickhoff A., Schulze J. Drug- and herb-induced liver injury in clinical and translational hepatology: Causality assessment methods, quo vadis? J Clin Transl Hepatol. 2013;1(1):59–74. DOI: 10.14218/JCTH.2013.D002X</mixed-citation></citation-alternatives></ref><ref id="cit151"><label>151</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashi P.H., Lucena M.I., Fontana R.J., Bjornsson E.S., Aithal G.P., Barnhart H., et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76(1):18–31. DOI: 10.1002/hep.32327</mixed-citation><mixed-citation xml:lang="en">Hayashi P.H., Lucena M.I., Fontana R.J., Bjornsson E.S., Aithal G.P., Barnhart H., et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76(1):18–31. DOI: 10.1002/hep.32327</mixed-citation></citation-alternatives></ref><ref id="cit152"><label>152</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao X., Wang Y., Lai R., Wang X., Yu Y., Li M., et al. Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients. Hepatol Commun. 2024;8(4):e0235. DOI: 10.1097/HC9.0000000000000235</mixed-citation><mixed-citation xml:lang="en">Zhao X., Wang Y., Lai R., Wang X., Yu Y., Li M., et al. Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients. Hepatol Commun. 2024;8(4):e0235. DOI: 10.1097/HC9.0000000000000235</mixed-citation></citation-alternatives></ref><ref id="cit153"><label>153</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashi P.H., Fontana R.J. Clinical features, diagnosis and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–44. DOI: 10.1055/s-0034-1375955</mixed-citation><mixed-citation xml:lang="en">Hayashi P.H., Fontana R.J. Clinical features, diagnosis and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–44. DOI: 10.1055/s-0034-1375955</mixed-citation></citation-alternatives></ref><ref id="cit154"><label>154</label><citation-alternatives><mixed-citation xml:lang="ru">Lucena M., Camargo R., Andrade R.J., Perez-Sanchez C.J., De LaCuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123–30. DOI: 10.1053/jhep.2001.20645</mixed-citation><mixed-citation xml:lang="en">Lucena M., Camargo R., Andrade R.J., Perez-Sanchez C.J., De LaCuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123–30. DOI: 10.1053/jhep.2001.20645</mixed-citation></citation-alternatives></ref><ref id="cit155"><label>155</label><citation-alternatives><mixed-citation xml:lang="ru">Takikawa H., Takamori Y., Kumagi T., Onji M., Watanabe M., Shibuya A., et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the international consensus meeting. Hepatol Res. 2003;27(3):192–5. DOI: 10.1016/s1386-6346(03)00232-8</mixed-citation><mixed-citation xml:lang="en">Takikawa H., Takamori Y., Kumagi T., Onji M., Watanabe M., Shibuya A., et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the international consensus meeting. Hepatol Res. 2003;27(3):192–5. DOI: 10.1016/s1386-6346(03)00232-8</mixed-citation></citation-alternatives></ref><ref id="cit156"><label>156</label><citation-alternatives><mixed-citation xml:lang="ru">Teschke R., Danan G. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993 — mid 2020: A comprehensive analysis. Medicines (Basel). 2020;7(10):62. DOI: 10.3390/medicines7100062</mixed-citation><mixed-citation xml:lang="en">Teschke R., Danan G. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993 — mid 2020: A comprehensive analysis. Medicines (Basel). 2020;7(10):62. DOI: 10.3390/medicines7100062</mixed-citation></citation-alternatives></ref><ref id="cit157"><label>157</label><citation-alternatives><mixed-citation xml:lang="ru">Teschke R., Frenzel C., Schulze J., Eickhoff A. Herbal hepatotoxicity: Challenges and pitfalls of causality assessment methods. World J Gastroenterol. 2013;19(19):2864– 82. DOI: 10.3748/wjg.v19.i19.2864</mixed-citation><mixed-citation xml:lang="en">Teschke R., Frenzel C., Schulze J., Eickhoff A. Herbal hepatotoxicity: Challenges and pitfalls of causality assessment methods. World J Gastroenterol. 2013;19(19):2864– 82. DOI: 10.3748/wjg.v19.i19.2864</mixed-citation></citation-alternatives></ref><ref id="cit158"><label>158</label><citation-alternatives><mixed-citation xml:lang="ru">Fontana R.J., Avigan M.I., Janssen H.L.A., Regev A., Mishra P., Gaggar A., et al. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. J Viral Hep. 2020;27(2):96–109. DOI: 10.1111/jvh.13223</mixed-citation><mixed-citation xml:lang="en">Fontana R.J., Avigan M.I., Janssen H.L.A., Regev A., Mishra P., Gaggar A., et al. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. J Viral Hep. 2020;27(2):96–109. DOI: 10.1111/jvh.13223</mixed-citation></citation-alternatives></ref><ref id="cit159"><label>159</label><citation-alternatives><mixed-citation xml:lang="ru">Regev A., Seeff L.B., Merz M., Ormarsdottir S., Aithal G.P., Gallivan J., et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37(Suppl. 1):S47–56. DOI: 10.1007/s40264-014-0185-4</mixed-citation><mixed-citation xml:lang="en">Regev A., Seeff L.B., Merz M., Ormarsdottir S., Aithal G.P., Gallivan J., et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37(Suppl. 1):S47–56. DOI: 10.1007/s40264-014-0185-4</mixed-citation></citation-alternatives></ref><ref id="cit160"><label>160</label><citation-alternatives><mixed-citation xml:lang="ru">Rochon J., Protiva P., Seeff L.B., Fontana R.J., Liang-punsakul S., Watkins P.B., et al.; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology. 2008;48(4):1175–83. DOI: 10.1002/hep.22442</mixed-citation><mixed-citation xml:lang="en">Rochon J., Protiva P., Seeff L.B., Fontana R.J., Liang-punsakul S., Watkins P.B., et al.; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology. 2008;48(4):1175–83. DOI: 10.1002/hep.22442</mixed-citation></citation-alternatives></ref><ref id="cit161"><label>161</label><citation-alternatives><mixed-citation xml:lang="ru">Thakkar S., Li T., Liu Z., Wu L., Roberts R., Tong W. Drug-induced liver injury severity and toxicity (DILIst): Binary classification of 1279 drugs by human hepatotoxicity. Drug Discov Today. 2020;25(1):201–8. DOI: 10.1016/j.drudis.2019.09.022</mixed-citation><mixed-citation xml:lang="en">Thakkar S., Li T., Liu Z., Wu L., Roberts R., Tong W. Drug-induced liver injury severity and toxicity (DILIst): Binary classification of 1279 drugs by human hepatotoxicity. Drug Discov Today. 2020;25(1):201–8. DOI: 10.1016/j.drudis.2019.09.022</mixed-citation></citation-alternatives></ref><ref id="cit162"><label>162</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022;97:26–31. DOI: 10.1016/j.ejim.2021.10.035</mixed-citation><mixed-citation xml:lang="en">Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022;97:26–31. DOI: 10.1016/j.ejim.2021.10.035</mixed-citation></citation-alternatives></ref><ref id="cit163"><label>163</label><citation-alternatives><mixed-citation xml:lang="ru">Tillmann H.L., Suzuki A., Barnhart H.X., Serrano J., Rockey D.C. Tools for causality assessment in drug-induced liver disease. Curr Opin Gastroenterol. 2019;35(3):183–90. DOI: 10.1097/MOG.0000000000000526</mixed-citation><mixed-citation xml:lang="en">Tillmann H.L., Suzuki A., Barnhart H.X., Serrano J., Rockey D.C. Tools for causality assessment in drug-induced liver disease. Curr Opin Gastroenterol. 2019;35(3):183– 90. DOI: 10.1097/MOG.0000000000000526</mixed-citation></citation-alternatives></ref><ref id="cit164"><label>164</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashi P.H., Barnhart H.X., Fontana R.J., Chalasani N., Davern T.J., Talwalkar J.A., et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the drug-induced liver injury network (DILIN). Liver Int. 2015;35(5):1623–32. DOI: 10.1111/liv.12540</mixed-citation><mixed-citation xml:lang="en">Hayashi P.H., Barnhart H.X., Fontana R.J., Chalasani N., Davern T.J., Talwalkar J.A., et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the drug-induced liver injury network (DILIN). Liver Int. 2015;35(5):1623–32. DOI: 10.1111/liv.12540</mixed-citation></citation-alternatives></ref><ref id="cit165"><label>165</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng G., Eslick G.D., Weltman M. Systematic review and meta-analysis: Comparing hepatocellular and cholestatic patterns of drug-induced liver injury. ILIVER. 2023;2(2):122–9. DOI: 10.1016/j.iliver.2023.05.002</mixed-citation><mixed-citation xml:lang="en">Zeng G., Eslick G.D., Weltman M. Systematic review and meta-analysis: Comparing hepatocellular and cholestatic patterns of drug-induced liver injury. ILIVER. 2023;2(2):122–9. DOI: 10.1016/j.iliver.2023.05.002</mixed-citation></citation-alternatives></ref><ref id="cit166"><label>166</label><citation-alternatives><mixed-citation xml:lang="ru">Fontana R.J., Hayashi P.H., Gu J., Reddy K.R., Barnhart H., Watkins P.B., et al.; DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108.e4. DOI: 10.1053/j.gastro.2014.03.045</mixed-citation><mixed-citation xml:lang="en">Fontana R.J., Hayashi P.H., Gu J., Reddy K.R., Barnhart H., Watkins P.B., et al.; DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108.e4. DOI: 10.1053/j.gastro.2014.03.045</mixed-citation></citation-alternatives></ref><ref id="cit167"><label>167</label><citation-alternatives><mixed-citation xml:lang="ru">Ghabril M., Gu J., Yoder L., Corbito L., Ringel A., Beyer C.D., et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(5):1245–52.e3. DOI: 10.1053/j.gastro.2019.07.006</mixed-citation><mixed-citation xml:lang="en">Ghabril M., Gu J., Yoder L., Corbito L., Ringel A., Beyer C.D., et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(5):1245–52.e3. DOI: 10.1053/j.gastro.2019.07.006</mixed-citation></citation-alternatives></ref><ref id="cit168"><label>168</label><citation-alternatives><mixed-citation xml:lang="ru">Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., et al.; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–34. DOI: 10.1053/j.gastro.2008.09.011</mixed-citation><mixed-citation xml:lang="en">Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., et al.; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–34. DOI: 10.1053/j.gastro.2008.09.011</mixed-citation></citation-alternatives></ref><ref id="cit169"><label>169</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9. DOI: 10.1002/hep.20800</mixed-citation><mixed-citation xml:lang="en">Björnsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9. DOI: 10.1002/hep.20800</mixed-citation></citation-alternatives></ref><ref id="cit170"><label>170</label><citation-alternatives><mixed-citation xml:lang="ru">Zimmerman H.J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts; 1978:351–5.</mixed-citation><mixed-citation xml:lang="en">Zimmerman H.J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts; 1978:351–5.</mixed-citation></citation-alternatives></ref><ref id="cit171"><label>171</label><citation-alternatives><mixed-citation xml:lang="ru">Jiménez M., Rodrigo L., Romero-Gomez M., Navarro J.M., Planas R., Costa J., et al.; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21. DOI: 10.1016/j.gastro.2005.05.006</mixed-citation><mixed-citation xml:lang="en">Jiménez M., Rodrigo L., Romero-Gomez M., Navarro J.M., Planas R., Costa J., et al.; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21. DOI: 10.1016/j.gastro.2005.05.006</mixed-citation></citation-alternatives></ref><ref id="cit172"><label>172</label><citation-alternatives><mixed-citation xml:lang="ru">Lo Re V. 3rd, Haynes K., Forde K.A., Goldberg D.S., Lewis J.D., Carbonari D.M., et al. Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of Hy’s law and a new prognostic model. Clin Gastroenterol Hepatol. 2015;13(13):2360–8. DOI: 10.1016/j.cgh.2015.06.020</mixed-citation><mixed-citation xml:lang="en">Lo Re V. 3rd, Haynes K., Forde K.A., Goldberg D.S., Lewis J.D., Carbonari D.M., et al. Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of Hy’s law and a new prognostic model. Clin Gastroenterol Hepatol. 2015;13(13):2360–8. DOI: 10.1016/j.cgh.2015.06.020</mixed-citation></citation-alternatives></ref><ref id="cit173"><label>173</label><citation-alternatives><mixed-citation xml:lang="ru">Robles-Diaz M., Lucena M.I., Kaplowitz N., Stephens C., Medina-Cáliz I., González-Jimenez A., et al.; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-based Translation Consortium. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109–18.e5. DOI: 10.1053/j.gastro.2014.03.050</mixed-citation><mixed-citation xml:lang="en">Robles-Diaz M., Lucena M.I., Kaplowitz N., Stephens C., Medina-Cáliz I., González-Jimenez A., et al.; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-based Translation Consortium. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109–18.e5. DOI: 10.1053/j.gastro.2014.03.050</mixed-citation></citation-alternatives></ref><ref id="cit174"><label>174</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Zou C.L., Zhang J., Qiu L.X., Huang Y.F., Zhao X.Y., et al. Development and validation of a novel model to predict liver-related mortality in patients with idiosyncratic drug-induced liver injury. Hepatobiliary Pancreat Dis Int. 2023;22(6):584–93. DOI: 10.1016/j.hbpd.2023.06.002</mixed-citation><mixed-citation xml:lang="en">Wang Y., Zou C.L., Zhang J., Qiu L.X., Huang Y.F., Zhao X.Y., et al. Development and validation of a novel model to predict liver-related mortality in patients with idiosyncratic drug-induced liver injury. Hepatobiliary Pancreat Dis Int. 2023;22(6):584–93. DOI: 10.1016/j.hbpd.2023.06.002</mixed-citation></citation-alternatives></ref><ref id="cit175"><label>175</label><citation-alternatives><mixed-citation xml:lang="ru">Xiong X., Xu Q., Wang B. A retrospective study to evaluate Hy’s law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver injury. Expert Opin Drug Saf. 2024;23(2):207–11. DOI: 10.1080/14740338.2023.2195624</mixed-citation><mixed-citation xml:lang="en">Xiong X., Xu Q., Wang B. A retrospective study to evaluate Hy’s law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver injury. Expert Opin Drug Saf. 2024;23(2):207–11. DOI: 10.1080/14740338.2023.2195624</mixed-citation></citation-alternatives></ref><ref id="cit176"><label>176</label><citation-alternatives><mixed-citation xml:lang="ru">Han L., Huang A., Chen J., Teng G., Sun Y., Chang B., et al. Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: A large multicenter cohort study. Hepatol Int. 2024;18(1):225–37. DOI: 10.1007/s12072-023-10541-w</mixed-citation><mixed-citation xml:lang="en">Han L., Huang A., Chen J., Teng G., Sun Y., Chang B., et al. Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: A large multicenter cohort study. Hepatol Int. 2024;18(1):225–37. DOI: 10.1007/s12072-023-10541-w</mixed-citation></citation-alternatives></ref><ref id="cit177"><label>177</label><citation-alternatives><mixed-citation xml:lang="ru">Ghabril M., Gu J., Yoder L., Corbito L., Ringel A., Beyer C.D., et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(5):1245–52.e3. DOI: 10.1053/j.gastro.2019.07.006</mixed-citation><mixed-citation xml:lang="en">Ghabril M., Gu J., Yoder L., Corbito L., Ringel A., Beyer C.D., et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(5):1245–52.e3. DOI: 10.1053/j.gastro.2019.07.006</mixed-citation></citation-alternatives></ref><ref id="cit178"><label>178</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Zou C., Wee A., Liu J., Ma Z., Guo T., et al. Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury. Hepatol Int. 2023;17(2):488–98. DOI: 10.1007/s12072-022-10405-9</mixed-citation><mixed-citation xml:lang="en">Wang Y., Zou C., Wee A., Liu J., Ma Z., Guo T., et al. Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury. Hepatol Int. 2023;17(2):488–98. DOI: 10.1007/s12072-022-10405-9</mixed-citation></citation-alternatives></ref><ref id="cit179"><label>179</label><citation-alternatives><mixed-citation xml:lang="ru">McPhail M.J., Farne H., Senvar N., Wendon J.A., Bernal W. Ability of King’s College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: A meta-analysis. Clin Gastroenterol Hepatol. 2016;14(4):516–25.e5. DOI: 10.1016/j.cgh.2015.10.007</mixed-citation><mixed-citation xml:lang="en">McPhail M.J., Farne H., Senvar N., Wendon J.A., Bernal W. Ability of King’s College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: A meta-analysis. Clin Gastroenterol Hepatol. 2016;14(4):516–25.e5. DOI: 10.1016/j.cgh.2015.10.007</mixed-citation></citation-alternatives></ref><ref id="cit180"><label>180</label><citation-alternatives><mixed-citation xml:lang="ru">Devarbhavi H., Patil M., Reddy V.V., Singh R., Joseph T., Ganga D. Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. Liver Int. 2018;38(7):1322–9. DOI: 10.1111/liv.13662</mixed-citation><mixed-citation xml:lang="en">Devarbhavi H., Patil M., Reddy V.V., Singh R., Joseph T., Ganga D. Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. Liver Int. 2018;38(7):1322–9. DOI: 10.1111/liv.13662</mixed-citation></citation-alternatives></ref><ref id="cit181"><label>181</label><citation-alternatives><mixed-citation xml:lang="ru">Church R.J., Kullak-Ublick G.A., Aubrecht J., Bonkovsky H.L., Chalasani N., Fontana R.J., et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology. 2019;69(2):760–73. DOI: 10.1002/hep.29802</mixed-citation><mixed-citation xml:lang="en">Church R.J., Kullak-Ublick G.A., Aubrecht J., Bonkovsky H.L., Chalasani N., Fontana R.J., et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology. 2019;69(2):760–73. DOI: 10.1002/hep.29802</mixed-citation></citation-alternatives></ref><ref id="cit182"><label>182</label><citation-alternatives><mixed-citation xml:lang="ru">Koch D.G., Tillman H., Durkalski V., Lee W.M., Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14(8):1199–206.e2. DOI: 10.1016/j.cgh.2016.03.046</mixed-citation><mixed-citation xml:lang="en">Koch D.G., Tillman H., Durkalski V., Lee W.M., Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14(8):1199–206.e2. DOI: 10.1016/j.cgh.2016.03.046</mixed-citation></citation-alternatives></ref><ref id="cit183"><label>183</label><citation-alternatives><mixed-citation xml:lang="ru">Stravitz R.T., Lee W.M. Acute liver failure. Lancet. 2019;394(10201):869–81. DOI: 10.1016/S0140-6736(19)31894-X</mixed-citation><mixed-citation xml:lang="en">Stravitz R.T., Lee W.M. Acute liver failure. Lancet. 2019;394(10201):869–81. DOI: 10.1016/S0140-6736(19)31894-X</mixed-citation></citation-alternatives></ref><ref id="cit184"><label>184</label><citation-alternatives><mixed-citation xml:lang="ru">O’Grady J.G., Alexander G.J., Hayllar K.M., Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439–45. DOI: 10.1016/0016-5085(89)90081-4</mixed-citation><mixed-citation xml:lang="en">O’Grady J.G., Alexander G.J., Hayllar K.M., Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439–45. DOI: 10.1016/0016-5085(89)90081-4</mixed-citation></citation-alternatives></ref><ref id="cit185"><label>185</label><citation-alternatives><mixed-citation xml:lang="ru">Panackel C., Raja K., Fawas M., Jacob M. Prognostic models in acute liver failure-historic evolution and newer updates “prognostic models in acute liver failure”. Best Pract Res Clin Gastroenterol. 2024;73:101957. DOI: 10.1016/j.bpg.2024.101957</mixed-citation><mixed-citation xml:lang="en">Panackel C., Raja K., Fawas M., Jacob M. Prognostic models in acute liver failure-historic evolution and newer updates “prognostic models in acute liver failure”. Best Pract Res Clin Gastroenterol. 2024;73:101957. DOI: 10.1016/j.bpg.2024.101957</mixed-citation></citation-alternatives></ref><ref id="cit186"><label>186</label><citation-alternatives><mixed-citation xml:lang="ru">McPhail M.J., Wendon J.A., Bernal W. Meta-analysis of performance of Kings’s College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol. 2010;53(3):492–9. DOI: 10.1016/j.jhep.2010.03.023</mixed-citation><mixed-citation xml:lang="en">McPhail M.J., Wendon J.A., Bernal W. Meta-analysis of performance of Kings’s College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol. 2010;53(3):492–9. DOI: 10.1016/j.jhep.2010.03.023</mixed-citation></citation-alternatives></ref><ref id="cit187"><label>187</label><citation-alternatives><mixed-citation xml:lang="ru">Лазебник Л.Б., Голованова Е.В., Хлынова О.В., Алексеенко С.А., Арямкина О.Л., Бакулин И.Г. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29–54. DOI: 10.31146/1682-8658-ecg-174-2-29-54</mixed-citation><mixed-citation xml:lang="en">Lazebnik L.B., Golovanova E.V., Hlynova O.V., Alekseenko S.A., Aryamkina O.I., Bakulin I.G., et al. Medicinal liver damage in adults. Experimental and Clinical Gastroenterology. 2020;174(2):29– 54. (In Russ.). DOI: 10.31146/1682-8658-ecg-174-2-29-54</mixed-citation></citation-alternatives></ref><ref id="cit188"><label>188</label><citation-alternatives><mixed-citation xml:lang="ru">M’Kada H., Perazzo H., Munteanu M., Ngo Y., Ramanujam N., Fautrel B., et al.; Drug Induced Liver Injury Groupe Hospitalier Pitié-Salpêtrière Group; Safer and Faster Evidence-based Translation Consortium. Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: A prospective pilot cohort study. PLoS ONE. 2012;7(8):e42418. DOI: 10.1371/journal.pone.0042418</mixed-citation><mixed-citation xml:lang="en">M’Kada H., Perazzo H., Munteanu M., Ngo Y., Ramanujam N., Fautrel B., et al.; Drug Induced Liver Injury Groupe Hospitalier Pitié-Salpêtrière Group; Safer and Faster Evidence-based Translation Consortium. Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: A prospective pilot cohort study. PLoS ONE. 2012;7(8):e42418. DOI: 10.1371/journal.pone.0042418</mixed-citation></citation-alternatives></ref><ref id="cit189"><label>189</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis J.H. ‘Hy’s law,’ the ‘Rezulin Rule,’ and other predictors of severe drug-induced hepatotoxicity: Putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf. 2006;15(4):221–9. DOI: 10.1002/pds.1209</mixed-citation><mixed-citation xml:lang="en">Lewis J.H. ‘Hy’s law,’ the ‘Rezulin Rule,’ and other predictors of severe drug-induced hepatotoxicity: Putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf. 2006;15(4):221–9. DOI: 10.1002/pds.1209</mixed-citation></citation-alternatives></ref><ref id="cit190"><label>190</label><citation-alternatives><mixed-citation xml:lang="ru">Dara L., Liu Z.X., Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36(2):158–65. DOI: 10.1111/liv.12988</mixed-citation><mixed-citation xml:lang="en">Dara L., Liu Z.X., Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36(2):158–65. DOI: 10.1111/liv.12988</mixed-citation></citation-alternatives></ref><ref id="cit191"><label>191</label><citation-alternatives><mixed-citation xml:lang="ru">Pratt D.S., Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266–71. DOI: 10.1056/nejm200004273421707</mixed-citation><mixed-citation xml:lang="en">Pratt D.S., Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266–71. DOI: 10.1056/nejm200004273421707</mixed-citation></citation-alternatives></ref><ref id="cit192"><label>192</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis J.H. The adaptive response (drug tolerance) helps to prevent drug-induced liver injury. Gastroenterol Hepatol (N Y). 2012;8(5):333–336.</mixed-citation><mixed-citation xml:lang="en">Lewis J.H. The adaptive response (drug tolerance) helps to prevent drug-induced liver injury. Gastroenterol Hepatol (N Y). 2012;8(5):333–336.</mixed-citation></citation-alternatives></ref><ref id="cit193"><label>193</label><citation-alternatives><mixed-citation xml:lang="ru">Singhal R., Harrill A.H., Menguy-Vacheron F., Jayyosi Z., Benzerdjeb H., Watkins P.B. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol. 2014;15:42. DOI: 10.1186/2050-6511-15-42</mixed-citation><mixed-citation xml:lang="en">Singhal R., Harrill A.H., Menguy-Vacheron F., Jayyosi Z., Benzerdjeb H., Watkins P.B. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol. 2014;15:42. DOI: 10.1186/2050-6511-15-42</mixed-citation></citation-alternatives></ref><ref id="cit194"><label>194</label><citation-alternatives><mixed-citation xml:lang="ru">FDA. Clinical white paper. 2000. URL: http://www.fda.gov/cder/livertox/clinical.pdf</mixed-citation><mixed-citation xml:lang="en">FDA. Clinical white paper. 2000. URL: http://www.fda.gov/cder/livertox/clinical.pdf</mixed-citation></citation-alternatives></ref><ref id="cit195"><label>195</label><citation-alternatives><mixed-citation xml:lang="ru">Arora N., Goldhaber S.Z. Anticoagulants and transaminase elevation. Circulation. 2006;113(15):e698–702. DOI: 10.1161/CIRCULATIONAHA.105.603100</mixed-citation><mixed-citation xml:lang="en">Arora N., Goldhaber S.Z. Anticoagulants and transaminase elevation. Circulation. 2006;113(15):e698–702. DOI: 10.1161/CIRCULATIONAHA.105.603100</mixed-citation></citation-alternatives></ref><ref id="cit196"><label>196</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis J.H., Khaldoyanidi S.K., Britten C.D., Wei A.H., Subklewe M. Clinical significance of transient asymptomatic elevations in aminotransferase (TAEAT) in oncology. Am J Clin Oncol. 2022;45(8):352–65. DOI: 10.1097/COC.0000000000000932</mixed-citation><mixed-citation xml:lang="en">Lewis J.H., Khaldoyanidi S.K., Britten C.D., Wei A.H., Subklewe M. Clinical significance of transient asymptomatic elevations in aminotransferase (TAEAT) in oncology. Am J Clin Oncol. 2022;45(8):352–65. DOI: 10.1097/COC.0000000000000932</mixed-citation></citation-alternatives></ref><ref id="cit197"><label>197</label><citation-alternatives><mixed-citation xml:lang="ru">FDA. Guidance for industry: Drug-induced liver injury: premarketing clinical evaluation. 2009. URL: https://www.fda.gov/media/116737/download</mixed-citation><mixed-citation xml:lang="en">FDA. Guidance for industry: Drug-induced liver injury: premarketing clinical evaluation. 2009. URL: https://www.fda.gov/media/116737/download</mixed-citation></citation-alternatives></ref><ref id="cit198"><label>198</label><citation-alternatives><mixed-citation xml:lang="ru">Ткаченко П.Е., Маевская М.В., Ивашкин В.Т. Гепатотоксичность. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2024;14(3s2):83–96. DOI: 10.18027/2224-5057-2024-14-3s2-2-05</mixed-citation><mixed-citation xml:lang="en">Tkachenko P.E., Maevskaya M.V., Ivashkin V.T. Hepatotoxicity. RUSSCO practical recommendations, Part 2. Malignant Tumors. 2024;14(3s2):83–96. (In Russ.). DOI: 10.18027/2224-5057-2024-14-3s2-2-05</mixed-citation></citation-alternatives></ref><ref id="cit199"><label>199</label><citation-alternatives><mixed-citation xml:lang="ru">Viganò M., La Milia M., Grassini M.V., Pugliese N., De Giorgio M., Fagiuoli S. Hepatotoxicity of small molecule protein kinase inhibitors for cancer. Cancers (Basel). 2023;15(6):1766. DOI: 10.3390/cancers15061766</mixed-citation><mixed-citation xml:lang="en">Viganò M., La Milia M., Grassini M.V., Pugliese N., De Giorgio M., Fagiuoli S. Hepatotoxicity of small molecule protein kinase inhibitors for cancer. Cancers (Basel). 2023;15(6):1766. DOI: 10.3390/cancers15061766</mixed-citation></citation-alternatives></ref><ref id="cit200"><label>200</label><citation-alternatives><mixed-citation xml:lang="ru">Минздрав РФ. Государственный реестр лекарственных средств (ГРЛС). URL: http://grls.rosminzdrav.ru</mixed-citation><mixed-citation xml:lang="en">Минздрав РФ. Государственный реестр лекарственных средств (ГРЛС). URL: http://grls.rosminzdrav.ru</mixed-citation></citation-alternatives></ref><ref id="cit201"><label>201</label><citation-alternatives><mixed-citation xml:lang="ru">Минздрав РФ. Рубрикатор клинических рекомендаций. URL: https://cr.minzdrav.gov.ru</mixed-citation><mixed-citation xml:lang="en">Минздрав РФ. Рубрикатор клинических рекомендаций. URL: https://cr.minzdrav.gov.ru</mixed-citation></citation-alternatives></ref><ref id="cit202"><label>202</label><citation-alternatives><mixed-citation xml:lang="ru">Cunningham M., Gupta R., Butler M. Checkpoint inhibitor hepatotoxicity: Pathogenesis and management. Hepatology. 2024;79(1):198–212. DOI: 10.1097/HEP.0000000000000045</mixed-citation><mixed-citation xml:lang="en">Cunningham M., Gupta R., Butler M. Checkpoint inhibitor hepatotoxicity: Pathogenesis and management. Hepatology. 2024;79(1):198–212. DOI: 10.1097/HEP.0000000000000045</mixed-citation></citation-alternatives></ref><ref id="cit203"><label>203</label><citation-alternatives><mixed-citation xml:lang="ru">Peeraphatdit T.B., Wang J., Odenwald M.A., Hu S., Hart J., Charlton M.R. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology. 2020;72(1):315–29. DOI: 10.1002/hep.31227</mixed-citation><mixed-citation xml:lang="en">Peeraphatdit T.B., Wang J., Odenwald M.A., Hu S., Hart J., Charlton M.R. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology. 2020;72(1):315–29. DOI: 10.1002/hep.31227</mixed-citation></citation-alternatives></ref><ref id="cit204"><label>204</label><citation-alternatives><mixed-citation xml:lang="ru">Huffman B.M., Kottschade L.A., Kamath P.S., Markovic S.N. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: Natural progression and management. Am J Clin Oncol. 2018;41(8):760–5. DOI: 10.1097/COC.0000000000000374</mixed-citation><mixed-citation xml:lang="en">Huffman B.M., Kottschade L.A., Kamath P.S., Markovic S.N. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: Natural progression and management. Am J Clin Oncol. 2018;41(8):760–5. DOI: 10.1097/COC.0000000000000374</mixed-citation></citation-alternatives></ref><ref id="cit205"><label>205</label><citation-alternatives><mixed-citation xml:lang="ru">Riveiro-Barciela M., Barreira-Díaz A., Callejo-Pérez A., Muñoz-Couselo E., Díaz-Mejía N., Díaz-González Á., et al. Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study. Clin Gastroenterol Hepatol. 2023;21(3):732–40. DOI: 10.1016/j.cgh.2022.03.050</mixed-citation><mixed-citation xml:lang="en">Riveiro-Barciela M., Barreira-Díaz A., Callejo-Pérez A., Muñoz-Couselo E., Díaz-Mejía N., Díaz-González Á., et al. Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study. Clin Gastroenterol Hepatol. 2023;21(3):732–40. DOI: 10.1016/j.cgh.2022.03.050</mixed-citation></citation-alternatives></ref><ref id="cit206"><label>206</label><citation-alternatives><mixed-citation xml:lang="ru">Licata A., Minissale M.G., Stankevičiūtė S., Sanabria-Cabrera J., Lucena M.I., Andrade R.J., et al. N-acetylcysteine for preventing acetaminophen-induced liver injury: A comprehensive review. Front Pharmacol. 2022;13:828565. DOI: 10.3389/fphar.2022.828565</mixed-citation><mixed-citation xml:lang="en">Licata A., Minissale M.G., Stankevičiūtė S., Sanabria-Cabrera J., Lucena M.I., Andrade R.J., et al. N-acetylcysteine for preventing acetaminophen-induced liver injury: A comprehensive review. Front Pharmacol. 2022;13:828565. DOI: 10.3389/fphar.2022.828565</mixed-citation></citation-alternatives></ref><ref id="cit207"><label>207</label><citation-alternatives><mixed-citation xml:lang="ru">Stine J.G., Lewis J.H. Current and future directions in the treatment and prevention of drug-induced liver injury: A systematic review. Expert Rev Gastroenterol Hepatol. 2016;10(4):517–36. DOI: 10.1586/17474124.2016.1127756</mixed-citation><mixed-citation xml:lang="en">Stine J.G., Lewis J.H. Current and future directions in the treatment and prevention of drug-induced liver injury: A systematic review. Expert Rev Gastroenterol Hepatol. 2016;10(4):517–36. DOI: 10.1586/17474124.2016.1127756</mixed-citation></citation-alternatives></ref><ref id="cit208"><label>208</label><citation-alternatives><mixed-citation xml:lang="ru">Woodhead J.L., Howell B.A., Yang Y., Harrill A.H., Clewell H.J. 3rd, Andersen M.E., et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther. 2012;342(2):529–40. DOI: 10.1124/jpet.112.192930</mixed-citation><mixed-citation xml:lang="en">Woodhead J.L., Howell B.A., Yang Y., Harrill A.H., Clewell H.J. 3rd, Andersen M.E., et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther. 2012;342(2):529–40. DOI: 10.1124/jpet.112.192930</mixed-citation></citation-alternatives></ref><ref id="cit209"><label>209</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y., Johansson E., Yang Y., Miller M.L., Shen D., Orlicky D.J., et al. Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis. J Hepatol. 2010;53(6):1085– 94. DOI: 10.1016/j.jhep.2010.05.028</mixed-citation><mixed-citation xml:lang="en">Chen Y., Johansson E., Yang Y., Miller M.L., Shen D., Orlicky D.J., et al. Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis. J Hepatol. 2010;53(6):1085– 94. DOI: 10.1016/j.jhep.2010.05.028</mixed-citation></citation-alternatives></ref><ref id="cit210"><label>210</label><citation-alternatives><mixed-citation xml:lang="ru">González R., Ferrín G., Hidalgo A.B., Ranchal I., López-Cillero P., Santos-Gónzalez M., et al. N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem Biol Interact. 2009;181(1):95–106. DOI: 10.1016/j.cbi.2009.06.003</mixed-citation><mixed-citation xml:lang="en">González R., Ferrín G., Hidalgo A.B., Ranchal I., López-Cillero P., Santos-Gónzalez M., et al. N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem Biol Interact. 2009;181(1):95–106. DOI: 10.1016/j.cbi.2009.06.003</mixed-citation></citation-alternatives></ref><ref id="cit211"><label>211</label><citation-alternatives><mixed-citation xml:lang="ru">Jin X., Wang L., Wu H.S., Zhang L., Wang C.Y., Tian Y., et al. N-acetylcysteine inhibits activation of tolllike receptor 2 and 4 gene expression in the liver and lung after partial hepatic ischemia-reperfusion injury in mice. Hepatobiliary Pancreat Dis Int. 2007;6(3):284–9.</mixed-citation><mixed-citation xml:lang="en">Jin X., Wang L., Wu H.S., Zhang L., Wang C.Y., Tian Y., et al. N-acetylcysteine inhibits activation of tolllike receptor 2 and 4 gene expression in the liver and lung after partial hepatic ischemia-reperfusion injury in mice. Hepatobiliary Pancreat Dis Int. 2007;6(3):284–9.</mixed-citation></citation-alternatives></ref><ref id="cit212"><label>212</label><citation-alternatives><mixed-citation xml:lang="ru">Popescu M., Bratu A., Agapie M., Borjog T., Jafal M., Sima R.M., et al. The use and potential benefits of N-acetylcysteine in non-acetaminophen acute liver failure: An etiology-based review. Biomedicines. 2024;12(3):676. DOI: 10.3390/biomedicines12030676</mixed-citation><mixed-citation xml:lang="en">Popescu M., Bratu A., Agapie M., Borjog T., Jafal M., Sima R.M., et al. The use and potential benefits of N-acetylcysteine in non-acetaminophen acute liver failure: An etiology-based review. Biomedicines. 2024;12(3):676. DOI: 10.3390/biomedicines12030676</mixed-citation></citation-alternatives></ref><ref id="cit213"><label>213</label><citation-alternatives><mixed-citation xml:lang="ru">Chiew A.L., Reith D., Pomerleau A., Wong A., Isoardi K.Z., Soderstrom J., Buckley N.A. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust. 2020;212(4):175–83. DOI: 10.5694/mja2.50428</mixed-citation><mixed-citation xml:lang="en">Chiew A.L., Reith D., Pomerleau A., Wong A., Isoardi K.Z., Soderstrom J., Buckley N.A. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust. 2020;212(4):175–83. DOI: 10.5694/mja2.50428</mixed-citation></citation-alternatives></ref><ref id="cit214"><label>214</label><citation-alternatives><mixed-citation xml:lang="ru">Green J.L., Heard K.J., Reynolds K.M., Albert D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and meta-analysis. West J Emerg Med. 2013;14(3):218–26. DOI: 10.5811/westjem.2012.4.6885</mixed-citation><mixed-citation xml:lang="en">Green J.L., Heard K.J., Reynolds K.M., Albert D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and meta-analysis. West J Emerg Med. 2013;14(3):218–26. DOI: 10.5811/westjem.2012.4.6885</mixed-citation></citation-alternatives></ref><ref id="cit215"><label>215</label><citation-alternatives><mixed-citation xml:lang="ru">Avigan M.I. DILI and drug development: A regulatory perspective. Semin Liver Dis. 2014;34(2):215–26. DOI: 10.1055/s-0034-1375961</mixed-citation><mixed-citation xml:lang="en">Avigan M.I. DILI and drug development: A regulatory perspective. Semin Liver Dis. 2014;34(2):215–26. DOI: 10.1055/s-0034-1375961</mixed-citation></citation-alternatives></ref><ref id="cit216"><label>216</label><citation-alternatives><mixed-citation xml:lang="ru">Hendrickson R.G. What is the most appropriate dose of N-acetylcysteine after massive acetaminophen overdose? Clin Toxicol (Phila). 2019;57(8):686–91. DOI: 10.1080/15563650.2019.1579914</mixed-citation><mixed-citation xml:lang="en">Hendrickson R.G. What is the most appropriate dose of N-acetylcysteine after massive acetaminophen overdose? Clin Toxicol (Phila). 2019;57(8):686–91. DOI: 10.1080/15563650.2019.1579914</mixed-citation></citation-alternatives></ref><ref id="cit217"><label>217</label><citation-alternatives><mixed-citation xml:lang="ru">Virmani M.A., Cirulli M. The role of l-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation. Int J Mol Sci. 2022;23(5):2717. DOI: 10.3390/ijms23052717</mixed-citation><mixed-citation xml:lang="en">Virmani M.A., Cirulli M. The role of l-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation. Int J Mol Sci. 2022;23(5):2717. DOI: 10.3390/ijms23052717</mixed-citation></citation-alternatives></ref><ref id="cit218"><label>218</label><citation-alternatives><mixed-citation xml:lang="ru">Perrott J., Murphy N.G., Zed P.J. L-carnitine for acute valproic acid overdose: A systematic review of published cases. Ann Pharmacother. 2010;44(7–8):1287–93. DOI: 10.1345/aph.1P135</mixed-citation><mixed-citation xml:lang="en">Perrott J., Murphy N.G., Zed P.J. L-carnitine for acute valproic acid overdose: A systematic review of published cases. Ann Pharmacother. 2010;44(7–8):1287–93. DOI: 10.1345/aph.1P135</mixed-citation></citation-alternatives></ref><ref id="cit219"><label>219</label><citation-alternatives><mixed-citation xml:lang="ru">Meijer R., Vivekananda U., Balestrini S., Walker M., Lachmann R., Haeberle J., et al. Ammonia: What adult neurologists need to know. Pract Neurol. 2020;practneurol-2020-002654. DOI: 10.1136/practneurol-2020-002654</mixed-citation><mixed-citation xml:lang="en">Meijer R., Vivekananda U., Balestrini S., Walker M., Lachmann R., Haeberle J., et al. Ammonia: What adult neurologists need to know. Pract Neurol. 2020;practneurol-2020-002654. DOI: 10.1136/practneurol-2020-002654</mixed-citation></citation-alternatives></ref><ref id="cit220"><label>220</label><citation-alternatives><mixed-citation xml:lang="ru">Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19(2):206– 10. DOI: 10.1097/MOP.0b013e32805e879a</mixed-citation><mixed-citation xml:lang="en">Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19(2):206– 10. DOI: 10.1097/MOP.0b013e32805e879a</mixed-citation></citation-alternatives></ref><ref id="cit221"><label>221</label><citation-alternatives><mixed-citation xml:lang="ru">Bohan T.P., Helton E., McDonald I., König S., Gazitt S., Sugimoto T., et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001;56(10):1405–9. DOI: 10.1212/wnl.56.10.1405</mixed-citation><mixed-citation xml:lang="en">Bohan T.P., Helton E., McDonald I., König S., Gazitt S., Sugimoto T., et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001;56(10):1405–9. DOI: 10.1212/wnl.56.10.1405</mixed-citation></citation-alternatives></ref><ref id="cit222"><label>222</label><citation-alternatives><mixed-citation xml:lang="ru">Schulte R., Hinson A., Huynh V., Breese E.H., Pierro J., Rotz S., et al. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021;10(21):7551– 60. DOI: 10.1002/cam4.4281</mixed-citation><mixed-citation xml:lang="en">Schulte R., Hinson A., Huynh V., Breese E.H., Pierro J., Rotz S., et al. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021;10(21):7551– 60. DOI: 10.1002/cam4.4281</mixed-citation></citation-alternatives></ref><ref id="cit223"><label>223</label><citation-alternatives><mixed-citation xml:lang="ru">Blackman A., Boutin A., Shimanovsky A., Baker W.J., Forcello N. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature. J Oncol Pharm Pract. 2018;24(5):393–7. DOI: 10.1177/1078155217710714</mixed-citation><mixed-citation xml:lang="en">Blackman A., Boutin A., Shimanovsky A., Baker W.J., Forcello N. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature. J Oncol Pharm Pract. 2018;24(5):393–7. DOI: 10.1177/1078155217710714</mixed-citation></citation-alternatives></ref><ref id="cit224"><label>224</label><citation-alternatives><mixed-citation xml:lang="ru">Bessone F., Hillotte G.L., Ahumada N., Jaureguizahar F., Medeot A.C., Roma M.G. UDCA for drug-induced liver disease: Clinical and pathophysiological basis. Semin Liver Dis. 2024;44(1):1–22. DOI: 10.1055/s-0044-1779520</mixed-citation><mixed-citation xml:lang="en">Bessone F., Hillotte G.L., Ahumada N., Jaureguizahar F., Medeot A.C., Roma M.G. UDCA for drug-induced liver disease: Clinical and pathophysiological basis. Semin Liver Dis. 2024;44(1):1–22. DOI: 10.1055/s-0044-1779520</mixed-citation></citation-alternatives></ref><ref id="cit225"><label>225</label><citation-alternatives><mixed-citation xml:lang="ru">Bessone F., Hillotte G.L., Tamagnone N., Arnedillo D., Roma M.G. Ursodeoxycholic acid for the management of drug-induced liver injury: Role of hepatoprotective and anti-cholestatic mechanisms. J Clin Transl Hepatol. 2025;13(2):162–8. DOI: 10.14218/JCTH.2024.00325</mixed-citation><mixed-citation xml:lang="en">Bessone F., Hillotte G.L., Tamagnone N., Arnedillo D., Roma M.G. Ursodeoxycholic acid for the management of drug-induced liver injury: Role of hepatoprotective and anti-cholestatic mechanisms. J Clin Transl Hepatol. 2025;13(2):162–8. DOI: 10.14218/JCTH.2024.00325</mixed-citation></citation-alternatives></ref><ref id="cit226"><label>226</label><citation-alternatives><mixed-citation xml:lang="ru">Devarbhavi H., Aithal G., Treeprasertsuk S., Takikawa H., Mao Y., Shasthry S.M., et al.; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2021;15(2):258–82. DOI: 10.1007/s12072-021-10144-3</mixed-citation><mixed-citation xml:lang="en">Devarbhavi H., Aithal G., Treeprasertsuk S., Takikawa H., Mao Y., Shasthry S.M., et al.; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2021;15(2):258–82. DOI: 10.1007/s12072-021-10144-3</mixed-citation></citation-alternatives></ref><ref id="cit227"><label>227</label><citation-alternatives><mixed-citation xml:lang="ru">Robles-Díaz M., Nezic L., Vujic-Aleksic V., Björnsson E.S. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review. Front Pharmacol. 2021;12:744488. DOI: 10.3389/fphar.2021.744488</mixed-citation><mixed-citation xml:lang="en">Robles-Díaz M., Nezic L., Vujic-Aleksic V., Björnsson E.S. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review. Front Pharmacol. 2021;12:744488. DOI: 10.3389/fphar.2021.744488</mixed-citation></citation-alternatives></ref><ref id="cit228"><label>228</label><citation-alternatives><mixed-citation xml:lang="ru">Wree A., Dechêne A., Herzer K., Hilgard P., Syn W.K., Gerken G., et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54–9. DOI: 10.1159/000322298</mixed-citation><mixed-citation xml:lang="en">Wree A., Dechêne A., Herzer K., Hilgard P., Syn W.K., Gerken G., et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54–9. DOI: 10.1159/000322298</mixed-citation></citation-alternatives></ref><ref id="cit229"><label>229</label><citation-alternatives><mixed-citation xml:lang="ru">Stepanov Y., Yagmur V., Melanich S., Popok D. Efficacy of ursodeoxycholic acid in the treatment of COVID-19 infection and drug-induced liver damage. Gastroenterology (Ukraine). 2021;55(1):14–20. DOI: 10.22141/23082097.55.1.2021.229431</mixed-citation><mixed-citation xml:lang="en">Stepanov Y., Yagmur V., Melanich S., Popok D. Efficacy of ursodeoxycholic acid in the treatment of COVID-19 infection and drug-induced liver damage. Gastroenterology (Ukraine). 2021;55(1):14–20. DOI: 10.22141/23082097.55.1.2021.229431</mixed-citation></citation-alternatives></ref><ref id="cit230"><label>230</label><citation-alternatives><mixed-citation xml:lang="ru">Lang S.M., Ortmann J., Rostig S., Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. Int J Mycobacteriol. 2019;8(1):89–92. DOI: 10.4103/ijmy.ijmy_159_18</mixed-citation><mixed-citation xml:lang="en">Lang S.M., Ortmann J., Rostig S., Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. Int J Mycobacteriol. 2019;8(1):89–92. DOI: 10.4103/ijmy.ijmy_159_18</mixed-citation></citation-alternatives></ref><ref id="cit231"><label>231</label><citation-alternatives><mixed-citation xml:lang="ru">Максимова Е.В., Кляритская И.Л. Гепатотоксичность у пациентов ревматологического профиля: особенности течения, возможности коррекции. Крымский терапевтический журнал. 2015;1:58–64.</mixed-citation><mixed-citation xml:lang="en">Maksimova E.V., Klyaritskaya I.L. Hepatotoxicity in patients with rheumatological profile: Features of the course, possibilities of correction. Crimean Therapeutic Journal. 2015;1:58– 64 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit232"><label>232</label><citation-alternatives><mixed-citation xml:lang="ru">Singh C., Bishop P., Willson R. Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: Response to ursodeoxycholic acid treatment. Am J Gastroenterol. 1996;91(4):783–5.</mixed-citation><mixed-citation xml:lang="en">Singh C., Bishop P., Willson R. Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: Response to ursodeoxycholic acid treatment. Am J Gastroenterol. 1996;91(4):783–5.</mixed-citation></citation-alternatives></ref><ref id="cit233"><label>233</label><citation-alternatives><mixed-citation xml:lang="ru">Cicognani C., Malavolti M., Morselli-Labate A.M., Sama C., Barbara L. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci. 1996;41(11):2219–21. DOI: 10.1007/BF02071403</mixed-citation><mixed-citation xml:lang="en">Cicognani C., Malavolti M., Morselli-Labate A.M., Sama C., Barbara L. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci. 1996;41(11):2219–21. DOI: 10.1007/BF02071403</mixed-citation></citation-alternatives></ref><ref id="cit234"><label>234</label><citation-alternatives><mixed-citation xml:lang="ru">Katsinelos P., Vasiliadis T., Xiarchos P., Patakiouta F., Christodoulou K., Pilpilidis I., et al. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol. 2000;12(3):365–8. DOI: 10.1097/00042737-200012030-00017</mixed-citation><mixed-citation xml:lang="en">Katsinelos P., Vasiliadis T., Xiarchos P., Patakiouta F., Christodoulou K., Pilpilidis I., et al. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol. 2000;12(3):365–8. DOI: 10.1097/00042737-200012030-00017</mixed-citation></citation-alternatives></ref><ref id="cit235"><label>235</label><citation-alternatives><mixed-citation xml:lang="ru">Sánchez-Osorio M., Duarte-Rojo A., Martínez-Benítez B., Torre A., Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int. 2008;28(2):278–82. DOI: 10.1111/j.1478-3231.2007.01579.x</mixed-citation><mixed-citation xml:lang="en">Sánchez-Osorio M., Duarte-Rojo A., Martínez-Benítez B., Torre A., Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int. 2008;28(2):278–82. DOI: 10.1111/j.1478-3231.2007.01579.x</mixed-citation></citation-alternatives></ref><ref id="cit236"><label>236</label><citation-alternatives><mixed-citation xml:lang="ru">Shah A., Bassi N., Parihar S., Mittal I., Yadav D.P., Kumar V., et al. Steroid-responsive intractable pruritus in drug-induced liver injury: A case series. J Clin Trans Res. 2024;10(1):25–32. DOI: 10.36922/jctr.00104</mixed-citation><mixed-citation xml:lang="en">Shah A., Bassi N., Parihar S., Mittal I., Yadav D.P., Kumar V., et al. Steroid-responsive intractable pruritus in drug-induced liver injury: A case series. J Clin Trans Res. 2024;10(1):25–32. DOI: 10.36922/jctr.00104</mixed-citation></citation-alternatives></ref><ref id="cit237"><label>237</label><citation-alternatives><mixed-citation xml:lang="ru">Mato J.M., Martínez-Chantar M.L., Lu S.C. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013;12(2):183–9. DOI: 10.1016/S1665-2681(19)31355-9</mixed-citation><mixed-citation xml:lang="en">Mato J.M., Martínez-Chantar M.L., Lu S.C. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013;12(2):183–9. DOI: 10.1016/S1665-2681(19)31355-9</mixed-citation></citation-alternatives></ref><ref id="cit238"><label>238</label><citation-alternatives><mixed-citation xml:lang="ru">Приходько В.А., Оковитый С.В. Хемопревентивный и противоопухолевый потенциал адеметионина при хронических заболеваниях печени. Терапия. 2024;10(3):125– 36. DOI: 10.18565/therapy.2024.3.125-136</mixed-citation><mixed-citation xml:lang="en">Prikhodko V.A., Okovity S.V. Chemopreventive and antitumor potential of ademetionine in chronic liver diseases. Therapy. 2024;10(3):125–36. (In Russ.). DOI: 10.18565/therapy.2024.3.125-136</mixed-citation></citation-alternatives></ref><ref id="cit239"><label>239</label><citation-alternatives><mixed-citation xml:lang="ru">Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46–63. DOI: 10.4254/wjh.v12.i2.46</mixed-citation><mixed-citation xml:lang="en">Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46–63. DOI: 10.4254/wjh.v12.i2.46</mixed-citation></citation-alternatives></ref><ref id="cit240"><label>240</label><citation-alternatives><mixed-citation xml:lang="ru">Chinese Medical Association Tuberculosis Branch. [Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version)]. Zhonghua Jie He He Hu Xi Za Zhi. 2024;47(11):1069–90. (In Chinese). DOI: 10.3760/cma.j.cn112147-20240614-00338</mixed-citation><mixed-citation xml:lang="en">Chinese Medical Association Tuberculosis Branch. [Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version)]. Zhonghua Jie He He Hu Xi Za Zhi. 2024;47(11):1069–90. (In Chinese). DOI: 10.3760/cma.j.cn112147-20240614-00338</mixed-citation></citation-alternatives></ref><ref id="cit241"><label>241</label><citation-alternatives><mixed-citation xml:lang="ru">Снеговой А.В., Ларионова В.Б., Зейналова П.А., Манзюк Л.В., Крейнина Ю.М., Кагония Л.М. Окончательные результаты проспективной многоцентровой программы p12-717 (применение Гептрала при хронической болезни печени, обусловленной лекарственноиндуцированным поражением печени вследствие химиотерапии). Вестник РОНЦ им. Н.Н. Блохина РАМН. 2016;27(2):142–56.</mixed-citation><mixed-citation xml:lang="en">Snegovoy A.V., Larionova V.B., Zeynalova P.A., Manyuk L.V., Kreynina Yu.M., Kagoniya L.M. Final results of the prospective multicenter program p12-717 (use of Heptral in chronic liver disease caused by drug-induced liver injury due to chemotherapy). Bulletin of the Blokhin Russian Cancer Research Center. 2016;27(2):142–56. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit242"><label>242</label><citation-alternatives><mixed-citation xml:lang="ru">Vincenzi B., Russo A., Terenzio A., Galvano A., Santini D., Vorini F., et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol. 2018;130:70–7. DOI: 10.1016/j.critrevonc.2018.06.019</mixed-citation><mixed-citation xml:lang="en">Vincenzi B., Russo A., Terenzio A., Galvano A., Santini D., Vorini F., et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol. 2018;130:70–7. DOI: 10.1016/j.critrevonc.2018.06.019</mixed-citation></citation-alternatives></ref><ref id="cit243"><label>243</label><citation-alternatives><mixed-citation xml:lang="ru">Ларионова В.Б., Снеговой А.В. Возможности коррекции лекарственной печеночной токсичности при лечении больных с опухолями системы крови. Онкогематология. 2020;15(4):65–81. DOI: 10.17650/1818-8346-2020-15-4-65-81</mixed-citation><mixed-citation xml:lang="en">Larionova V.B., Snegovoy A.V. Correction possibilities of drug-induced liver toxicity in the treatment of patients with blood system tumors. Oncohematology. 2020;15(4):65–81. (In Russ). DOI: 10.17650/1818-8346-2020-15-4-65-81</mixed-citation></citation-alternatives></ref><ref id="cit244"><label>244</label><citation-alternatives><mixed-citation xml:lang="ru">Снеговой А.В., Манзюк Л.В. Эффективность Гептрала в лечении печеночной токсичности, обусловленной цитостатической химиотерапией. Опухоли женской репродуктивной системы. 2010;2:47–52. DOI: 10.17650/1994-4098-2010-0-2-47-52</mixed-citation><mixed-citation xml:lang="en">Snegovoy A.V., Manzyuk L.V. Efficacy of Heptral® in the treatment of hepatic toxicity induced by cytostatic chemotherapy. Tumors of female reproductive system. 2010;2:47–52. (In Russ.). DOI: 10.17650/1994-4098-2010-0-2-47-52</mixed-citation></citation-alternatives></ref><ref id="cit245"><label>245</label><citation-alternatives><mixed-citation xml:lang="ru">Perlamutrov Y., Bakulev A., Korsunskaya I., Orlov E., Bolotnikova N. Ademetionine in treatment of drug induced liver injury: An observational study in Russian patients, receiving immunosuppressive therapy for psoriasis. Int J Pharm Sci Res. 2014;5(12):5163–9. DOI: 10.13040/IJPSR.0975-8232.5(12).5163-69</mixed-citation><mixed-citation xml:lang="en">Perlamutrov Y., Bakulev A., Korsunskaya I., Orlov E., Bolotnikova N. Ademetionine in treatment of drug induced liver injury: An observational study in Russian patients, receiving immunosuppressive therapy for psoriasis. Int J Pharm Sci Res. 2014;5(12):5163–9. DOI: 10.13040/IJPSR.0975-8232.5(12).5163-69</mixed-citation></citation-alternatives></ref><ref id="cit246"><label>246</label><citation-alternatives><mixed-citation xml:lang="ru">Силивончик Н.Н., Адаменко Е.И., Богуш Л.С. Адеметионин: физиологические эффектыи применение в лечении заболеваний печени. Международные обзоры: клиническая практика и здоровье, 2017;(2):33–49.</mixed-citation><mixed-citation xml:lang="en">Силивончик Н.Н., Адаменко Е.И., Богуш Л.С. Адеметионин: физиологические эффектыи применение в лечении заболеваний печени. Международные обзоры: клиническая практика и здоровье, 2017;(2):33–49.</mixed-citation></citation-alternatives></ref><ref id="cit247"><label>247</label><citation-alternatives><mixed-citation xml:lang="ru">Суханов Д.С., Павлова М.В., Яблонский П.К., Виноградова Т.И. Сравнительная эффективность клинического применения реамберина, ремаксола и адеметионина у больных туберкулезом органов дыхания с лекарственными поражениями печени. Антибиотики и химиотерапия. 2013;58(1–2):13–8.</mixed-citation><mixed-citation xml:lang="en">Sukhanov D.S., Pavlova M.V., Yablonsky P.K., Vinogradova T.I. Comparative efficacy of clinical use of reamberin, remaxol, and ademetionine in patients with respiratory tuberculosis and drug-induced liver injury. Antibiotics and chemotherapy. 2013;58(1–2):13–8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit248"><label>248</label><citation-alternatives><mixed-citation xml:lang="ru">Суханов Д.С. Антиоксидантные свойства ремаксола, реамберина и адеметионина при лекарственных поражениях печени у больных на фоне противотуберкулезной терапии. Экспериментальная и клиническая фармакология. 2013;76(4):45–8.</mixed-citation><mixed-citation xml:lang="en">Sukhanov D.S. Antioxidant properties of remaxol, reamberin, and ademetionine in drug-induced liver injury in patients undergoing anti-tuberculosis therapy. Experimental and Clinical Pharmacology. 2013;76(4):45–8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit249"><label>249</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y.H., Da R.F., Xu H.B., Jiang Y., Xie H.P. Therapeutic efficacy of polyene phosphatidylcholine in patients with antituberculosis agents-induced liver injury. Journal of Practical Hepatology (Shiyong Ganzangbing Zazhi). 2021; 24(02):228–31. DOI: 10.3969/j.issn.1672-5069.2021.02.020</mixed-citation><mixed-citation xml:lang="en">Liu Y.H., Da R.F., Xu H.B., Jiang Y., Xie H.P. Therapeutic efficacy of polyene phosphatidylcholine in patients with antituberculosis agents-induced liver injury. Journal of Practical Hepatology (Shiyong Ganzangbing Zazhi). 2021; 24(02):228–31. DOI: 10.3969/j.issn.1672-5069.2021.02.020</mixed-citation></citation-alternatives></ref><ref id="cit250"><label>250</label><citation-alternatives><mixed-citation xml:lang="ru">Osipova D., Kokoreva K., Lazebnik L., Golovanova E., Pavlov C., Dukhanin A., et al. Regression of liver steatosis following phosphatidylcholine administration: A review of molecular and metabolic pathways involved. Front Pharmacol. 2022;13:797923. DOI: 10.3389/fphar.2022.797923</mixed-citation><mixed-citation xml:lang="en">Osipova D., Kokoreva K., Lazebnik L., Golovanova E., Pavlov C., Dukhanin A., et al. Regression of liver steatosis following phosphatidylcholine administration: A review of molecular and metabolic pathways involved. Front Pharmacol. 2022;13:797923. DOI: 10.3389/fphar.2022.797923</mixed-citation></citation-alternatives></ref><ref id="cit251"><label>251</label><citation-alternatives><mixed-citation xml:lang="ru">Lei P., Cao L., Zhang H., Fu J., Wei X., Zhou F., et al. Polyene phosphatidylcholine enhances the therapeutic response of oxaliplatin in gastric cancer through Nrf2/HMOX1 mediated ferroptosis. Transl Oncol. 2024;43:101911. DOI: 10.1016/j.tranon.2024.101911</mixed-citation><mixed-citation xml:lang="en">Lei P., Cao L., Zhang H., Fu J., Wei X., Zhou F., et al. Polyene phosphatidylcholine enhances the therapeutic response of oxaliplatin in gastric cancer through Nrf2/HMOX1 mediated ferroptosis. Transl Oncol. 2024;43:101911. DOI: 10.1016/j.tranon.2024.101911</mixed-citation></citation-alternatives></ref><ref id="cit252"><label>252</label><citation-alternatives><mixed-citation xml:lang="ru">Lei X., Zhang J., Xu Q., Li J., Qian Y., Zhang J., et al. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison. J Int Med Res. 2021;49(8):3000605211039810. DOI: 10.1177/03000605211039810</mixed-citation><mixed-citation xml:lang="en">Lei X., Zhang J., Xu Q., Li J., Qian Y., Zhang J., et al. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison. J Int Med Res. 2021;49(8):3000605211039810. DOI: 10.1177/03000605211039810</mixed-citation></citation-alternatives></ref><ref id="cit253"><label>253</label><citation-alternatives><mixed-citation xml:lang="ru">Li C., Yang X., Quan Y., Wu A., Wang Y. Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury. Medicine (Baltimore). 2023;102(50):e36538. DOI: 10.1097/MD.0000000000036538</mixed-citation><mixed-citation xml:lang="en">Li C., Yang X., Quan Y., Wu A., Wang Y. Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury. Medicine (Baltimore). 2023;102(50):e36538. DOI: 10.1097/MD.0000000000036538</mixed-citation></citation-alternatives></ref><ref id="cit254"><label>254</label><citation-alternatives><mixed-citation xml:lang="ru">Пальгова Л.К., Борисова И.В., Жесткова Н.В., Тарасова М.А. Применение эссенциальных фосфолипидов в лечении лекарственных поражений печени при беременности. Журнал акушерства и женских болезней. 2017;66(2):14–23. DOI: 10.17816/JOWD66214-23</mixed-citation><mixed-citation xml:lang="en">Palgova L.K., Borisova I.V., Zhestkova N.V., Tarasova M.A. Essential phospholipids use in the treatment of drug-induced liver injury in pregnant women. Journal of Obstetrics and Women’s Diseases. 2017;66(2):14–23. (In Russ.). DOI: 10.17816/JOWD66214-23</mixed-citation></citation-alternatives></ref><ref id="cit255"><label>255</label><citation-alternatives><mixed-citation xml:lang="ru">Алыева А.А., Никитин И.Г., Архипов А.В. Сопроводительная терапия острого лекарственного повреждения печени на фоне химиотерапевтического лечения у пациенток с раком молочной железы. Лечебное дело. 2018;2:74–85. DOI: 10.24411/2071-5315-2018-12005</mixed-citation><mixed-citation xml:lang="en">Alieva A.A., Nikitin I.G., Arkhipov A.V. Concomitant therapy for acute drug-induced liver injury during chemotherapy in patients with breast cancer. Lechebnoe Delo. 2018;2:74–85. (In Russ.). DOI: 10.24411/2071-5315-2018-12005</mixed-citation></citation-alternatives></ref><ref id="cit256"><label>256</label><citation-alternatives><mixed-citation xml:lang="ru">Денисова Е.В., Дворянкова Е.В., Плиева К.Т., Соболев В.В., Корсунская И.М. Патологии гепатобилиарной системы у больных псориазом. Эффективная фармакотерапия. 2018;21:18–23. .</mixed-citation><mixed-citation xml:lang="en">Denisova E.V., Dvoryankova E.V., Plieva K.T., Sobolev V.V., Korsunskaya I.M. Pathology of the hepatobiliary system in patients with psoriasis. Effective Pharmacotherapy. 2018;21:18– 23. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit257"><label>257</label><citation-alternatives><mixed-citation xml:lang="ru">Новикова Т.И., Новиков В.С. Опыт применения препарата «Фосфоглив» в терапии поражения печени на фоне химиотерапии легких. Материалы конференции «Туберкулез и болезни легких», IX Cъезд фтизиатров России. 2011:768.</mixed-citation><mixed-citation xml:lang="en">Novikova T.I., Novikov V.S. Experience with the use of the drug “Phosphogliv” in the treatment of liver damage during pulmonary chemotherapy. IX Congress of Phthisiologists of Russia: Proceedings of the conference “Tuberculosis and Lung Diseases”. 2011:768. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit258"><label>258</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Никитин И.Г. Анализ безопасности применения глицирризиновой кислоты у человека. Эффективная фармакотерапия. 2023;19(8):92–103. DOI: 10.33978/23073586-2023-19-8-92-103</mixed-citation><mixed-citation xml:lang="en">Okovity S.V., Nikitin I.G. Analysis of the safety of glycyrrhizic acid in humans. Effective Pharmacotherapy. 2023;19(8):92–103. (In Russ.). DOI: 10.33978/23073586-2023-19-8-92-103</mixed-citation></citation-alternatives></ref><ref id="cit259"><label>259</label><citation-alternatives><mixed-citation xml:lang="ru">Butterworth R.F., Canbay A. Hepatoprotection by L-ornithine L-aspartate in non-alcoholic fatty liver disease. Dig Dis. 2019;37(1):63–8. DOI: 10.1159/000491429</mixed-citation><mixed-citation xml:lang="en">Butterworth R.F., Canbay A. Hepatoprotection by L-ornithine L-aspartate in non-alcoholic fatty liver disease. Dig Dis. 2019;37(1):63–8. DOI: 10.1159/000491429</mixed-citation></citation-alternatives></ref><ref id="cit260"><label>260</label><citation-alternatives><mixed-citation xml:lang="ru">Canbay A., Sowa J.P. L-ornithine L-aspartate (LOLA) as a novel approach for therapy of non-alcoholic fatty liver disease. Drugs. 2019;79(Suppl. 1):39–44. DOI: 10.1007/ s40265-018-1020-5</mixed-citation><mixed-citation xml:lang="en">Canbay A., Sowa J.P. L-ornithine L-aspartate (LOLA) as a novel approach for therapy of non-alcoholic fatty liver disease. Drugs. 2019;79(Suppl. 1):39–44. DOI: 10.1007/ s40265-018-1020-5</mixed-citation></citation-alternatives></ref><ref id="cit261"><label>261</label><citation-alternatives><mixed-citation xml:lang="ru">Максимова Е.В., Кляритская И.Л. Печеночная энцефалопатия, диагностика, дифференциальная диагностика и терапия при помощи орнитина. Consilium Medicum. 2018;20(12):110–6. DOI: 10.26442/20751753.2018.12.000019</mixed-citation><mixed-citation xml:lang="en">Maksimova E.V., Klyaritskaya I.L. Hepatic encephalopathy: Diagnosis, differential diagnosis, and therapy with ornithine. Consilium Medicum. 2018;20(12):110–6. (In Russ.). DOI: 10.26442/20751753.2018.12.000019</mixed-citation></citation-alternatives></ref><ref id="cit262"><label>262</label><citation-alternatives><mixed-citation xml:lang="ru">Ларионова В.Б., Горожанская Э.Г. Перспективы применения Гепа-Мерц (L-орнитин-L-аспартат) для профилактики и лечения лекарственного поражения печени. Эффективная фармакотерапия. 2009;23:6–15.</mixed-citation><mixed-citation xml:lang="en">Larionova V.B., Gorozhanskaya E.G. Prospects for the use of Hepa-Merz (L-ornithine-L-aspartate) for the prevention and treatment of drug-induced liver injury. Effective Pharmacotherapy. 2009;23:6–15. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit263"><label>263</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Надинская М.Ю., Маевская М.В., Гладков О.А., Васенина Е.Е., Гречишникова В.Р. и др. Резолюция экспертного совета «Орнитин в онкологической практике». Медицинский совет. 2025;8:8–16. DOI: 10.21518/ms2025-237</mixed-citation><mixed-citation xml:lang="en">Okovityi S.V., Nadinskaia M.Yu., Maevskaya M.V., Gladkov O.A., Vasenina E.E., Grechishnikova V.R., et al. Materials of the Expert Council “Ornithine in Oncological Practice”. Medical Council. 2025;8:8–16. (In Russ.). DOI: 10.21518/ms2025-237</mixed-citation></citation-alternatives></ref><ref id="cit264"><label>264</label><citation-alternatives><mixed-citation xml:lang="ru">Бриштель М.В. Применение препарата L-орнитина — L-аспартат (Гепа-Мерц) для терапии гепатотоксичности при лечении злокачественных новообразований. Медицинские новости. 2024;3:68–70.</mixed-citation><mixed-citation xml:lang="en">Brishtel M.V. Use of L-ornithine-L-aspartate (Gepa-Merz) for the treatment of hepatotoxicity in malignant neoplasms. Meditsinskie Novosti. 2024;3:68–70. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit265"><label>265</label><citation-alternatives><mixed-citation xml:lang="ru">Скрыпник И.Н., Маслова А.С., Скрыпник Р.И. Влияние L-орнитина-L-аспартата на проявления минимальной печеночной энцефалопатии в динамике цитостатической терапии. Современная гастроэнтерология. 2018;6:29– 34. DOI: 10.30978/MG-2018-6-29</mixed-citation><mixed-citation xml:lang="en">Skripnik I.N., Maslova A.S., Skripnik R.I. Effect of L-ornithine-L-aspartate on the manifestations of minimal hepatic encephalopathy during cytostatic therapy. Modern Gastroenterology. 2018;6:29–34. (In Russ.). DOI: 10.30978/MG-2018-6-29</mixed-citation></citation-alternatives></ref><ref id="cit266"><label>266</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Драпкина О.М., Маевская М.В., Жаркова М.С., Гречишникова В.Р. и др. Цирроз и фиброз печени: клинические рекомендации. М.; 2025. URL: https://cr.minzdrav.gov.ru/preview-cr/715_2</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Drapkina O.M., Maevskaya M.V., Zharkova M.S., Grechishnikova V.R., et al. Liver cirrhosis and fibrosis: Clinical guidelines. Moscow; 2025. (In Russ.). URL: https://cr.minzdrav.gov.ru/preview-cr/715_2</mixed-citation></citation-alternatives></ref><ref id="cit267"><label>267</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Радько С.В. Митохондриальная дисфункция в патогенезе различных поражений печени. Доктор.Ру. 2015;12(113):30–3.</mixed-citation><mixed-citation xml:lang="en">Okovityi S.V., Radko S.V. Mitochondrial dysfunction in the pathogenesis of various liver lesions. Doctor.Ru. 2015;12(113):30–3. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit268"><label>268</label><citation-alternatives><mixed-citation xml:lang="ru">Ильченко Л.Ю., Оковитый С.В. Ремаксол: механизмы действия и применение в клинической практике. Ч. 2. Архивъ внутренней медицины. 2016;6(3):8–18. DOI: 10.20514/2226-6704-2016-6-3-8-18</mixed-citation><mixed-citation xml:lang="en">Ilchenko L.Yu., Okovityi S.V. Remaxol: Mechanisms of action and application in real clinical practice. Part II. The Russian Archives of Internal Medicine. 2016;6(3):8–18. (In Russ.). DOI: 10.20514/2226-6704-2016-6-3-8-18</mixed-citation></citation-alternatives></ref><ref id="cit269"><label>269</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Приходько В.А., Безбородкина Н.Н., Кудрявцев Б.Н. Гепатопротекторы: руководство для врачей. 2-е изд. М.: ГЭОТАР-Медиа, 2022.</mixed-citation><mixed-citation xml:lang="en">Okovityi S.V., Prikhodko V.A., Bezborodkina N.N., Kudryavtsev B.N. Hepatoprotectors: A guide for doctors. 2nd ed. Moscow: GEOTAR-Media, 2022. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit270"><label>270</label><citation-alternatives><mixed-citation xml:lang="ru">Коломиец В.М., Коваленко А.Л., Таликова Е.В. Эффективность использования ремаксола в терапии сопровождения при запущенном туберкулезе. Антибиотики и химиотерапия. 2019;64(5–6):44–8. DOI: 10.24411/0235-2990-2019-100030</mixed-citation><mixed-citation xml:lang="en">Kolomiets V.M., Kovalenko A.L., Talikova E.V. Efficiency of using remaxol in supportive therapy for advanced tuberculosis. Antibiotics and Chemotherapy. 2019;64(5–6):44–8. (In Russ.). DOI: 10.24411/0235-2990-2019-100030</mixed-citation></citation-alternatives></ref><ref id="cit271"><label>271</label><citation-alternatives><mixed-citation xml:lang="ru">Красова Е.К., Ковалева Е.А., Оковитый С.В. Оценка эффективности и безопасности сукцинатов при лекарственных поражениях печени: систематический обзор. Медицинский совет. 2025;19(15):102–17. DOI: 10.21518/ms2025-325</mixed-citation><mixed-citation xml:lang="en">Krasova E.K., Kovaleva E.A., Okovityi S.V. Evaluation of the efficacy and safety of succinates in drug-induced liver injury: A systematic review. Medical Council. 2025;19(15):102–17. (In Russ.). DOI: 10.21518/ms2025-325</mixed-citation></citation-alternatives></ref><ref id="cit272"><label>272</label><citation-alternatives><mixed-citation xml:lang="ru">Коломиец В.М., Коваленко А.Л., Петров А.Ю., Павленко Е.П., Таликова Е.В. Некоторые особенности терапии современного коморбидного туберкулеза. Антибиотики и химиотерапия. 2022;67(11–12):46– 50. DOI: 10.37489/0235-2990-2022-67-11-12-46-50</mixed-citation><mixed-citation xml:lang="en">Kolomiets V.M., Kovalenko A.L., Petrov A.Yu., Pavlenko E.P., Talikova E.V. Some peculiarities of modern comorbid tuberculosis therapy. Antibiotics and Chemotherapy. 2022;67(11–12):46–50. (In Russ.). DOI: 10.37489/0235-2990-2022-67-11-12-46-50</mixed-citation></citation-alternatives></ref><ref id="cit273"><label>273</label><citation-alternatives><mixed-citation xml:lang="ru">Коломиец В.М., Коваленко А.Л., Петров А.Ю., Павленко Е.П., Таликова Е.В. Эффективность сукцинатсодержащего препарата в терапии сопровождения при лечении коморбидного туберкулеза в условиях пенитенциарного учреждения. Антибиотики и химиотерапия. 2020;65(9–10):32–6. DOI: 10.37489/0235-2990-2020-65-9-10-32-36</mixed-citation><mixed-citation xml:lang="en">Kolomiets V.M., Kovalenko A.L., Pavlenko E.P., Talikova E.V. The effectiveness of a succinate-containing medication in accompanying therapy of comorbid tuberculosis in a penitentiary institution. Antibiotics and Chemotherapy. 2020;65(9–10):32–6. (In Russ.). DOI: 10.37489/0235-2990-2020-65-9-10-32-36</mixed-citation></citation-alternatives></ref><ref id="cit274"><label>274</label><citation-alternatives><mixed-citation xml:lang="ru">Мордык А.В., Иванова О.Г., Нагибина Л.А., Ситникова С.В., Марьехина О.А. Лекарственные поражения печени и их лечение в клинике туберкулеза. Туберкулез и болезни легких. 2015;9:47–53.</mixed-citation><mixed-citation xml:lang="en">Mordyk A.V., Ivanova O.G., Nagibina L.A., Sitnikova S.V., Maryekhina O.A. Drug-induced liver damage and its treatment in the tuberculosis clinic. Tuberculosis and Lung Diseases. 2015;9:47–53. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit275"><label>275</label><citation-alternatives><mixed-citation xml:lang="ru">Шевырева Е.В., Иванов А.К., Суханов Д.С., Мурзина А.А. Гепатопротекторная терапия ремаксолом у больных туберкулезом и ВИЧ-инфекцией в дневном стационаре противотуберкулезного диспансера. Антибиотики и химиотерапия. 2012;57(7–8):31–7.</mixed-citation><mixed-citation xml:lang="en">Shevyreva E.V., Ivanov A.K., Sukhanov D.S., Murzina A.A. Hepatoprotective therapy with remaxol in patients with tuberculosis and HIV infection in the day hospital of the tuberculosis dispensary. Antibiotics and Chemotherapy. 2012;57(7–8): 31–7. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit276"><label>276</label><citation-alternatives><mixed-citation xml:lang="ru">Сас Е.И., Гриневич В.Б. Многокомпонентные инфузионные гепатопротекторы при лекарственном поражении печени. Медицинский совет. 2019;3:84–8. DOI: 10.21518/2079-701X-2019-3-84-88</mixed-citation><mixed-citation xml:lang="en">Sas E.I., Grinevich V.B. Multi-component infusion hepatoprotectors for liver damage. Medical Council. 2019;3:84–8. (In Russ.). DOI: 10.21518/2079-701X-2019-3-84-88</mixed-citation></citation-alternatives></ref><ref id="cit277"><label>277</label><citation-alternatives><mixed-citation xml:lang="ru">Павлов А.И., Балабанов А.С., Бакирова В.Э., Каракозов А.Г., Андреев Д.Н., Молодова А.И. и др. Оценка эффективности гепатопротектора в лечении токсического (лекарственного) поражения печени. Медицинский совет. 2025;19(8):126–33. DOI: 10.21518/ms2025-232</mixed-citation><mixed-citation xml:lang="en">Pavlov A.I., Balabanov A.S., Bakirova V.E., Karakozov A.G., Andreev D.N., Molodova A.I., et al. Evaluation of the efficacy of a hepatoprotector for the treatment of toxic (drug-induced) liver injury. Medical Council. 2025;19(8):126–33. (In Russ.). DOI: 10.21518/ms2025-232</mixed-citation></citation-alternatives></ref><ref id="cit278"><label>278</label><citation-alternatives><mixed-citation xml:lang="ru">Конопацкова О.М., Аверьянова С.В. Применение Ремаксола при полихимиотерапии у больных раком молочной железы. Онкология. Журнал им. П.А. Герцена. 2015;4(6):35–7.</mixed-citation><mixed-citation xml:lang="en">Konopatskaya O.M., Averianova S.V. Use of Remaxol in polychemotherapy in patients with breast cancer. P.A. Herzen Journal of Oncology. 2015;4(6):35–7. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit279"><label>279</label><citation-alternatives><mixed-citation xml:lang="ru">Бондаренко Д.А., Смирнов Д.В., Симонова Н.В., Доровских В.А. Опыт применения ремаксола при полихимиотерапии рака яичников. Онкология. Журнал им. П.А. Герцена. 2020;9(6):39–44. DOI: 10.17116/onkolog2020906139</mixed-citation><mixed-citation xml:lang="en">Bondarenko D.A., Smirnov D.V., Simonova N.V., Dorovskikh V.A. Experience with remaxol in the polychemotherapy of ovarian cancer. P.A. Herzen Journal of Oncology. 2020;9(6):39–44. (In Russ.). DOI: 10.17116/onkolog2020906139</mixed-citation></citation-alternatives></ref><ref id="cit280"><label>280</label><citation-alternatives><mixed-citation xml:lang="ru">Черенков В.Г., Петров А.Б., Васильева Т.М., Строженков М.М. Возможности ремаксола для профилактики токсических гепатитов при химиотерапии онкологических больных. Вопросы онкологии. 2013;59(3):369–74.</mixed-citation><mixed-citation xml:lang="en">Cherenkov V.G., Petrov A.B., Vasilyeva T.M., Strozhenkov M.M. Potential of remaxol for the prevention of toxic hepatitis during chemotherapy of cancer patients. Voprosy Onkologii. 2013;59(3):369–74. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit281"><label>281</label><citation-alternatives><mixed-citation xml:lang="ru">Дрогомирецкая Е.И., Трашков А.П., Балашов В.К., Бобраков М.А., Ерохина Е.А., Круглов А.Н. и др. Экспериментальный и клинический опыт применения Ремаксола как препарата сопровождения при противоопухолевом лечении. Эффективная фармакотерапия. 2018;(25):34–41.</mixed-citation><mixed-citation xml:lang="en">Drogomiretskaya E.I., Trashkov A.P., Balashov V.K., Bobrakov M.A., Erokhina E.A., Kruglov A.N., et al. Experimental and clinical experience with the use of Remaxol as an adjuvant drug in antitumor treatment. Effective Pharmacotherapy. 2018;(25):34–41. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit282"><label>282</label><citation-alternatives><mixed-citation xml:lang="ru">Конопацкова О.М., Аверьянова С.В. Сопроводительная терапия при проведении полихимиотерапии колоректального рака. Онкология. Журнал им. П.А. Герцена. 2016;5(1):42–6.</mixed-citation><mixed-citation xml:lang="en">Konopatskaya O.M., Averianova S.V. Concomitant therapy during polychemotherapy of colorectal cancer. P.A. Herzen Journal of Oncology. 2016;5(1):42–6. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit283"><label>283</label><citation-alternatives><mixed-citation xml:lang="ru">Безбородова О.А., Немцова Е.Р., Венедиктова Ю.Б., Якубовская Р.И., Александрова Л.Н., Коваленко А.Л. Экспериментальное изучение ремаксола как препарата поддерживающей терапии при традиционной и высокодозной химиотерапии опухоли. Экспериментальная и клиническая фармакология. 2013;76(5):18–22. DOI: 10.30906/0869-2092-2013-76-5-18-22</mixed-citation><mixed-citation xml:lang="en">Bezborodova O.A., Nemtsova E.R., Venediktova Yu.B., Yakubovskaya R.I., Aleksandrova L.N., Kovalenko A.L. Experimental study of remaxol as a maintenance therapy drug in traditional and high-dose tumor chemotherapy. Experimental and Clinical Pharmacology. 2013;76(5):18–22. (In Russ.). DOI: 10.30906/0869-2092-2013-76-5-18-22</mixed-citation></citation-alternatives></ref><ref id="cit284"><label>284</label><citation-alternatives><mixed-citation xml:lang="ru">Филиппова Н.В., Барыльник Ю.Б., Шульдяков А.А. Применение ремаксола в качестве гепатопротектора при длительной психофармакотерапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(4):43–6. DOI: 10.17116/jnevro201911901143</mixed-citation><mixed-citation xml:lang="en">Filippova N.V., Barylnik Iu.B., Shuldyakov A.A. The efficacy of remaxol as a hepatoprotective agent in long-term psychopharmacotherapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):43–6. (In Russ.). DOI: 10.17116/jnevro201911901143</mixed-citation></citation-alternatives></ref><ref id="cit285"><label>285</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao T., Mao L., Yu Z., Hui Y., Feng H., Wang X., et al. Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine. Int Immunopharmacol. 2021;91:107308. DOI: 10.1016/j.intimp.2020.107308</mixed-citation><mixed-citation xml:lang="en">Zhao T., Mao L., Yu Z., Hui Y., Feng H., Wang X., et al. Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine. Int Immunopharmacol. 2021;91:107308. DOI: 10.1016/j.intimp.2020.107308</mixed-citation></citation-alternatives></ref><ref id="cit286"><label>286</label><citation-alternatives><mixed-citation xml:lang="ru">Yao X.M., Wang B.L., Gu Y., Li Y. Effects of bicyclol on the activity and expression of CYP450 enzymes of rats after partial hepatectomy. Yao Xue Xue Bao. 2011;46(6):656–63.</mixed-citation><mixed-citation xml:lang="en">Yao X.M., Wang B.L., Gu Y., Li Y. Effects of bicyclol on the activity and expression of CYP450 enzymes of rats after partial hepatectomy. Yao Xue Xue Bao. 2011;46(6):656–63.</mixed-citation></citation-alternatives></ref><ref id="cit287"><label>287</label><citation-alternatives><mixed-citation xml:lang="ru">Bao X., Liu G., Wang Y., Nie H., Zhao X., Qin Y., et al. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/ AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer. 2016;16(1):742. DOI: 10.1186/s12885-016-2767-2</mixed-citation><mixed-citation xml:lang="en">Bao X., Liu G., Wang Y., Nie H., Zhao X., Qin Y., et al. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/ AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer. 2016;16(1):742. DOI: 10.1186/s12885-016-2767-2</mixed-citation></citation-alternatives></ref><ref id="cit288"><label>288</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X., Zhao M., Mi J., Chen H., Sheng L., Li Y. Protective effect of bicyclol on anti-tuberculosis drug induced liver injury in rats. Molecules. 2017;22(4):524. DOI: 10.3390/molecules22040524</mixed-citation><mixed-citation xml:lang="en">Liu X., Zhao M., Mi J., Chen H., Sheng L., Li Y. Protective effect of bicyclol on anti-tuberculosis drug induced liver injury in rats. Molecules. 2017;22(4):524. DOI: 10.3390/molecules22040524</mixed-citation></citation-alternatives></ref><ref id="cit289"><label>289</label><citation-alternatives><mixed-citation xml:lang="ru">Chen F., Zou H., Zhang P., Yan Y. Investigation on the in vitro metabolism of bicyclol using liver microsomes, hepatocytes and human recombinant cytochrome P450 enzymes. Xenobiotica. 2023;53(4):231–40. DOI: 10.1080/00498254.2023.2222385</mixed-citation><mixed-citation xml:lang="en">Chen F., Zou H., Zhang P., Yan Y. Investigation on the in vitro metabolism of bicyclol using liver microsomes, hepatocytes and human recombinant cytochrome P450 enzymes. Xenobiotica. 2023;53(4):231–40. DOI: 10.1080/00498254.2023.2222385</mixed-citation></citation-alternatives></ref><ref id="cit290"><label>290</label><citation-alternatives><mixed-citation xml:lang="ru">Li X., Zhou J., Chen S., Guan M., Wang Y., Zhao L., et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–14. DOI: 10.1177/0300060514527058</mixed-citation><mixed-citation xml:lang="en">Li X., Zhou J., Chen S., Guan M., Wang Y., Zhao L., et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–14. DOI: 10.1177/0300060514527058</mixed-citation></citation-alternatives></ref><ref id="cit291"><label>291</label><citation-alternatives><mixed-citation xml:lang="ru">Naiqiong W., Liansheng W., Zhanying H., Yuanlin G., Chenggang Z., Ying G., et al. A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury. Med Sci Monit. 2017;23:5760–6. DOI: 10.12659/msm.904090</mixed-citation><mixed-citation xml:lang="en">Naiqiong W., Liansheng W., Zhanying H., Yuanlin G., Chenggang Z., Ying G., et al. A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury. Med Sci Monit. 2017;23:5760–6. DOI: 10.12659/msm.904090</mixed-citation></citation-alternatives></ref><ref id="cit292"><label>292</label><citation-alternatives><mixed-citation xml:lang="ru">Niu H., Sanabria-Cabrera J., Alvarez-Alvarez I., Robles-Diaz M., Stankevičiūtė S., Aithal G.P., et al. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacol Res. 2021;164:105404. DOI: 10.1016/j.phrs.2020.105404</mixed-citation><mixed-citation xml:lang="en">Niu H., Sanabria-Cabrera J., Alvarez-Alvarez I., Robles-Diaz M., Stankevičiūtė S., Aithal G.P., et al. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacol Res. 2021;164:105404. DOI: 10.1016/j.phrs.2020.105404</mixed-citation></citation-alternatives></ref><ref id="cit293"><label>293</label><citation-alternatives><mixed-citation xml:lang="ru">Chu N.H., Li L., Zhang X., Gu J., Du Y.D., Cai C., et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19(4):475–80. DOI: 10.5588/ijtld.14.0579</mixed-citation><mixed-citation xml:lang="en">Chu N.H., Li L., Zhang X., Gu J., Du Y.D., Cai C., et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19(4):475–80. DOI: 10.5588/ijtld.14.0579</mixed-citation></citation-alternatives></ref><ref id="cit294"><label>294</label><citation-alternatives><mixed-citation xml:lang="ru">Du Y., Gu J., Yang Y., Chen Y., Wang Y., Mei Z., et al. Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury. Int J Tuberc Lung Dis. 2024;28(1):6–12. DOI: 10.5588/ijtld.23.0038</mixed-citation><mixed-citation xml:lang="en">Du Y., Gu J., Yang Y., Chen Y., Wang Y., Mei Z., et al. Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury. Int J Tuberc Lung Dis. 2024;28(1):6–12. DOI: 10.5588/ijtld.23.0038</mixed-citation></citation-alternatives></ref><ref id="cit295"><label>295</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X., Zhao S., Wang Q., Ma A. Protective effect of bicyclol on anti-tuberculosis drug-induced hepatotoxicity: A meta-analysis. Chin J Dis Control Prev. 2018;22(4):390–5. DOI: 10.16462/j.cnki.zhjbkz.2018.04.016</mixed-citation><mixed-citation xml:lang="en">Wang X., Zhao S., Wang Q., Ma A. Protective effect of bicyclol on anti-tuberculosis drug-induced hepatotoxicity: A meta-analysis. Chin J Dis Control Prev. 2018;22(4):390–5. DOI: 10.16462/j.cnki.zhjbkz.2018.04.016</mixed-citation></citation-alternatives></ref><ref id="cit296"><label>296</label><citation-alternatives><mixed-citation xml:lang="ru">Tang J., Gu J., Chu N., Chen Y., Wang Y., Xue D., et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial. Liver Int. 2022;42(8):1803–13. DOI: 10.1111/liv.15290</mixed-citation><mixed-citation xml:lang="en">Tang J., Gu J., Chu N., Chen Y., Wang Y., Xue D., et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial. Liver Int. 2022;42(8):1803–13. DOI: 10.1111/liv.15290</mixed-citation></citation-alternatives></ref><ref id="cit297"><label>297</label><citation-alternatives><mixed-citation xml:lang="ru">Приходько В.А., Оковитый С.В. Возможности применения морфолиния тиазотата в качестве средства фармакотерапии состояний гепатокардиального континуума. Медицинский совет. 2024;18(23):94–103. DOI: 10.21518/ms2024-517</mixed-citation><mixed-citation xml:lang="en">Prikhodko V.A., Okovityi S.V. Perspectives for the use of morpholinium tiazotate as a pharmacotherapy for hepato-cardiac disorders. Medical Council. 2024;18(23):94–103. (In Russ.). DOI: 10.21518/ms2024-517</mixed-citation></citation-alternatives></ref><ref id="cit298"><label>298</label><citation-alternatives><mixed-citation xml:lang="ru">Bielenichev I.F., Maslennikov S.O., Dobrelia N.V., Khromov O.S., Holovakha M.L., Ryzhenko V.P., et al. The role of adipose tissue cell elements in the regulation of the nitroxidergic system and possible ways of pharmacological modulation. Mod Med Technol. 2024;16(2):122–31. DOI: 10.14739/mmt.2024.2.299862.14</mixed-citation><mixed-citation xml:lang="en">Bielenichev I.F., Maslennikov S.O., Dobrelia N.V., Khromov O.S., Holovakha M.L., Ryzhenko V.P., et al. The role of adipose tissue cell elements in the regulation of the nitroxidergic system and possible ways of pharmacological modulation. Mod Med Technol. 2024;16(2):122–31. DOI: 10.14739/mmt.2024.2.299862.14</mixed-citation></citation-alternatives></ref><ref id="cit299"><label>299</label><citation-alternatives><mixed-citation xml:lang="ru">Popazova O., Belenichev I., Bukhtiyarova N., Ryzhenko V., Oksenych V., Kamyshnyi A. Cardioprotective activity of pharmacological agents affecting NO production and bioavailability in the early postnatal period after intrauterine hypoxia in rats. Biomedicines. 2023;11(10):2854. DOI: 10.3390/biomedicines11102854</mixed-citation><mixed-citation xml:lang="en">Popazova O., Belenichev I., Bukhtiyarova N., Ryzhenko V., Oksenych V., Kamyshnyi A. Cardioprotective activity of pharmacological agents affecting NO production and bioavailability in the early postnatal period after intrauterine hypoxia in rats. Biomedicines. 2023;11(10):2854. DOI: 10.3390/biomedicines11102854</mixed-citation></citation-alternatives></ref><ref id="cit300"><label>300</label><citation-alternatives><mixed-citation xml:lang="ru">Топчий Н.В., Топорков А.С. Возможности применения Тиотриазолина в качестве средства метаболической терапии. РМЖ. 2015;23(15):890–4.</mixed-citation><mixed-citation xml:lang="en">Topchiy N.V., Toporkov A.S. Possibilities of using Thiotriazoline as a means of metabolic therapy. RMJ. 2015;23(15):890–4. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit301"><label>301</label><citation-alternatives><mixed-citation xml:lang="ru">Маевская М.В., Оковитый С.В., Приходько В.А. Морфолиния тиазотат в лечении заболеваний печени и сочетанном поражении печени и сердечно-сосудистой системы (описательный обзор). Медицинский совет. 2025;8:64–71. DOI: 10.21518/ms2025-211</mixed-citation><mixed-citation xml:lang="en">Maevskaya М.V., Okovityi S.V., Prikhodko V.A. Morpholinium thiazotati in the treatment of liver diseases and combined liver and heart diseases (narrative review). Medical Council. 2025;8:64–71. (In Russ.). DOI: 10.21518/ms2025-211</mixed-citation></citation-alternatives></ref><ref id="cit302"><label>302</label><citation-alternatives><mixed-citation xml:lang="ru">Кольцов А.В., Тыренко В.В. Опыт лечения сердечной недостаточности как проявления кардиотоксичности химиотерапии у онкологических пациентов. Эффективная фармакотерапия. 2023;19(33):18–22. DOI: 10.33978/2307-3586-2023-19-33-18-22</mixed-citation><mixed-citation xml:lang="en">Koltsov A.V., Tyrenko V.V. Experience in the treatment of heart failure as manifestations of cardiotoxicity of chemotherapy in cancer patients. Effective Pharmacotherapy. 2023;19(33):18– 22. (In Russ.). DOI: 10.33978/2307-3586-2023-19-33-18-22</mixed-citation></citation-alternatives></ref><ref id="cit303"><label>303</label><citation-alternatives><mixed-citation xml:lang="ru">Гречканев Г.О., Чурикова М.С. Влияние препарата Тиотриазолин® на функциональную активность печени, перекисное окисление липидов и антиоксидантную систему крови у пациенток с воспалительными заболеваниями органов малого таза, длительно получающих антибактериальную терапию. Поликлиника. 2012;(4–1): 67–70.</mixed-citation><mixed-citation xml:lang="en">Grechkanev G.O., Churikova M.S. Effect of Thiotriazolin® on liver function, lipid peroxidation, and the blood antioxidant system in patients with pelvic inflammatory diseases receiving long-term antibacterial therapy. Poliklinika. 2012;(4-1):67–70. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit304"><label>304</label><citation-alternatives><mixed-citation xml:lang="ru">Шовкун Л.А., Кампос Е.Д., Романцева Н.Э. Гепатопротекторные и антиоксидантные эффекты тиотриазолина при лечении больных туберкулезом легких. Журнал фундаментальной медицины и биологии. 2013;2:72–8.</mixed-citation><mixed-citation xml:lang="en">Shovkun L.A., Kampos E.D., Romantseva N.E. Hepatoprotective and antioxidant effects of thiotriazoline in the treatment of patients with pulmonary tuberculosis. Journal of Fundamental Medicine and Biology. 2013;2:72–8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit305"><label>305</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Райхельсон К.Л., Приходько В.А. Комбинированная гепатопротекторная фармакотерапия заболеваний печени. Экспериментальная и клиническая гастроэнтерология. 2022;7:5–20. DOI: 10.31146/1682-8658-ecg-203-7-5-20</mixed-citation><mixed-citation xml:lang="en">Okovityi S.V., Raikhelson K.L., Prikhodko V.A. Combined hepatoprotective pharmacotherapy for liver disease. Experimental and Clinical Gastroenterology. 2022;7:5–20. (In Russ.). DOI: 10.31146/1682-8658-ecg-203-7-5-20</mixed-citation></citation-alternatives></ref><ref id="cit306"><label>306</label><citation-alternatives><mixed-citation xml:lang="ru">Скрипник І.М., Маслова Г.С. Особливості профілактики уражень печінки у хворих на гостру лімфобластну лейкемію у поєднанні з ожирінням. Украинский терапевтический журнал. 2020;2:14–9. DOI: 10.30978/UTJ2020-2-14</mixed-citation><mixed-citation xml:lang="en">Skripnik I.M., Maslova G.S. Features of prevention of liver damage in patients with acute lymphoblastic leukemia in obese patients. Ukrainian Therapeutic Journal. 2020;2:14–9. (In Ukrainian). DOI: 10.30978/UTJ2020-2-14</mixed-citation></citation-alternatives></ref><ref id="cit307"><label>307</label><citation-alternatives><mixed-citation xml:lang="ru">Ye Y.J., Yu J.P., Xu Y.M., Wang H., Xie Q. The treatment effect of ursodeoxycholic acid combined with S-adenosyl-L-methionine on drug-induced cholestatic liver injury. Chin Hepatol. 2017;22(12):1090–3. DOI: 10.14000/j.cnki.issn.1008-1704.2017.12.007</mixed-citation><mixed-citation xml:lang="en">Ye Y.J., Yu J.P., Xu Y.M., Wang H., Xie Q. The treatment effect of ursodeoxycholic acid combined with S-adenosyl-L-methionine on drug-induced cholestatic liver injury. Chin Hepatol. 2017;22(12):1090–3. DOI: 10.14000/j.cnki.issn.1008-1704.2017.12.007</mixed-citation></citation-alternatives></ref><ref id="cit308"><label>308</label><citation-alternatives><mixed-citation xml:lang="ru">Wree A., Dechêne A., Herzer K., Hilgard P., Syn W.K., Gerken G., et al. Steroid and ursodeoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54–9. DOI: 10.1159/000322298</mixed-citation><mixed-citation xml:lang="en">Wree A., Dechêne A., Herzer K., Hilgard P., Syn W.K., Gerken G., et al. Steroid and ursodeoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54–9. DOI: 10.1159/000322298</mixed-citation></citation-alternatives></ref><ref id="cit309"><label>309</label><citation-alternatives><mixed-citation xml:lang="ru">Onishi S., Tajika M., Bando H., Matsubara Y., Hosoda W., Muro K., et al. Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: A case report. J Med Case Rep. 2020;14(1):230. DOI: 10.1186/s13256-020-02541-3</mixed-citation><mixed-citation xml:lang="en">Onishi S., Tajika M., Bando H., Matsubara Y., Hosoda W., Muro K., et al. Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: A case report. J Med Case Rep. 2020;14(1):230. DOI: 10.1186/s13256-020-02541-3</mixed-citation></citation-alternatives></ref><ref id="cit310"><label>310</label><citation-alternatives><mixed-citation xml:lang="ru">Wu J., Xie L.X., Xiu J. Short-term efficacy of polyene phosphatidylcholine and bicyclol combination in treatment of gastric cancer patients with chemotherapy-induced liver injury. J Prac Hepatol. 2020;23(5):666–9. DOI: 10.3969/j.issn.1672-5069.2020.05.016</mixed-citation><mixed-citation xml:lang="en">Wu J., Xie L.X., Xiu J. Short-term efficacy of polyene phosphatidylcholine and bicyclol combination in treatment of gastric cancer patients with chemotherapy-induced liver injury. J Prac Hepatol. 2020;23(5):666–9. DOI: 10.3969/j.issn.1672-5069.2020.05.016</mixed-citation></citation-alternatives></ref><ref id="cit311"><label>311</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H.X., Zhu Q.J., Zhang Y.J., Mao C. Efficacy of acetylcysteine combined with magnesium isoglycyrrhizinate in treatment of patients with drug-induced liver injuries. J Prac Hepatol. 2020;23(2):227–30. DOI: 10.3969/j.issn.1672-5069.2020.02.020</mixed-citation><mixed-citation xml:lang="en">Wang H.X., Zhu Q.J., Zhang Y.J., Mao C. Efficacy of acetylcysteine combined with magnesium isoglycyrrhizinate in treatment of patients with drug-induced liver injuries. J Prac Hepatol. 2020;23(2):227–30. DOI: 10.3969/j.issn.1672-5069.2020.02.020</mixed-citation></citation-alternatives></ref><ref id="cit312"><label>312</label><citation-alternatives><mixed-citation xml:lang="ru">Bordbar M., Shakibazad N., Fattahi M., Haghpanah S., Honar N. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29(2):203–9. DOI: 10.5152/tjg.2018.17521</mixed-citation><mixed-citation xml:lang="en">Bordbar M., Shakibazad N., Fattahi M., Haghpanah S., Honar N. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29(2):203–9. DOI: 10.5152/tjg.2018.17521</mixed-citation></citation-alternatives></ref><ref id="cit313"><label>313</label><citation-alternatives><mixed-citation xml:lang="ru">Stirnimann G., Robles-Díaz M. Role of corticosteroids in drug-induced liver injury. A systematic review. Front Pharmacol. 2022;13:820724. DOI: 10.3389/fphar.2022.820724</mixed-citation><mixed-citation xml:lang="en">Stirnimann G., Robles-Díaz M. Role of corticosteroids in drug-induced liver injury. A systematic review. Front Pharmacol. 2022;13:820724. DOI: 10.3389/fphar.2022.820724</mixed-citation></citation-alternatives></ref><ref id="cit314"><label>314</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004. DOI: 10.1016/j.jhep.2015.06.030</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004. DOI: 10.1016/j.jhep.2015.06.030</mixed-citation></citation-alternatives></ref><ref id="cit315"><label>315</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson E.S., Medina-Cádiz I., Andrade R.J., Lucena M.L. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022;6(8):1895–909. DOI: 10.1002/hep4.1959</mixed-citation><mixed-citation xml:lang="en">Björnsson E.S., Medina-Cádiz I., Andrade R.J., Lucena M.L. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022;6(8):1895–909. DOI: 10.1002/hep4.1959</mixed-citation></citation-alternatives></ref><ref id="cit316"><label>316</label><citation-alternatives><mixed-citation xml:lang="ru">Wilkenfeld S.R., Lin C., Frigo D.E. Communication between genomic and non-genomic signaling events coordinate steroid hormone actions. Steroids. 2018;133:2–7. DOI: 10.1016/j.steroids.2017.11.005</mixed-citation><mixed-citation xml:lang="en">Wilkenfeld S.R., Lin C., Frigo D.E. Communication between genomic and non-genomic signaling events coordinate steroid hormone actions. Steroids. 2018;133:2–7. DOI: 10.1016/j.steroids.2017.11.005</mixed-citation></citation-alternatives></ref><ref id="cit317"><label>317</label><citation-alternatives><mixed-citation xml:lang="ru">Panettieri R.A., Schaafsma D., Amrani Y., Koziol-White C., Ostrom R., Tliba O. Non-genomic effects of glucocorticoids: An updated view. Trends Pharmacol Sci. 2019;40(1):38–49. DOI: 10.1016/j.tips.2018.11.002</mixed-citation><mixed-citation xml:lang="en">Panettieri R.A., Schaafsma D., Amrani Y., Koziol-White C., Ostrom R., Tliba O. Non-genomic effects of glucocorticoids: An updated view. Trends Pharmacol Sci. 2019;40(1):38–49. DOI: 10.1016/j.tips.2018.11.002</mixed-citation></citation-alternatives></ref><ref id="cit318"><label>318</label><citation-alternatives><mixed-citation xml:lang="ru">Karkhanis J., Verna E.C., Chang M.S., Stravitz R.T., Schilsky M., Lee W.M., et al. Steroid use in acute liver failure. Hepatology. 2014;59(2):612–21. DOI: 10.1002/hep.26678</mixed-citation><mixed-citation xml:lang="en">Karkhanis J., Verna E.C., Chang M.S., Stravitz R.T., Schilsky M., Lee W.M., et al. Steroid use in acute liver failure. Hepatology. 2014;59(2):612–21. DOI: 10.1002/hep.26678</mixed-citation></citation-alternatives></ref><ref id="cit319"><label>319</label><citation-alternatives><mixed-citation xml:lang="ru">Song F.J., Liu H.L., Sun Y., Xu T.J., Li D.Z., Wang H.B., et al. Prednisolone therapy accelerates recovery of severe drug-induced liver injury: A prospective, randomized controlled study. ILIVER. 2023;2(3):156–62. DOI: 10.1016/j.iliver.2023.06.001</mixed-citation><mixed-citation xml:lang="en">Song F.J., Liu H.L., Sun Y., Xu T.J., Li D.Z., Wang H.B., et al. Prednisolone therapy accelerates recovery of severe drug-induced liver injury: A prospective, randomized controlled study. ILIVER. 2023;2(3):156–62. DOI: 10.1016/j.iliver.2023.06.001</mixed-citation></citation-alternatives></ref><ref id="cit320"><label>320</label><citation-alternatives><mixed-citation xml:lang="ru">Niu H., Ma J., Medina-Caliz I., Robles-Diaz M., Bonilla-Toyos E., Ghabril M., et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2023;57(8):886–96. DOI: 10.1111/apt.17373</mixed-citation><mixed-citation xml:lang="en">Niu H., Ma J., Medina-Caliz I., Robles-Diaz M., Bonilla-Toyos E., Ghabril M., et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2023;57(8):886–96. DOI: 10.1111/apt.17373</mixed-citation></citation-alternatives></ref><ref id="cit321"><label>321</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson E.S., Vucic V., Stirnimann G., Robles-Díaz M. Role of corticosteroids in drug-induced liver injury. A systematic review. Front Pharmacol. 2022;13:820724. DOI: 10.3389/fphar.2022.820724</mixed-citation><mixed-citation xml:lang="en">Björnsson E.S., Vucic V., Stirnimann G., Robles-Díaz M. Role of corticosteroids in drug-induced liver injury. A systematic review. Front Pharmacol. 2022;13:820724. DOI: 10.3389/fphar.2022.820724</mixed-citation></citation-alternatives></ref><ref id="cit322"><label>322</label><citation-alternatives><mixed-citation xml:lang="ru">Hu P.F., Wang P.Q., Chen H., Hu X.F., Xie Q.P., Shi J., et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis. 2016;17(9):618–27. DOI: 10.1111/1751-2980.12383</mixed-citation><mixed-citation xml:lang="en">Hu P.F., Wang P.Q., Chen H., Hu X.F., Xie Q.P., Shi J., et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis. 2016;17(9):618–27. DOI: 10.1111/1751-2980.12383</mixed-citation></citation-alternatives></ref><ref id="cit323"><label>323</label><citation-alternatives><mixed-citation xml:lang="ru">Mack C.L., Adams D., Assis D.N., Kerkar N., Manns M.P., Mayo M.J., et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722. DOI: 10.1002/hep.31065</mixed-citation><mixed-citation xml:lang="en">Mack C.L., Adams D., Assis D.N., Kerkar N., Manns M.P., Mayo M.J., et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722. DOI: 10.1002/hep.31065</mixed-citation></citation-alternatives></ref><ref id="cit324"><label>324</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Q., Huang A., Wang J.B., Zou Z. Chronic drug-induced liver injury: Updates and future challenges. Front Pharmacol. 2021;12:627133. DOI: 10.3389/fphar.2021.627133</mixed-citation><mixed-citation xml:lang="en">Wang Q., Huang A., Wang J.B., Zou Z. Chronic drug-induced liver injury: Updates and future challenges. Front Pharmacol. 2021;12:627133. DOI: 10.3389/fphar.2021.627133</mixed-citation></citation-alternatives></ref><ref id="cit325"><label>325</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider B.J., Naidoo J., Santomasso B.D., Lacchetti C., Adkins S., Anadkat M., et al. Management of immunerelated adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. J Clin Oncol. 2021;39(36):4073–126. DOI: 10.1200/JCO.21.01440</mixed-citation><mixed-citation xml:lang="en">Schneider B.J., Naidoo J., Santomasso B.D., Lacchetti C., Adkins S., Anadkat M., et al. Management of immunerelated adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. J Clin Oncol. 2021;39(36):4073–126. DOI: 10.1200/JCO.21.01440</mixed-citation></citation-alternatives></ref><ref id="cit326"><label>326</label><citation-alternatives><mixed-citation xml:lang="ru">Li M., Wong D., Vogel A.S., Sack J.S., Rahma O.E., Hodi F.S., et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022;75(3):531–40. DOI: 10.1002/hep.32215</mixed-citation><mixed-citation xml:lang="en">Li M., Wong D., Vogel A.S., Sack J.S., Rahma O.E., Hodi F.S., et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022;75(3):531–40. DOI: 10.1002/hep.32215</mixed-citation></citation-alternatives></ref><ref id="cit327"><label>327</label><citation-alternatives><mixed-citation xml:lang="ru">Delire B., De Martin E., Meunier L., Larrey D., Horsmans Y. Immunotherapy and gene therapy: New challenges in the diagnosis and management of drug-induced liver injury. Front Pharmacol. 2022;12:786174. DOI: 10.3389/fphar.2021.786174</mixed-citation><mixed-citation xml:lang="en">Delire B., De Martin E., Meunier L., Larrey D., Horsmans Y. Immunotherapy and gene therapy: New challenges in the diagnosis and management of drug-induced liver injury. Front Pharmacol. 2022;12:786174. DOI: 10.3389/fphar.2021.786174</mixed-citation></citation-alternatives></ref><ref id="cit328"><label>328</label><citation-alternatives><mixed-citation xml:lang="ru">Dougan M., Wang Y., Rubio-Tapia A., Lim J.K. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review. Gastroenterology. 2021;160(4):1384–93. DOI: 10.1053/j.gastro.2020.08.063</mixed-citation><mixed-citation xml:lang="en">Dougan M., Wang Y., Rubio-Tapia A., Lim J.K. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review. Gastroenterology. 2021;160(4):1384–93. DOI: 10.1053/j.gastro.2020.08.063</mixed-citation></citation-alternatives></ref><ref id="cit329"><label>329</label><citation-alternatives><mixed-citation xml:lang="ru">Peeraphatdit T.B., Wang J., Odenwald M.A., Hu S., Hart J., Charlton M.R. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology. 2020;72(1):315–29. DOI: 10.1002/hep.31227</mixed-citation><mixed-citation xml:lang="en">Peeraphatdit T.B., Wang J., Odenwald M.A., Hu S., Hart J., Charlton M.R. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology. 2020;72(1):315–29. DOI: 10.1002/hep.31227</mixed-citation></citation-alternatives></ref><ref id="cit330"><label>330</label><citation-alternatives><mixed-citation xml:lang="ru">De Martin E., Michot J.M., Papouin B., Champiat S., Mateus C., Lambotte O., et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68(6):1181–90. DOI: 10.1016/j.jhep.2018.01.033</mixed-citation><mixed-citation xml:lang="en">De Martin E., Michot J.M., Papouin B., Champiat S., Mateus C., Lambotte O., et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68(6):1181–90. DOI: 10.1016/j.jhep.2018.01.033</mixed-citation></citation-alternatives></ref><ref id="cit331"><label>331</label><citation-alternatives><mixed-citation xml:lang="ru">Gauci M.L., Baroudjian B., Zeboulon C., Pages C., Poté N., Roux O., et al. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed? J Hepatol. 2018;69(2):548–50. DOI: 10.1016/j.jhep.2018.03.034</mixed-citation><mixed-citation xml:lang="en">Gauci M.L., Baroudjian B., Zeboulon C., Pages C., Poté N., Roux O., et al. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed? J Hepatol. 2018;69(2):548–50. DOI: 10.1016/j.jhep.2018.03.034</mixed-citation></citation-alternatives></ref><ref id="cit332"><label>332</label><citation-alternatives><mixed-citation xml:lang="ru">Haanen J., Obeid M., Spain L., Carbonnel F., Wang Y., Robert C., et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–38. DOI: 10.1016/j.annonc.2022.10.001</mixed-citation><mixed-citation xml:lang="en">Haanen J., Obeid M., Spain L., Carbonnel F., Wang Y., Robert C., et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–38. DOI: 10.1016/j.annonc.2022.10.001</mixed-citation></citation-alternatives></ref><ref id="cit333"><label>333</label><citation-alternatives><mixed-citation xml:lang="ru">Omori G., Takada K., Murase K., Hayasaka N., Nakamura H., Iyama S., et al. Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer. Clin Case Rep. 2020;9(2):654–9. DOI: 10.1002/ccr3.3597</mixed-citation><mixed-citation xml:lang="en">Omori G., Takada K., Murase K., Hayasaka N., Nakamura H., Iyama S., et al. Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer. Clin Case Rep. 2020;9(2):654–9. DOI: 10.1002/ccr3.3597</mixed-citation></citation-alternatives></ref><ref id="cit334"><label>334</label><citation-alternatives><mixed-citation xml:lang="ru">Iwamoto K., Ishitsuka Y., Tanaka R., Sekine I., Fujimoto M. Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events. Eur J Dermatol. 2017;27(3):301–3. DOI: 10.1684/ejd.2017.2973</mixed-citation><mixed-citation xml:lang="en">Iwamoto K., Ishitsuka Y., Tanaka R., Sekine I., Fujimoto M. Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events. Eur J Dermatol. 2017;27(3):301–3. DOI: 10.1684/ejd.2017.2973</mixed-citation></citation-alternatives></ref><ref id="cit335"><label>335</label><citation-alternatives><mixed-citation xml:lang="ru">Cheung V., Gupta T., Payne M., Middleton M.R., Collier J.D., Simmons A., et al. Immunotherapy-related hepatitis: Real-world experience from a tertiary centre. Frontline Gastroenterol. 2019;10(4):364–71. DOI: 10.1136/flgastro-2018-101146</mixed-citation><mixed-citation xml:lang="en">Cheung V., Gupta T., Payne M., Middleton M.R., Collier J.D., Simmons A., et al. Immunotherapy-related hepatitis: Real-world experience from a tertiary centre. Frontline Gastroenterol. 2019;10(4):364–71. DOI: 10.1136/flgastro-2018-101146</mixed-citation></citation-alternatives></ref><ref id="cit336"><label>336</label><citation-alternatives><mixed-citation xml:lang="ru">Riveiro-Barciela M., Muñoz-Couselo E., Fernandez-Sojo J., Diaz-Mejia N., Parra-López R., Buti M. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? J Hepatol. 2019;70(3):564–6. DOI: 10.1016/j.jhep.2018.10.020</mixed-citation><mixed-citation xml:lang="en">Riveiro-Barciela M., Muñoz-Couselo E., Fernandez-Sojo J., Diaz-Mejia N., Parra-López R., Buti M. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? J Hepatol. 2019;70(3):564–6. DOI: 10.1016/j.jhep.2018.10.020</mixed-citation></citation-alternatives></ref><ref id="cit337"><label>337</label><citation-alternatives><mixed-citation xml:lang="ru">Ziogas D.C., Gkoufa A., Cholongitas E., Diamantopoulos P., Anastasopoulou A., Ascierto P.A., et al. When steroids are not enough in immune-related hepatitis: Current clinical challenges discussed on the basis of a case report. J Immunother Cancer. 2020;8(2):e001322. DOI: 10.1136/jitc-2020-001322</mixed-citation><mixed-citation xml:lang="en">Ziogas D.C., Gkoufa A., Cholongitas E., Diamantopoulos P., Anastasopoulou A., Ascierto P.A., et al. When steroids are not enough in immune-related hepatitis: Current clinical challenges discussed on the basis of a case report. J Immunother Cancer. 2020;8(2):e001322. DOI: 10.1136/jitc-2020-001322</mixed-citation></citation-alternatives></ref><ref id="cit338"><label>338</label><citation-alternatives><mixed-citation xml:lang="ru">Hountondji L., Faure S., Palassin P., Pageaux G.P., Maria A.T.J., Meunier L. Ursodeoxycholic acid alone is effective and safe to treat cholestatic checkpoint inhibitor induced liver injury. Liver Int. 2025;45(5):e70073. DOI: 10.1111/liv.70073</mixed-citation><mixed-citation xml:lang="en">Hountondji L., Faure S., Palassin P., Pageaux G.P., Maria A.T.J., Meunier L. Ursodeoxycholic acid alone is effective and safe to treat cholestatic checkpoint inhibitor induced liver injury. Liver Int. 2025;45(5):e70073. DOI: 10.1111/liv.70073</mixed-citation></citation-alternatives></ref><ref id="cit339"><label>339</label><citation-alternatives><mixed-citation xml:lang="ru">Hama N., Abe R., Gibson A., Phillips E.J. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): Clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155–67.e5. DOI: 10.1016/j.jaip.2022.02.004</mixed-citation><mixed-citation xml:lang="en">Hama N., Abe R., Gibson A., Phillips E.J. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): Clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155–67.e5. DOI: 10.1016/j.jaip.2022.02.004</mixed-citation></citation-alternatives></ref><ref id="cit340"><label>340</label><citation-alternatives><mixed-citation xml:lang="ru">Wei B.M., Fox L.P., Kaffenberger B.H., Korman A.M., Micheletti R.G., Mostaghimi A., et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II. Diagnosis and management. J Am Acad Dermatol. 2024;90(5):911–26. DOI: 10.1016/j.jaad.2023.02.073</mixed-citation><mixed-citation xml:lang="en">Wei B.M., Fox L.P., Kaffenberger B.H., Korman A.M., Micheletti R.G., Mostaghimi A., et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II. Diagnosis and management. J Am Acad Dermatol. 2024;90(5):911–26. DOI: 10.1016/j.jaad.2023.02.073</mixed-citation></citation-alternatives></ref><ref id="cit341"><label>341</label><citation-alternatives><mixed-citation xml:lang="ru">Shiohara T., Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301–8. DOI: 10.1016/j.alit.2019.03.006</mixed-citation><mixed-citation xml:lang="en">Shiohara T., Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301–8. DOI: 10.1016/j.alit.2019.03.006</mixed-citation></citation-alternatives></ref><ref id="cit342"><label>342</label><citation-alternatives><mixed-citation xml:lang="ru">Morita C., Yanase T., Shiohara T., Aoyama Y. Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)/ drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome. BMJ Case Rep. 2018;2018:bcr2018225528. DOI: 10.1136/bcr-2018-225528</mixed-citation><mixed-citation xml:lang="en">Morita C., Yanase T., Shiohara T., Aoyama Y. Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)/ drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome. BMJ Case Rep. 2018;2018:bcr2018225528. DOI: 10.1136/bcr-2018-225528</mixed-citation></citation-alternatives></ref><ref id="cit343"><label>343</label><citation-alternatives><mixed-citation xml:lang="ru">Ushigome Y., Kano Y., Ishida T., Hirahara K., Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68(5):721–8. DOI: 10.1016/j.jaad.2012.10.017</mixed-citation><mixed-citation xml:lang="en">Ushigome Y., Kano Y., Ishida T., Hirahara K., Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68(5):721–8. DOI: 10.1016/j.jaad.2012.10.017</mixed-citation></citation-alternatives></ref><ref id="cit344"><label>344</label><citation-alternatives><mixed-citation xml:lang="ru">Avancini J., Maragno L., Santi C.G., Criado P.R. Drug reaction with eosinophilia and systemic symptoms/ drug-induced hypersensitivity syndrome: Clinical features of 27 patients. Clin Exp Dermatol. 2015;40(8):851–9. DOI: 10.1111/ced.12682</mixed-citation><mixed-citation xml:lang="en">Avancini J., Maragno L., Santi C.G., Criado P.R. Drug reaction with eosinophilia and systemic symptoms/ drug-induced hypersensitivity syndrome: Clinical features of 27 patients. Clin Exp Dermatol. 2015;40(8):851–9. DOI: 10.1111/ced.12682</mixed-citation></citation-alternatives></ref><ref id="cit345"><label>345</label><citation-alternatives><mixed-citation xml:lang="ru">Giri P.P., Roy S., Bhattyacharya S., Pal P., Dhar S. Dress syndrome with sepsis, acute respiratory distress syndrome and pneumomediastinum. Indian J Dermatol. 2011;56(6):763–5. DOI: 10.4103/0019-5154.91850</mixed-citation><mixed-citation xml:lang="en">Giri P.P., Roy S., Bhattyacharya S., Pal P., Dhar S. Dress syndrome with sepsis, acute respiratory distress syndrome and pneumomediastinum. Indian J Dermatol. 2011;56(6):763–5. DOI: 10.4103/0019-5154.91850</mixed-citation></citation-alternatives></ref><ref id="cit346"><label>346</label><citation-alternatives><mixed-citation xml:lang="ru">Martínez-Cabriales S.A., Rodríguez-Bolaños F., Shear N.H. Drug reaction with eosinophilia and systemic symptoms (DReSS): How far have we come? Am J Clin Dermatol. 2019;20(2):217–36. DOI: 10.1007/s40257-018-00416-4</mixed-citation><mixed-citation xml:lang="en">Martínez-Cabriales S.A., Rodríguez-Bolaños F., Shear N.H. Drug reaction with eosinophilia and systemic symptoms (DReSS): How far have we come? Am J Clin Dermatol. 2019;20(2):217–36. DOI: 10.1007/s40257-018-00416-4</mixed-citation></citation-alternatives></ref><ref id="cit347"><label>347</label><citation-alternatives><mixed-citation xml:lang="ru">Sato K., Hayashi M., Abe K., Fujita M., Takahashi A., Ohira H. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: A case report. Clin J Gastroenterol. 2020;13(6):1310–4. DOI: 10.1007/s12328-020-01178-5</mixed-citation><mixed-citation xml:lang="en">Sato K., Hayashi M., Abe K., Fujita M., Takahashi A., Ohira H. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: A case report. Clin J Gastroenterol. 2020;13(6):1310–4. DOI: 10.1007/s12328-020-01178-5</mixed-citation></citation-alternatives></ref><ref id="cit348"><label>348</label><citation-alternatives><mixed-citation xml:lang="ru">Takinami M., Ono A., Kawabata T., Mamesaya N., Kobayashi H., Omori S., et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021;39(6):1716–23. DOI: 10.1007/s10637-021-01136-z</mixed-citation><mixed-citation xml:lang="en">Takinami M., Ono A., Kawabata T., Mamesaya N., Kobayashi H., Omori S., et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021;39(6):1716–23. DOI: 10.1007/s10637-021-01136-z</mixed-citation></citation-alternatives></ref><ref id="cit349"><label>349</label><citation-alternatives><mixed-citation xml:lang="ru">Stein S., Henze L., Poch T., Carambia A., Krech T., Preti M., et al. IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. J Hepatol. 2021;74(4):919–30. DOI: 10.1016/j.jhep.2020.10.035</mixed-citation><mixed-citation xml:lang="en">Stein S., Henze L., Poch T., Carambia A., Krech T., Preti M., et al. IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. J Hepatol. 2021;74(4):919–30. DOI: 10.1016/j.jhep.2020.10.035</mixed-citation></citation-alternatives></ref><ref id="cit350"><label>350</label><citation-alternatives><mixed-citation xml:lang="ru">Karnsakul W., Arkachaisri T., Atisook K., Wisuthsarewong W., Sattawatthamrong Y., Aanpreung P. Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: An interplay of unbalanced immune regulatory mechanisms. Ann Hepatol. 2006;5(2):116–9.</mixed-citation><mixed-citation xml:lang="en">Karnsakul W., Arkachaisri T., Atisook K., Wisuthsarewong W., Sattawatthamrong Y., Aanpreung P. Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: An interplay of unbalanced immune regulatory mechanisms. Ann Hepatol. 2006;5(2):116–9.</mixed-citation></citation-alternatives></ref><ref id="cit351"><label>351</label><citation-alternatives><mixed-citation xml:lang="ru">Xie W., Wang Q., Gao Y., Pan C.Q. Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: A case report. BMC Gastroenterology. 2018:18:142. DOI: 10.1186/s12876-018-0869-9</mixed-citation><mixed-citation xml:lang="en">Xie W., Wang Q., Gao Y., Pan C.Q. Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: A case report. BMC Gastroenterology. 2018:18:142. DOI: 10.1186/s12876-018-0869-9</mixed-citation></citation-alternatives></ref><ref id="cit352"><label>352</label><citation-alternatives><mixed-citation xml:lang="ru">Sousa-Pimenta M., Martins Â., Estevinho L.M., Pinho Vaz C., Leite L., Mariz J. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) primary prophylaxis in patients undergoing hematopoietic stem cell transplantation: A network meta-analysis of randomized controlled trials. J Clin Med. 2024;13(22):6917. DOI: 10.3390/jcm13226917</mixed-citation><mixed-citation xml:lang="en">Sousa-Pimenta M., Martins Â., Estevinho L.M., Pinho Vaz C., Leite L., Mariz J. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) primary prophylaxis in patients undergoing hematopoietic stem cell transplantation: A network meta-analysis of randomized controlled trials. J Clin Med. 2024;13(22):6917. DOI: 10.3390/jcm13226917</mixed-citation></citation-alternatives></ref><ref id="cit353"><label>353</label><citation-alternatives><mixed-citation xml:lang="ru">Corbacioglu S., Topaloglu O., Aggarwal S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome. Clin Drug Investig. 2022;42(6):465–76. DOI: 10.1007/s40261-022-01140-y</mixed-citation><mixed-citation xml:lang="en">Corbacioglu S., Topaloglu O., Aggarwal S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome. Clin Drug Investig. 2022;42(6):465–76. DOI: 10.1007/s40261-022-01140-y</mixed-citation></citation-alternatives></ref><ref id="cit354"><label>354</label><citation-alternatives><mixed-citation xml:lang="ru">Miller M.J., Fontana R.J. Acute liver failure: Do we have a consensus regarding management? Liver Transpl. 2024;30(12):1209–11. DOI: 10.1097/LVT.0000000000000464</mixed-citation><mixed-citation xml:lang="en">Miller M.J., Fontana R.J. Acute liver failure: Do we have a consensus regarding management? Liver Transpl. 2024;30(12):1209–11. DOI: 10.1097/LVT.0000000000000464</mixed-citation></citation-alternatives></ref><ref id="cit355"><label>355</label><citation-alternatives><mixed-citation xml:lang="ru">Fontana R.J., Bari K. Acute liver failure. In: Schiff E.R., Maddrey W.C., Reddy K.R. (eds.). Schiff`s diseases of the liver. John Wiley &amp; Sons; 2017:411–31.</mixed-citation><mixed-citation xml:lang="en">Fontana R.J., Bari K. Acute liver failure. In: Schiff E.R., Maddrey W.C., Reddy K.R. (eds.). Schiff`s diseases of the liver. John Wiley &amp; Sons; 2017:411–31.</mixed-citation></citation-alternatives></ref><ref id="cit356"><label>356</label><citation-alternatives><mixed-citation xml:lang="ru">Stravitz R.T., Fontana R.J., Karvellas C., Durkals-ki V., McGuire B., Rule J.A., et al. Future directions in acute liver failure. Hepatology. 2023;78(4):1266–89. DOI: 10.1097/HEP.0000000000000458</mixed-citation><mixed-citation xml:lang="en">Stravitz R.T., Fontana R.J., Karvellas C., Durkals-ki V., McGuire B., Rule J.A., et al. Future directions in acute liver failure. Hepatology. 2023;78(4):1266–89. DOI: 10.1097/HEP.0000000000000458</mixed-citation></citation-alternatives></ref><ref id="cit357"><label>357</label><citation-alternatives><mixed-citation xml:lang="ru">Chughlay M.F., Kramer N., Spearman C.W., Werfalli M., Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: A systematic review. Br J Clin Pharmacol. 2016;81(6):1021–9. DOI: 10.1111/bcp.12880</mixed-citation><mixed-citation xml:lang="en">Chughlay M.F., Kramer N., Spearman C.W., Werfalli M., Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: A systematic review. Br J Clin Pharmacol. 2016;81(6):1021–9. DOI: 10.1111/bcp.12880</mixed-citation></citation-alternatives></ref><ref id="cit358"><label>358</label><citation-alternatives><mixed-citation xml:lang="ru">Sanabria-Cabrera J., Tabbai S., Niu H., Alvarez-Alvarez I., Licata A., Björnsson E., et al. N-acetylcysteine for the management of non-acetaminophen drug-induced liver injury in adults: A systematic review. Front Pharmacol. 2022;13:876868. DOI: 10.3389/fphar.2022.876868</mixed-citation><mixed-citation xml:lang="en">Sanabria-Cabrera J., Tabbai S., Niu H., Alvarez-Alvarez I., Licata A., Björnsson E., et al. N-acetylcysteine for the management of non-acetaminophen drug-induced liver injury in adults: A systematic review. Front Pharmacol. 2022;13:876868. DOI: 10.3389/fphar.2022.876868</mixed-citation></citation-alternatives></ref><ref id="cit359"><label>359</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Hynan L.S., Lee W.M.; Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci. 2013;58(5):1397–402. DOI: 10.1007/s10620-012-2512-x</mixed-citation><mixed-citation xml:lang="en">Singh S., Hynan L.S., Lee W.M.; Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci. 2013;58(5):1397–402. DOI: 10.1007/s10620-012-2512-x</mixed-citation></citation-alternatives></ref><ref id="cit360"><label>360</label><citation-alternatives><mixed-citation xml:lang="ru">Lee W.M., Hynan L.S., Rossaro L., Fontana R.J., Stravitz R.T., Larson A.M., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–64. DOI: 10.1053/j.gastro.2009.06.006</mixed-citation><mixed-citation xml:lang="en">Lee W.M., Hynan L.S., Rossaro L., Fontana R.J., Stravitz R.T., Larson A.M., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–64. DOI: 10.1053/j.gastro.2009.06.006</mixed-citation></citation-alternatives></ref><ref id="cit361"><label>361</label><citation-alternatives><mixed-citation xml:lang="ru">Amjad W., Thuluvath P., Mansoor M., Dutta A., Ali F., Qureshi W. N-acetylcysteine in non-acetaminophen-induced acute liver failure: A systematic review and meta-analysis of prospective studies. Prz Gastroenterol. 2022;17(1):9–16. DOI: 10.5114/pg.2021.107797</mixed-citation><mixed-citation xml:lang="en">Amjad W., Thuluvath P., Mansoor M., Dutta A., Ali F., Qureshi W. N-acetylcysteine in non-acetaminophen-induced acute liver failure: A systematic review and meta-analysis of prospective studies. Prz Gastroenterol. 2022;17(1):9–16. DOI: 10.5114/pg.2021.107797</mixed-citation></citation-alternatives></ref><ref id="cit362"><label>362</label><citation-alternatives><mixed-citation xml:lang="ru">Moosa M.S., Maartens G., Gunter H., Allie S., Chughlay M.F., Setshedi M., et al. A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury. Clin Infect Dis. 2021;73(9):e3377–83. DOI: 10.1093/cid/ciaa1255</mixed-citation><mixed-citation xml:lang="en">Moosa M.S., Maartens G., Gunter H., Allie S., Chughlay M.F., Setshedi M., et al. A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury. Clin Infect Dis. 2021;73(9):e3377–83. DOI: 10.1093/cid/ciaa1255</mixed-citation></citation-alternatives></ref><ref id="cit363"><label>363</label><citation-alternatives><mixed-citation xml:lang="ru">Hu P.F., Xie W.F. Corticosteroid therapy in drug-induced liver injury: Pros and cons. J Dig Dis. 2019;20(3):122–6. DOI: 10.1111/1751-2980.12697</mixed-citation><mixed-citation xml:lang="en">Hu P.F., Xie W.F. Corticosteroid therapy in drug-induced liver injury: Pros and cons. J Dig Dis. 2019;20(3):122–6. DOI: 10.1111/1751-2980.12697</mixed-citation></citation-alternatives></ref><ref id="cit364"><label>364</label><citation-alternatives><mixed-citation xml:lang="ru">Yu Y.C., Mao Y.M., Chen C.W., Chen J.J., Chen J., Cong W.M., et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41. DOI: 10.1007/s12072-017-9793-2</mixed-citation><mixed-citation xml:lang="en">Yu Y.C., Mao Y.M., Chen C.W., Chen J.J., Chen J., Cong W.M., et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41. DOI: 10.1007/s12072-017-9793-2</mixed-citation></citation-alternatives></ref><ref id="cit365"><label>365</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024;81(6):1040–86. DOI: 10.1016/j.jhep.2024.07.032</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024;81(6):1040–86. DOI: 10.1016/j.jhep.2024.07.032</mixed-citation></citation-alternatives></ref><ref id="cit366"><label>366</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization (WHO). The use of the WHO-UMC system for standardised case causality assessment. URL: https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf</mixed-citation><mixed-citation xml:lang="en">World Health Organization (WHO). The use of the WHO-UMC system for standardised case causality assessment. URL: https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf</mixed-citation></citation-alternatives></ref><ref id="cit367"><label>367</label><citation-alternatives><mixed-citation xml:lang="ru">Ganger D.R., Rule J., Rakela J., Bass N., Reuben A., Stravitz R.T., et al.; Acute Liver Failure Study Group. Acute liver failure of indeterminate etiology: A comprehensive systematic approach by an expert committee to establish causality. Am J Gastroenterol. 2018;113(9):1319. DOI: 10.1038/s41395-018-0160-2</mixed-citation><mixed-citation xml:lang="en">Ganger D.R., Rule J., Rakela J., Bass N., Reuben A., Stravitz R.T., et al.; Acute Liver Failure Study Group. Acute liver failure of indeterminate etiology: A comprehensive systematic approach by an expert committee to establish causality. Am J Gastroenterol. 2018;113(9):1319. DOI: 10.1038/s41395-018-0160-2</mixed-citation></citation-alternatives></ref><ref id="cit368"><label>368</label><citation-alternatives><mixed-citation xml:lang="ru">Germani G., Theocharidou E., Adam R., Karam V., Wendon J., O’Grady J., et al. Liver transplantation for acute liver failure in Europe: Outcomes over 20 years from the ELTR database. J Hepatol. 2012;57(2):288–96. DOI: 10.1016/j.jhep.2012.03.017</mixed-citation><mixed-citation xml:lang="en">Germani G., Theocharidou E., Adam R., Karam V., Wendon J., O’Grady J., et al. Liver transplantation for acute liver failure in Europe: Outcomes over 20 years from the ELTR database. J Hepatol. 2012;57(2):288–96. DOI: 10.1016/j.jhep.2012.03.017</mixed-citation></citation-alternatives></ref><ref id="cit369"><label>369</label><citation-alternatives><mixed-citation xml:lang="ru">Ozturk N.B., Herdan E., Saner F.H., Gurakar A. A comprehensive review of the diagnosis and management of acute liver failure. J Clin Med. 2023;12(23):7451. DOI: 10.3390/jcm12237451</mixed-citation><mixed-citation xml:lang="en">Ozturk N.B., Herdan E., Saner F.H., Gurakar A. A comprehensive review of the diagnosis and management of acute liver failure. J Clin Med. 2023;12(23):7451. DOI: 10.3390/jcm12237451</mixed-citation></citation-alternatives></ref><ref id="cit370"><label>370</label><citation-alternatives><mixed-citation xml:lang="ru">Reuben A., Tillman H., Fontana R.J., Davern T., McGuire B., Stravitz R.T., et al. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study. Ann Intern Med. 2016;164(11):724– 32. DOI: 10.7326/M15-2211</mixed-citation><mixed-citation xml:lang="en">Reuben A., Tillman H., Fontana R.J., Davern T., McGuire B., Stravitz R.T., et al. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study. Ann Intern Med. 2016;164(11):724– 32. DOI: 10.7326/M15-2211</mixed-citation></citation-alternatives></ref><ref id="cit371"><label>371</label><citation-alternatives><mixed-citation xml:lang="ru">Rao A., Rule J.A., Hameed B., Ganger D., Fontana R.J., Lee W.M. Secular trends in severe idiosyncratic drug-induced liver injury in North America: An update from the Acute Liver Failure Study Group Registry. Am J Gastroenterol. 2022;117(4):617–26. DOI: 10.14309/ajg.0000000000001655</mixed-citation><mixed-citation xml:lang="en">Rao A., Rule J.A., Hameed B., Ganger D., Fontana R.J., Lee W.M. Secular trends in severe idiosyncratic drug-induced liver injury in North America: An update from the Acute Liver Failure Study Group Registry. Am J Gastroenterol. 2022;117(4):617–26. DOI: 10.14309/ajg.0000000000001655</mixed-citation></citation-alternatives></ref><ref id="cit372"><label>372</label><citation-alternatives><mixed-citation xml:lang="ru">Галимова С.Ф. Лекарственные поражения печени (часть I). Трансплантология. 2011;1:13–21. DOI: 10.23873/2074-0506-2011-0-1-13-21</mixed-citation><mixed-citation xml:lang="en">Galimova S.F. Drug-induced liver injury (part I). Transplantology. 2011;1:13–21. DOI: 10.23873/2074-0506-2011-0-1-13-21</mixed-citation></citation-alternatives></ref><ref id="cit373"><label>373</label><citation-alternatives><mixed-citation xml:lang="ru">Fontana R.J., Bjornsson E.S., Reddy R., Andrade R.J. The evolving profile of idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2023;21(8):2088–99. DOI: 10.1016/j.cgh.2022.12.040</mixed-citation><mixed-citation xml:lang="en">Fontana R.J., Bjornsson E.S., Reddy R., Andrade R.J. The evolving profile of idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2023;21(8):2088–99. DOI: 10.1016/j.cgh.2022.12.040</mixed-citation></citation-alternatives></ref><ref id="cit374"><label>374</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical practice guidelines panel; Wendon J., Cordoba J., Dhawan A., Larsen F.S., Manns M., Samuel D., et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–81. DOI: 10.1016/j.jhep.2016.12.003</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical practice guidelines panel; Wendon J., Cordoba J., Dhawan A., Larsen F.S., Manns M., Samuel D., et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–81. DOI: 10.1016/j.jhep.2016.12.003</mixed-citation></citation-alternatives></ref><ref id="cit375"><label>375</label><citation-alternatives><mixed-citation xml:lang="ru">Bernal W., Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525–34. DOI: 10.1056/NEJMra1208937</mixed-citation><mixed-citation xml:lang="en">Bernal W., Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525–34. DOI: 10.1056/NEJMra1208937</mixed-citation></citation-alternatives></ref><ref id="cit376"><label>376</label><citation-alternatives><mixed-citation xml:lang="ru">Dawwas M.F., Gimson A.E., Lewsey J.D., Copley L.P., van der Meulen J.H. Survival after liver transplantation in the United Kingdom and Ireland compared with the United States. Gut. 2007;56(11):1606–13. DOI: 10.1136/gut.2006.111369</mixed-citation><mixed-citation xml:lang="en">Dawwas M.F., Gimson A.E., Lewsey J.D., Copley L.P., van der Meulen J.H. Survival after liver transplantation in the United Kingdom and Ireland compared with the United States. Gut. 2007;56(11):1606–13. DOI: 10.1136/gut.2006.111369</mixed-citation></citation-alternatives></ref><ref id="cit377"><label>377</label><citation-alternatives><mixed-citation xml:lang="ru">Ozturk N.B., Bartosek N., Toruner M.D., Mumtaz A., Simsek C., Dao D., et al. Approach to liver transplantation: Is there a difference between East and West? J Clin Med. 2024;13(7):1890. DOI: 10.3390/jcm13071890</mixed-citation><mixed-citation xml:lang="en">Ozturk N.B., Bartosek N., Toruner M.D., Mumtaz A., Simsek C., Dao D., et al. Approach to liver transplantation: Is there a difference between East and West? J Clin Med. 2024;13(7):1890. DOI: 10.3390/jcm13071890</mixed-citation></citation-alternatives></ref><ref id="cit378"><label>378</label><citation-alternatives><mixed-citation xml:lang="ru">Abaalkhail F.A., Al Sebayel M.I., Shagrani M.A., O’Hali W.A., Almasri N.M., Alalwan A.A., et al. Clinical practice guidelines for liver transplantation in Saudi Arabia. Saudi Med J. 2021;42(9):927–68. DOI: 10.15537/smj.2021.42.9.20210126</mixed-citation><mixed-citation xml:lang="en">Abaalkhail F.A., Al Sebayel M.I., Shagrani M.A., O’Hali W.A., Almasri N.M., Alalwan A.A., et al. Clinical practice guidelines for liver transplantation in Saudi Arabia. Saudi Med J. 2021;42(9):927–68. DOI: 10.15537/smj.2021.42.9.20210126</mixed-citation></citation-alternatives></ref><ref id="cit379"><label>379</label><citation-alternatives><mixed-citation xml:lang="ru">Оковитый С.В., Райхельсон К.Л., Ахмедов В.А., Вологжанина Л.Г., Гладков О.А., Гречишникова В.Р. и др. Гепатотропная терапия при лекарственных поражениях печени (совещание экспертов). Пермский медицинский журнал. 2025;42(3):58–74. DOI: 10.17816/pmj42358-74</mixed-citation><mixed-citation xml:lang="en">Okovityi S.V., Raikhelson K.L., Akhmedov V.А., Vologzanina L.G., Gladkov O.A., Grechishnikova V.R., et al. Hepatotropic therapy for drug-induced liver injury (Expert meeting). Perm Medical Journal. 2025;42(3):58–74. (In Russ.). DOI: 10.17816/pmj42358-74</mixed-citation></citation-alternatives></ref><ref id="cit380"><label>380</label><citation-alternatives><mixed-citation xml:lang="ru">Chinese Medical Association Tuberculosis Branch. Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version). 2024;47(11):1069–90. (In Chinese) DOI: 10.3760/cma.j.cn112147-20240614-00338</mixed-citation><mixed-citation xml:lang="en">Chinese Medical Association Tuberculosis Branch. Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version). 2024;47(11):1069–90. (In Chinese) DOI: 10.3760/cma.j.cn112147-20240614-00338</mixed-citation></citation-alternatives></ref><ref id="cit381"><label>381</label><citation-alternatives><mixed-citation xml:lang="ru">Туманян С.В., Верещак М.А., Горошинская И.А., Меньшенина А.П., Розенко Д.А., Орос О.В. и др. Функциональное состояние печени и профилактика синдрома эндогенной интоксикации у онкогинекологических больных, оперированных в условиях мультимодальной анестезии. Анестезиология и реаниматология. 2022;5:46–52. DOI: 10.17116/anaesthesiology202205146</mixed-citation><mixed-citation xml:lang="en">Tumanyan S.V., Vereshchak M.A., Goroshinskaya I.A., Menshenina A.P., Rozenko D.A., Oros O.V., et al. Liver functional status and prevention of endogenous intoxication in patients with gynecological cancers after surgery with multimodal analgesia. Russian Journal of Anesthesiology and Reanimatology. 2022;5:46–52. (In Russ.). DOI: 10.17116/anaesthesiology202205146</mixed-citation></citation-alternatives></ref><ref id="cit382"><label>382</label><citation-alternatives><mixed-citation xml:lang="ru">Qiao F., Chen Q., Lu W., Fang N. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report. Medicine (Baltimore). 2022;101(27):e29629. DOI: 10.1097/MD.0000000000029629</mixed-citation><mixed-citation xml:lang="en">Qiao F., Chen Q., Lu W., Fang N. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report. Medicine (Baltimore). 2022;101(27):e29629. DOI: 10.1097/MD.0000000000029629</mixed-citation></citation-alternatives></ref><ref id="cit383"><label>383</label><citation-alternatives><mixed-citation xml:lang="ru">Rong J., Xie Z., Chen E., Ma S., Zhang S., Zhao Y., et al. Fructus Psoraleae-induced severe liver injury and treatment with two artificial liver support systems: A case series study. Ther Apher Dial. 2020;24(3):324–32. DOI: 10.1111/1744-9987.13438</mixed-citation><mixed-citation xml:lang="en">Rong J., Xie Z., Chen E., Ma S., Zhang S., Zhao Y., et al. Fructus Psoraleae-induced severe liver injury and treatment with two artificial liver support systems: A case series study. Ther Apher Dial. 2020;24(3):324–32. DOI: 10.1111/1744-9987.13438</mixed-citation></citation-alternatives></ref><ref id="cit384"><label>384</label><citation-alternatives><mixed-citation xml:lang="ru">Aydemir S., Ustundag Y., Bayraktaroglu T., Tekin I.O., Peksoy I., Unal A.U. Fulminant hepatic failure associated with propylthiouracil: A case report with treatment emphasis on the use of plasmapheresis. J Clin Apher. 2005;20(4):235–8. DOI: 10.1002/jca.20063</mixed-citation><mixed-citation xml:lang="en">Aydemir S., Ustundag Y., Bayraktaroglu T., Tekin I.O., Peksoy I., Unal A.U. Fulminant hepatic failure associated with propylthiouracil: A case report with treatment emphasis on the use of plasmapheresis. J Clin Apher. 2005;20(4):235–8. DOI: 10.1002/jca.20063</mixed-citation></citation-alternatives></ref><ref id="cit385"><label>385</label><citation-alternatives><mixed-citation xml:lang="ru">Скрыпник И.Н., Маслова А.С. Роль S-адеметионина в сопроводительной терапии острых миелобластных лейкемий. Свiт медицини та бiологii. 2019;15(4):159–63. DOI: 10.26724/2079-8334-2019-4-70-159-163</mixed-citation><mixed-citation xml:lang="en">Skripnik I.N., Maslova A.S. The role of S-ademetionine in the concomitant therapy of acute myeloid leukemia. World of Medicine and Biology. 2019;15(4):159–63. (In Russ.). DOI: 10.26724/2079-8334-2019-4-70-159-163</mixed-citation></citation-alternatives></ref><ref id="cit386"><label>386</label><citation-alternatives><mixed-citation xml:lang="ru">Lubarska M., Hałasiński P., Hryhorowicz S., Mahadea D.S., Łykowska-Szuber L., Eder P., et al. Liver dangers of herbal products: A case report of Ashwagandha-induced liver injury. Int J Environ Res Public Health. 2023;20(5):3921. DOI: 10.3390/ijerph20053921</mixed-citation><mixed-citation xml:lang="en">Lubarska M., Hałasiński P., Hryhorowicz S., Mahadea D.S., Łykowska-Szuber L., Eder P., et al. Liver dangers of herbal products: A case report of Ashwagandha-induced liver injury. Int J Environ Res Public Health. 2023;20(5):3921. DOI: 10.3390/ijerph20053921</mixed-citation></citation-alternatives></ref><ref id="cit387"><label>387</label><citation-alternatives><mixed-citation xml:lang="ru">Tan E.X., Wang M.X., Pang J., Lee G.H. Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review. World J Gastroenterol. 2020;26(2):219–45. DOI: 10.3748/wjg.v26.i2.219</mixed-citation><mixed-citation xml:lang="en">Tan E.X., Wang M.X., Pang J., Lee G.H. Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review. World J Gastroenterol. 2020;26(2):219–45. DOI: 10.3748/wjg.v26.i2.219</mixed-citation></citation-alternatives></ref><ref id="cit388"><label>388</label><citation-alternatives><mixed-citation xml:lang="ru">Кутепов Д.Е., Пасечник И.Н., Бояринцев В.В. Экстракорпоральные методы детоксикации у больных с печеночной недостаточностью: тридцать лет спустя. Кремлевская медицина. Клинический вестник. 2024;2:110–6. DOI: 10.48612/cgma/ufpr-z5m7-m2ta</mixed-citation><mixed-citation xml:lang="en">Kutepov D.E., Pasechnik I.N., Boyarintsev V.V. Extracorporeal methods of detoxification in patients with liver failure: Thirty years later. Kremlin Medicine. Clinical Bulletin. 2024;2:110–6. (In Russ.). DOI: 10.48612/cgma/ufpr-z5m7-m2ta</mixed-citation></citation-alternatives></ref><ref id="cit389"><label>389</label><citation-alternatives><mixed-citation xml:lang="ru">Narayanan M., Vora R.S., Flynn M.M., Subramanian R.M. The efficacy of albumin dialysis in the treatment of severe cholestatic drug-induced liver injury. Crit Care Explor. 2022;4(8):e0752. DOI: 10.1097/CCE.0000000000000752</mixed-citation><mixed-citation xml:lang="en">Narayanan M., Vora R.S., Flynn M.M., Subramanian R.M. The efficacy of albumin dialysis in the treatment of severe cholestatic drug-induced liver injury. Crit Care Explor. 2022;4(8):e0752. DOI: 10.1097/CCE.0000000000000752</mixed-citation></citation-alternatives></ref><ref id="cit390"><label>390</label><citation-alternatives><mixed-citation xml:lang="ru">Stüben B.O., Hoyer D.P., Radunz S., Saner F., Schmidt H., Baba H.A., et al. Idiosyncratic drug-induced liver injury in a healthy patient following PCSK9-inhibitor injection. Case Reports Hepatol. 2024;2024:5556907. DOI: 10.1155/2024/5556907</mixed-citation><mixed-citation xml:lang="en">Stüben B.O., Hoyer D.P., Radunz S., Saner F., Schmidt H., Baba H.A., et al. Idiosyncratic drug-induced liver injury in a healthy patient following PCSK9-inhibitor injection. Case Reports Hepatol. 2024;2024:5556907. DOI: 10.1155/2024/5556907</mixed-citation></citation-alternatives></ref><ref id="cit391"><label>391</label><citation-alternatives><mixed-citation xml:lang="ru">Mertens J.E., Bömmer M.T.C., Regier M.B., Gabriëls G., Pavenstädt H., Grünewald I., et al. Liver injury after selective androgen receptor modulator intake: A case report and review of the literature. Z Gastroenterol. 2024;62(6):935–43. DOI: 10.1055/a-2165-6323</mixed-citation><mixed-citation xml:lang="en">Mertens J.E., Bömmer M.T.C., Regier M.B., Gabriëls G., Pavenstädt H., Grünewald I., et al. Liver injury after selective androgen receptor modulator intake: A case report and review of the literature. Z Gastroenterol. 2024;62(6):935–43. DOI: 10.1055/a-2165-6323</mixed-citation></citation-alternatives></ref><ref id="cit392"><label>392</label><citation-alternatives><mixed-citation xml:lang="ru">Díaz F.C., Sáez-González E., Benlloch S., Álvarez-Sotomayor D., Conde I., Polo B., et al. Albumin dialysis with MARS for the treatment of anabolic steroid-induced cholestasis. Ann Hepatol. 2016;15(6):939–43. DOI: 10.5604/16652681.1222114</mixed-citation><mixed-citation xml:lang="en">Díaz F.C., Sáez-González E., Benlloch S., Álvarez-Sotomayor D., Conde I., Polo B., et al. Albumin dialysis with MARS for the treatment of anabolic steroid-induced cholestasis. Ann Hepatol. 2016;15(6):939–43. DOI: 10.5604/16652681.1222114</mixed-citation></citation-alternatives></ref><ref id="cit393"><label>393</label><citation-alternatives><mixed-citation xml:lang="ru">Bellmann R., Feistritzer C., Zoller H., Graziadei I.W., Schwaighofer H., Propst A., et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: A report of two cases. ASAIO J. 2004;50(4):387–91. DOI: 10.1097/01.mat.0000132552.58214.00</mixed-citation><mixed-citation xml:lang="en">Bellmann R., Feistritzer C., Zoller H., Graziadei I.W., Schwaighofer H., Propst A., et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: A report of two cases. ASAIO J. 2004;50(4):387–91. DOI: 10.1097/01.mat.0000132552.58214.00</mixed-citation></citation-alternatives></ref><ref id="cit394"><label>394</label><citation-alternatives><mixed-citation xml:lang="ru">Halegoua-DeMarzio D., Navarro V. Challenges in herbal-induced liver injury identification and prevention. Liver Int. 2025;45(3):e16071. DOI: 10.1111/liv.16071</mixed-citation><mixed-citation xml:lang="en">Halegoua-DeMarzio D., Navarro V. Challenges in herbal-induced liver injury identification and prevention. Liver Int. 2025;45(3):e16071. DOI: 10.1111/liv.16071</mixed-citation></citation-alternatives></ref><ref id="cit395"><label>395</label><citation-alternatives><mixed-citation xml:lang="ru">Benić M.S., Nežić L., Vujić-Aleksić V., Mititelu-Tartau L. Novel therapies for the treatment of drug-induced liver injury: A systematic review. Front Pharmacol. 2022;12:785790. DOI: 10.3389/fphar.2021.785790</mixed-citation><mixed-citation xml:lang="en">Benić M.S., Nežić L., Vujić-Aleksić V., Mititelu-Tartau L. Novel therapies for the treatment of drug-induced liver injury: A systematic review. Front Pharmacol. 2022;12:785790. DOI: 10.3389/fphar.2021.785790</mixed-citation></citation-alternatives></ref><ref id="cit396"><label>396</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C.T., Chen T.H., Cheng C.Y. Successful treatment of drug-induced acute liver failure with high-volume plasma exchange. J Clin Apher. 2013;28(6):430–4. DOI: 10.1002/jca.21291</mixed-citation><mixed-citation xml:lang="en">Liu C.T., Chen T.H., Cheng C.Y. Successful treatment of drug-induced acute liver failure with high-volume plasma exchange. J Clin Apher. 2013;28(6):430–4. DOI: 10.1002/jca.21291</mixed-citation></citation-alternatives></ref><ref id="cit397"><label>397</label><citation-alternatives><mixed-citation xml:lang="ru">Sachan D., Verghese J., Saha S., Ilankumaran K., Rela M. Role of therapeutic plasma exchange (TPE) in patients with drug induced liver injury. Vox Sang. 2017;112(S1):5–295. DOI: 10.1111/vox.12530</mixed-citation><mixed-citation xml:lang="en">Sachan D., Verghese J., Saha S., Ilankumaran K., Rela M. Role of therapeutic plasma exchange (TPE) in patients with drug induced liver injury. Vox Sang. 2017;112(S1):5–295. DOI: 10.1111/vox.12530</mixed-citation></citation-alternatives></ref><ref id="cit398"><label>398</label><citation-alternatives><mixed-citation xml:lang="ru">Singh K.A., Kumar S.E., Zachariah U.G., Daniel D., David V., Subramani K., et al. Single-centre experience with low-volume plasma exchange and low-dose steroid to treat patients with idiosyncratic drug-induced acute liver failure. J Clin Exp Hepatol. 2024;14(2):101303. DOI: 10.1016/j.jceh.2023.11.003</mixed-citation><mixed-citation xml:lang="en">Singh K.A., Kumar S.E., Zachariah U.G., Daniel D., David V., Subramani K., et al. Single-centre experience with low-volume plasma exchange and low-dose steroid to treat patients with idiosyncratic drug-induced acute liver failure. J Clin Exp Hepatol. 2024;14(2):101303. DOI: 10.1016/j.jceh.2023.11.003</mixed-citation></citation-alternatives></ref><ref id="cit399"><label>399</label><citation-alternatives><mixed-citation xml:lang="ru">Regev A., Avigan M.I., Kiazand A., Vierling J.M., Lewis J.H., Omokaro S.O., et al. Best practices for detection, assessment and management of suspected immunemediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020;114:102514. DOI: 10.1016/j.jaut.2020.102514</mixed-citation><mixed-citation xml:lang="en">Regev A., Avigan M.I., Kiazand A., Vierling J.M., Lewis J.H., Omokaro S.O., et al. Best practices for detection, assessment and management of suspected immunemediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020;114:102514. DOI: 10.1016/j.jaut.2020.102514</mixed-citation></citation-alternatives></ref><ref id="cit400"><label>400</label><citation-alternatives><mixed-citation xml:lang="ru">FDA Guidance for Industry. Drug-induced liver injury: Premarketing clinical evaluation. Silver Spring, MD; 2019.</mixed-citation><mixed-citation xml:lang="en">FDA Guidance for Industry. Drug-induced liver injury: Premarketing clinical evaluation. Silver Spring, MD; 2019.</mixed-citation></citation-alternatives></ref><ref id="cit401"><label>401</label><citation-alternatives><mixed-citation xml:lang="ru">Papay J.I., Clines D., Rafi R., Yuen N., Britt S.D., Walsh J.S., et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009;54(1):84–90. DOI: 10.1016/j.yrtph.2009.03.003</mixed-citation><mixed-citation xml:lang="en">Papay J.I., Clines D., Rafi R., Yuen N., Britt S.D., Walsh J.S., et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009;54(1):84–90. DOI: 10.1016/j.yrtph.2009.03.003</mixed-citation></citation-alternatives></ref><ref id="cit402"><label>402</label><citation-alternatives><mixed-citation xml:lang="ru">Cajanding R.J.M. MDMA-associated liver toxicity: Pathophysiology, management, and current state of knowledge. AACN Adv Crit Care. 2019;30(3):232–48. DOI: 10.4037/aacnacc2019852</mixed-citation><mixed-citation xml:lang="en">Cajanding R.J.M. MDMA-associated liver toxicity: Pathophysiology, management, and current state of knowledge. AACN Adv Crit Care. 2019;30(3):232–48. DOI: 10.4037/aacnacc2019852</mixed-citation></citation-alternatives></ref><ref id="cit403"><label>403</label><citation-alternatives><mixed-citation xml:lang="ru">Weber S., Gerbes A.L. Update on herbal and dietary supplement-induced liver injury: Current gaps and future directions. Hepatobiliary Surg Nutr. 2023;12(5):752–5. DOI: 10.21037/hbsn-23-329</mixed-citation><mixed-citation xml:lang="en">Weber S., Gerbes A.L. Update on herbal and dietary supplement-induced liver injury: Current gaps and future directions. Hepatobiliary Surg Nutr. 2023;12(5):752–5. DOI: 10.21037/hbsn-23-329</mixed-citation></citation-alternatives></ref><ref id="cit404"><label>404</label><citation-alternatives><mixed-citation xml:lang="ru">Ye J.H., Ho Y.F., On A.W., Chen W.W., Huang Y.M., Huang W.I., et al. Trends in reporting drug-associated liver injuries in Taiwan: A focus on amiodarone. Int J Clin Pharm. 2018;40(4):911–20. DOI: 10.1007/s11096-018-0698-5</mixed-citation><mixed-citation xml:lang="en">Ye J.H., Ho Y.F., On A.W., Chen W.W., Huang Y.M., Huang W.I., et al. Trends in reporting drug-associated liver injuries in Taiwan: A focus on amiodarone. Int J Clin Pharm. 2018;40(4):911–20. DOI: 10.1007/s11096-018-0698-5</mixed-citation></citation-alternatives></ref><ref id="cit405"><label>405</label><citation-alternatives><mixed-citation xml:lang="ru">Uetake H., Sugihara K., Muro K., Sunaya T., Hori-uchi-Yamamoto Y., Takikawa H. Clinical features of Regorafenib-induced liver injury in Japanese patients from postmarketing experience. Clin Colorectal Cancer. 2018;17(1):e49–58. DOI: 10.1016/j.clcc.2017.09.004</mixed-citation><mixed-citation xml:lang="en">Uetake H., Sugihara K., Muro K., Sunaya T., Hori-uchi-Yamamoto Y., Takikawa H. Clinical features of Regorafenib-induced liver injury in Japanese patients from postmarketing experience. Clin Colorectal Cancer. 2018;17(1):e49–58. DOI: 10.1016/j.clcc.2017.09.004</mixed-citation></citation-alternatives></ref><ref id="cit406"><label>406</label><citation-alternatives><mixed-citation xml:lang="ru">Björnsson E.S., Andrade R.J. Long-term sequelae of drug-induced liver injury. J Hepatol. 2022;76(2):435– 45. DOI: 10.1016/j.jhep.2021.10.011</mixed-citation><mixed-citation xml:lang="en">Björnsson E.S., Andrade R.J. Long-term sequelae of drug-induced liver injury. J Hepatol. 2022;76(2):435– 45. DOI: 10.1016/j.jhep.2021.10.011</mixed-citation></citation-alternatives></ref><ref id="cit407"><label>407</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng H.S., Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: Utility of transient elastography. Psoriasis (Auckl). 2018;8:21–9. DOI: 10.2147/PTT.S141629</mixed-citation><mixed-citation xml:lang="en">Cheng H.S., Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: Utility of transient elastography. Psoriasis (Auckl). 2018;8:21–9. DOI: 10.2147/PTT.S141629</mixed-citation></citation-alternatives></ref><ref id="cit408"><label>408</label><citation-alternatives><mixed-citation xml:lang="ru">Neri S., Signorelli S. Role of ademetionine (S-adenosylmethionine) in cyclosporine-induced cholestasis. Clin Drug Invest. 2002;22(3):191–5. DOI: 10.2165/00044011200222030-00006</mixed-citation><mixed-citation xml:lang="en">Neri S., Signorelli S. Role of ademetionine (S-adenosylmethionine) in cyclosporine-induced cholestasis. Clin Drug Invest. 2002;22(3):191–5. DOI: 10.2165/00044011200222030-00006</mixed-citation></citation-alternatives></ref><ref id="cit409"><label>409</label><citation-alternatives><mixed-citation xml:lang="ru">Vincenzi B., Santini D., Frezza A.M., Berti P., Vespasiani U., Picardi A., et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: A retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345–9. DOI: 10.1517/14740338.2011.562888</mixed-citation><mixed-citation xml:lang="en">Vincenzi B., Santini D., Frezza A.M., Berti P., Vespasiani U., Picardi A., et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: A retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345–9. DOI: 10.1517/14740338.2011.562888</mixed-citation></citation-alternatives></ref><ref id="cit410"><label>410</label><citation-alternatives><mixed-citation xml:lang="ru">Vincenzi B., Daniele S., Frezza A.M., Berti P., Vespasiani U., Picardi A., et al. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: A retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer. 2012;20(1):135–9. DOI: 10.1007/s00520-010-1078-4</mixed-citation><mixed-citation xml:lang="en">Vincenzi B., Daniele S., Frezza A.M., Berti P., Vespasiani U., Picardi A., et al. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: A retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer. 2012;20(1):135–9. DOI: 10.1007/s00520-010-1078-4</mixed-citation></citation-alternatives></ref><ref id="cit411"><label>411</label><citation-alternatives><mixed-citation xml:lang="ru">Baniasadi S., Eftekhari P., Tabarsi P., Fahimi F., Raoufy M.R., Masjedi M.R., et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2010;22(10):1235–8. DOI: 10.1097/MEG.0b013e32833aa11b</mixed-citation><mixed-citation xml:lang="en">Baniasadi S., Eftekhari P., Tabarsi P., Fahimi F., Raoufy M.R., Masjedi M.R., et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2010;22(10):1235–8. DOI: 10.1097/MEG.0b013e32833aa11b</mixed-citation></citation-alternatives></ref><ref id="cit412"><label>412</label><citation-alternatives><mixed-citation xml:lang="ru">Горошко А.И., Щелкунов А.И., Симонова Н.В. Клиническая эффективность ремаксола для профилактики гепатотоксических осложнений противотуберкулезной химиотерапии. Экспериментальная и клиническая фармакология. 2025;88(3):22–8. DOI: 10.30906/0869-2092-2025-88-3-22-28</mixed-citation><mixed-citation xml:lang="en">Goroshko A.I., Shchelkunov A.I., Simonova N.V. Clinical efficacy of remaxol for the prevention of hepatotoxic complications of anti-tuberculosis chemotherapy. Experimental and Clinical Pharmacology. 2025;88(3):22–8. (In Russ.). DOI: 10.30906/0869-2092-2025-88-3-22-28</mixed-citation></citation-alternatives></ref><ref id="cit413"><label>413</label><citation-alternatives><mixed-citation xml:lang="ru">Akkahadsee P., Sawangjit R., Phumart P., Chaiyakunapruk N., Sakloetsakun D. Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury. Sci Rep. 2023;13(1):19880. DOI: 10.1038/s41598-023-46565-3</mixed-citation><mixed-citation xml:lang="en">Akkahadsee P., Sawangjit R., Phumart P., Chaiyakunapruk N., Sakloetsakun D. Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury. Sci Rep. 2023;13(1):19880. DOI: 10.1038/s41598-023-46565-3</mixed-citation></citation-alternatives></ref><ref id="cit414"><label>414</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng S.L. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur Respir J. 2016;48(Suppl. 60):PA2716. DOI: 10.1183/13993003.congress-2016.PA2716</mixed-citation><mixed-citation xml:lang="en">Cheng S.L. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur Respir J. 2016;48(Suppl. 60):PA2716. DOI: 10.1183/13993003.congress-2016.PA2716</mixed-citation></citation-alternatives></ref><ref id="cit415"><label>415</label><citation-alternatives><mixed-citation xml:lang="ru">Li X., Zhou J., Chen S., Guan M., Wang Y., Zhao L., et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–14. DOI: 10.1177/0300060514527058</mixed-citation><mixed-citation xml:lang="en">Li X., Zhou J., Chen S., Guan M., Wang Y., Zhao L., et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–14. DOI: 10.1177/0300060514527058</mixed-citation></citation-alternatives></ref><ref id="cit416"><label>416</label><citation-alternatives><mixed-citation xml:lang="ru">Shang W., Feng Y., Li J., Wang X., Xie H., Feng G. Effect of bicyclol tablets on drug induced liver injuries after kidney transplantation. Open Med (Wars). 2017;12:62–9. DOI: 10.1515/med-2017-0012</mixed-citation><mixed-citation xml:lang="en">Shang W., Feng Y., Li J., Wang X., Xie H., Feng G. Effect of bicyclol tablets on drug induced liver injuries after kidney transplantation. Open Med (Wars). 2017;12:62–9. DOI: 10.1515/med-2017-0012</mixed-citation></citation-alternatives></ref><ref id="cit417"><label>417</label><citation-alternatives><mixed-citation xml:lang="ru">Kojima M., Kamoi K., Ukimura O., Fujito A., Nakao M., Tanaka S., et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study. Int J Urol. 2002;9(1):42–6. DOI: 10.1046/j.1442-2042.2002.00412.x</mixed-citation><mixed-citation xml:lang="en">Kojima M., Kamoi K., Ukimura O., Fujito A., Nakao M., Tanaka S., et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study. Int J Urol. 2002;9(1):42–6. DOI: 10.1046/j.1442-2042.2002.00412.x</mixed-citation></citation-alternatives></ref><ref id="cit418"><label>418</label><citation-alternatives><mixed-citation xml:lang="ru">Леденцова С.С., Гуляев Н.И., Гордиенко А.В., Гаврилова Н.П., Орешко Л.С., Селиверстов П.В. Меры профилактики возможных осложнений, вызываемых системными ретиноидами, при лечении акне в стандартных схемах. Лечащий врач. 2020;6:85–8. DOI: 10.26295/OS.2020.30.33.015</mixed-citation><mixed-citation xml:lang="en">Ledentsova S.S., Gulyaev N.I., Gordienko A.V., Gavrilova N.P., Oreshko L.S., Seliverstov P.V. Combination of acne treatment in women with prevention of complications using standard schemes of systemic retinoids. Lechaschi Vrach. 2020;6:85–8. (In Russ.). DOI: 10.26295/OS.2020.30.33.015</mixed-citation></citation-alternatives></ref><ref id="cit419"><label>419</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лерман О.В., Невзорова В.А., Резник И.И. и др. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и/или путей с помощью урсодеоксихолевой кислоты. Терапевтический архив. 2014;86(12):48–52.</mixed-citation><mixed-citation xml:lang="en">Martsevich S.Yu., Kutishenko N.P., Drozdova L.Yu., Lerman O.V., Nevzorova V.A., Reznik I.I., et al. The RAKURS study: Improving the efficacy and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases using ursodeoxycholic acid. Terapevticheskii Arkhiv. 2014;86(12):48–52. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit420"><label>420</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Драпкина О.М., Маевская М.В., Райхельсон К.Л., Оковитый С.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российского общества профилактики неинфекционных заболеваний, Российской ассоциации эндокринологов, Российского научного медицинского общества терапевтов, Национального общества профилактической кардиологии, Российской ассоциации геронтологов и гериатров по неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2025;35(1):94–152. DOI: 10.22416/1382-4376-2025-35-1-94-152</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Drapkina O.M., Maevskaya M.V., Raikhelson K.L., Okovityi S.V., Zharkova M.S., et al. Clinical guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on non-alcoholic fatty liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2025;35(1):94–152. (In Russ.). DOI: 10.22416/1382-4376-2025-35-1-94-152</mixed-citation></citation-alternatives></ref><ref id="cit421"><label>421</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492– 542. DOI: 10.1016/j.jhep.2024.04.031</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492– 542. DOI: 10.1016/j.jhep.2024.04.031</mixed-citation></citation-alternatives></ref><ref id="cit422"><label>422</label><citation-alternatives><mixed-citation xml:lang="ru">García D.S., Saturansky E.I., Poncino D., Martínez-Artola Y., Rosenberg S., Abritta G., et al. “Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?” Ann Hepatol. 2019;18(5):765–9. DOI: 10.1016/j.aohep.2019.01.011</mixed-citation><mixed-citation xml:lang="en">García D.S., Saturansky E.I., Poncino D., Martínez-Artola Y., Rosenberg S., Abritta G., et al. “Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?” Ann Hepatol. 2019;18(5):765–9. DOI: 10.1016/j.aohep.2019.01.011</mixed-citation></citation-alternatives></ref><ref id="cit423"><label>423</label><citation-alternatives><mixed-citation xml:lang="ru">Shea B., Swinden M.V., Tanjong Ghogomu E., Ortiz Z., Katchamart W., Rader T., et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013(5):CD000951. DOI: 10.1002/14651858.CD000951.pub2</mixed-citation><mixed-citation xml:lang="en">Shea B., Swinden M.V., Tanjong Ghogomu E., Ortiz Z., Katchamart W., Rader T., et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013(5):CD000951. DOI: 10.1002/14651858.CD000951.pub2</mixed-citation></citation-alternatives></ref><ref id="cit424"><label>424</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральный закон от 12 апреля 2010 г. № 61-ФЗ «Об обращении лекарственных средств». URL: http://www.consultant.ru/document/cons_doc_LAW_99350/</mixed-citation><mixed-citation xml:lang="en">Федеральный закон от 12 апреля 2010 г. № 61-ФЗ «Об обращении лекарственных средств». URL: http://www.consultant.ru/document/cons_doc_LAW_99350/</mixed-citation></citation-alternatives></ref><ref id="cit425"><label>425</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральный закон от 21 ноября 2011 г. № 323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации». URL: http://www.consultant.ru/document/cons_doc_LAW_121895/</mixed-citation><mixed-citation xml:lang="en">Федеральный закон от 21 ноября 2011 г. № 323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации». URL: http://www.consultant.ru/document/cons_doc_LAW_121895/</mixed-citation></citation-alternatives></ref><ref id="cit426"><label>426</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ Министерства здравоохранения Российской Федерации от 12 ноября 2012 г. № 906н «Об утверждении порядка оказания медицинской помощи населению по профилю «Гастроэнтерология». Зарегистрировано в Минюсте России 21 января 2013 г. № 2664. URL: http://www.consultant.ru/document/cons_doc_LAW_141611/</mixed-citation><mixed-citation xml:lang="en">Приказ Министерства здравоохранения Российской Федерации от 12 ноября 2012 г. № 906н «Об утверждении порядка оказания медицинской помощи населению по профилю «Гастроэнтерология». Зарегистрировано в Минюсте России 21 января 2013 г. № 2664. URL: http://www.consultant.ru/document/cons_doc_LAW_141611/</mixed-citation></citation-alternatives></ref><ref id="cit427"><label>427</label><citation-alternatives><mixed-citation xml:lang="ru">Keays R., Harrison P.M., Wendon J.A., Forbes A., Gove C., Alexander G.J., et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial. BMJ. 1991;303(6809):1026–9. DOI: 10.1136/bmj.303.6809.1026</mixed-citation><mixed-citation xml:lang="en">Keays R., Harrison P.M., Wendon J.A., Forbes A., Gove C., Alexander G.J., et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial. BMJ. 1991;303(6809):1026–9. DOI: 10.1136/bmj.303.6809.1026</mixed-citation></citation-alternatives></ref><ref id="cit428"><label>428</label><citation-alternatives><mixed-citation xml:lang="ru">Chiew A.L., Gluud C., Brok J., Buckley N.A. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2018;2(2):CD003328. DOI: 10.1002/14651858.CD003328.pub3</mixed-citation><mixed-citation xml:lang="en">Chiew A.L., Gluud C., Brok J., Buckley N.A. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2018;2(2):CD003328. DOI: 10.1002/14651858.CD003328.pub3</mixed-citation></citation-alternatives></ref><ref id="cit429"><label>429</label><citation-alternatives><mixed-citation xml:lang="ru">Buckley N., Eddleston M. Paracetamol (acetaminophen) poisoning. BMJ Clin Evid. 2007;2007:2101.</mixed-citation><mixed-citation xml:lang="en">Buckley N., Eddleston M. Paracetamol (acetaminophen) poisoning. BMJ Clin Evid. 2007;2007:2101.</mixed-citation></citation-alternatives></ref><ref id="cit430"><label>430</label><citation-alternatives><mixed-citation xml:lang="ru">Niu H., Atallah E., Alvarez-Alvarez I., Medina-Caliz I., Aithal G.P., Arikan C., et al. Therapeutic management of idiosyncratic drug-induced liver injury and acetaminophen hepatotoxicity in the paediatric population: A systematic review. Drug Saf. 2022;45(11):1329–48. DOI: 10.1007/s40264-022-01224-w</mixed-citation><mixed-citation xml:lang="en">Niu H., Atallah E., Alvarez-Alvarez I., Medina-Caliz I., Aithal G.P., Arikan C., et al. Therapeutic management of idiosyncratic drug-induced liver injury and acetaminophen hepatotoxicity in the paediatric population: A systematic review. Drug Saf. 2022;45(11):1329–48. DOI: 10.1007/s40264-022-01224-w</mixed-citation></citation-alternatives></ref><ref id="cit431"><label>431</label><citation-alternatives><mixed-citation xml:lang="ru">Barkholt L., Remberger M., Hassan Z., Fransson K., Omazic B., Svahn B.M., et al. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(9):785–90. DOI: 10.1038/sj.bmt.1705969</mixed-citation><mixed-citation xml:lang="en">Barkholt L., Remberger M., Hassan Z., Fransson K., Omazic B., Svahn B.M., et al. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(9):785–90. DOI: 10.1038/sj.bmt.1705969</mixed-citation></citation-alternatives></ref><ref id="cit432"><label>432</label><citation-alternatives><mixed-citation xml:lang="ru">Van Asseldonk D.P., Crouwel F., Seinen M.L., Scheffer P.G., Veldkamp A.I., de Boer N.K., et al. Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury in inflammatory bowel disease: A randomized crossover pilot study. Basic Clin Pharmacol Toxicol. 2024;134(4):507–18. DOI: 10.1111/bcpt.13978</mixed-citation><mixed-citation xml:lang="en">Van Asseldonk D.P., Crouwel F., Seinen M.L., Scheffer P.G., Veldkamp A.I., de Boer N.K., et al. Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury in inflammatory bowel disease: A randomized crossover pilot study. Basic Clin Pharmacol Toxicol. 2024;134(4):507–18. DOI: 10.1111/bcpt.13978</mixed-citation></citation-alternatives></ref><ref id="cit433"><label>433</label><citation-alternatives><mixed-citation xml:lang="ru">Jaiswal P., Attar B.M., Yap J.E., Devani K., Jaiswal R., Wang Y., et al. Acute liver failure with amiodarone infusion: A case report and systematic review. J Clin Pharm Ther. 2018;43(1):129–33. DOI: 10.1111/jcpt.12594</mixed-citation><mixed-citation xml:lang="en">Jaiswal P., Attar B.M., Yap J.E., Devani K., Jaiswal R., Wang Y., et al. Acute liver failure with amiodarone infusion: A case report and systematic review. J Clin Pharm Ther. 2018;43(1):129–33. DOI: 10.1111/jcpt.12594</mixed-citation></citation-alternatives></ref><ref id="cit434"><label>434</label><citation-alternatives><mixed-citation xml:lang="ru">Farazi A., Sofian M., Jabbariasl M. Efficacy of N-acetylcysteine on prevention of antituberculosis drug-induced hepatotoxicity. World J Med Sci. 2015;12(4):413–8. DOI: 10.5829/idosi.wjms.2015.12.4.10114</mixed-citation><mixed-citation xml:lang="en">Farazi A., Sofian M., Jabbariasl M. Efficacy of N-acetylcysteine on prevention of antituberculosis drug-induced hepatotoxicity. World J Med Sci. 2015;12(4):413–8. DOI: 10.5829/idosi.wjms.2015.12.4.10114</mixed-citation></citation-alternatives></ref><ref id="cit435"><label>435</label><citation-alternatives><mixed-citation xml:lang="ru">Singh A.K., Verma S., Kumar M.P., Soni H., Sharma S., Sharma S., et al. Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2020;13(11):1253–62. DOI: 10.1080/17512433.2020.1835468</mixed-citation><mixed-citation xml:lang="en">Singh A.K., Verma S., Kumar M.P., Soni H., Sharma S., Sharma S., et al. Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2020;13(11):1253–62. DOI: 10.1080/17512433.2020.1835468</mixed-citation></citation-alternatives></ref><ref id="cit436"><label>436</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed S., Rao N.A. Role of N-acetylcysteine (NAC) in preventing development of anti tuberculosis therapy (ATT) induced liver injury in pulmonary tuberculosis (PTB) patients, a simple randomized single blind clinical trial. Eur Respir J. 2020;56(Suppl. 64):5301. DOI: 10.1183/13993003.congress-2020.5301</mixed-citation><mixed-citation xml:lang="en">Ahmed S., Rao N.A. Role of N-acetylcysteine (NAC) in preventing development of anti tuberculosis therapy (ATT) induced liver injury in pulmonary tuberculosis (PTB) patients, a simple randomized single blind clinical trial. Eur Respir J. 2020;56(Suppl. 64):5301. DOI: 10.1183/13993003.congress-2020.5301</mixed-citation></citation-alternatives></ref><ref id="cit437"><label>437</label><citation-alternatives><mixed-citation xml:lang="ru">Sukumaran D., Usharani P., Paramjyothi G.K., Subbalaxmi M.V.S., Sireesha K., Abid Ali M. A study to evaluate the hepatoprotective effect of N-acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. Indian J Tuberc. 2023;70(3):303–10. DOI: 10.1016/j.ijtb.2022.05.012</mixed-citation><mixed-citation xml:lang="en">Sukumaran D., Usharani P., Paramjyothi G.K., Subbalaxmi M.V.S., Sireesha K., Abid Ali M. A study to evaluate the hepatoprotective effect of N-acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. Indian J Tuberc. 2023;70(3):303–10. DOI: 10.1016/j.ijtb.2022.05.012</mixed-citation></citation-alternatives></ref><ref id="cit438"><label>438</label><citation-alternatives><mixed-citation xml:lang="ru">Tincu R., Cobilinschi C., Tomescu D., Ghiorghiu Z., Macovei R. P331 Benefits of L-carnitine in valproic acid induced encephalopathy. Crit Care. 2016;20(Suppl. 2):94. DOI: 10.1186/s13054-016-1208-6</mixed-citation><mixed-citation xml:lang="en">Tincu R., Cobilinschi C., Tomescu D., Ghiorghiu Z., Macovei R. P331 Benefits of L-carnitine in valproic acid induced encephalopathy. Crit Care. 2016;20(Suppl. 2):94. DOI: 10.1186/s13054-016-1208-6</mixed-citation></citation-alternatives></ref><ref id="cit439"><label>439</label><citation-alternatives><mixed-citation xml:lang="ru">Hatamkhani S., Khalili H., Karimzadeh I., Dashti-Khavidaki S., Abdollahi A., Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: A randomized, clinical trial. J Gastroenterol Hepatol. 2014;29(5):997–1004. DOI: 10.1111/jgh.12474</mixed-citation><mixed-citation xml:lang="en">Hatamkhani S., Khalili H., Karimzadeh I., Dashti-Khavidaki S., Abdollahi A., Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: A randomized, clinical trial. J Gastroenterol Hepatol. 2014;29(5):997–1004. DOI: 10.1111/jgh.12474</mixed-citation></citation-alternatives></ref><ref id="cit440"><label>440</label><citation-alternatives><mixed-citation xml:lang="ru">Овчаренко Л.С., Вертегел А.А., Андриенко Т.Г. Терапия проявлений гепатотоксичности при применении цефтриаксона у детей с патологией респираторного тракта. Современная педиатрия. 2013;1:60.</mixed-citation><mixed-citation xml:lang="en">Ovcharenko L.S., Vertegel A.A., Andrienko T.G. Therapy of manifestations of hepatotoxicity during the use of ceftriaxone in children with respiratory tract pathology. Modern Pediatrics. 2013;1:60. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit441"><label>441</label><citation-alternatives><mixed-citation xml:lang="ru">Борзакова С.Н., Аксенова В.А., Рейзис А.Р. Апоптоз лимфоцитов при лекарственно-индуцированных поражениях печени на фоне туберкулеза у детей. Доктор.Ру. 2012;9:67–73.</mixed-citation><mixed-citation xml:lang="en">Borzakova S.N., Aksenova V.A., Reizis A.R. Lymphocyte apoptosis in drug-induced liver damage against the background of tuberculosis in children. Doctor.Ru. 2012;9:67–73. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit442"><label>442</label><citation-alternatives><mixed-citation xml:lang="ru">Борзакова С.Н., Рейзис А.Р. Лекарственные поражения печени у детей с туберкулезом. Экспериментальная и клиническая гастроэнтерология. 2016;1:49–53. [</mixed-citation><mixed-citation xml:lang="en">Borzakova S.N., Reizis A.R. Drug-induced liver damage in children with tuberculosis. Experimental and Clinical Gastroenterology. 2016;1:49–53. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit443"><label>443</label><citation-alternatives><mixed-citation xml:lang="ru">Курманова Г.М., Курманова К.Б., Садыкова Ш.С. Эффекты урсодезоксихолевой кислоты при стандартной противовирусной терапии больных хроническим гепатитом С и В. Экспериментальная и клиническая гастроэнтерология. 2015;9:99–104.</mixed-citation><mixed-citation xml:lang="en">Kurmanova G.M., Kurmanova K.B., Sadykova Sh.S. Effects of ursodeoxycholic acid in standard antiviral therapy of patients with chronic hepatitis C and B. Experimental and Clinical Gastroenterology. 2015;9:99–104. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit444"><label>444</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.Н., Маев И.В., Дичева Д.Т., Бектемирова Л.Г. Эффективность урсодезоксихолевой кислоты в рамках минимизации гепатотоксичного потенциала эрадикационной терапии инфекции Helicobacter pylori. Лечащий врач. 2020;4:51. DOI: 10.26295/OS.2020.78.94.009</mixed-citation><mixed-citation xml:lang="en">Andreev D.N., Mayev I.V., Dicheva D.T., Bektemirova L.G. Efficiency of ursodeoxycholic acid in the frameworks of minimization of hepatotoxic potential of eradication therapy of Helicobacter pylori infection. Lechaschi Vrach. 2020;4:51. (In Russ.). DOI: 10.26295/OS.2020.78.94.009</mixed-citation></citation-alternatives></ref><ref id="cit445"><label>445</label><citation-alternatives><mixed-citation xml:lang="ru">Shahramian I., Bazi A., Mostafaee R., Mohammadi M.H. Protective effects of ursodeoxycholic acid on valproic acid induced hepatotoxicity in epileptic children with recurrent seizure; a double-blinded randomized clinical trial. Pharmaceutical Sciences. 2020;26(1):25–31. DOI: 10.34172/PS.2019.62</mixed-citation><mixed-citation xml:lang="en">Shahramian I., Bazi A., Mostafaee R., Mohammadi M.H. Protective effects of ursodeoxycholic acid on valproic acid induced hepatotoxicity in epileptic children with recurrent seizure; a double-blinded randomized clinical trial. Pharmaceutical Sciences. 2020;26(1):25–31. DOI: 10.34172/PS.2019.62</mixed-citation></citation-alternatives></ref><ref id="cit446"><label>446</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammed Saif M., Farid S.F., Khaleel S.A., Sabry N.A., El-Sayed M.H. Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2012;29(7):627–32. DOI: 10.3109/08880018.2012.713083</mixed-citation><mixed-citation xml:lang="en">Mohammed Saif M., Farid S.F., Khaleel S.A., Sabry N.A., El-Sayed M.H. Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2012;29(7):627–32. DOI: 10.3109/08880018.2012.713083</mixed-citation></citation-alternatives></ref><ref id="cit447"><label>447</label><citation-alternatives><mixed-citation xml:lang="ru">Bordbar M., Shakibazad N., Fattahi M., Haghpanah S., Honar N. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29(2):203–9. DOI: 10.5152/tjg.2018.17521</mixed-citation><mixed-citation xml:lang="en">Bordbar M., Shakibazad N., Fattahi M., Haghpanah S., Honar N. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29(2):203–9. DOI: 10.5152/tjg.2018.17521</mixed-citation></citation-alternatives></ref><ref id="cit448"><label>448</label><citation-alternatives><mixed-citation xml:lang="ru">Santini D., Vincenzi B., Massacesi C., Picardi A., Gentilucci U.V., Esposito V., et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res. 2003;23(6D):5173–9.</mixed-citation><mixed-citation xml:lang="en">Santini D., Vincenzi B., Massacesi C., Picardi A., Gentilucci U.V., Esposito V., et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res. 2003;23(6D):5173–9.</mixed-citation></citation-alternatives></ref><ref id="cit449"><label>449</label><citation-alternatives><mixed-citation xml:lang="ru">Суханов Д.С. Эффективность гепатопротекторного действия и оценка риска при использовании реамберина, ремаксола и адеметионина у больных туберкулезом органов дыхания с лекарственными поражениями печени. Терапевтический архив. 2012;84(11):26–9.</mixed-citation><mixed-citation xml:lang="en">Sukhanov D.S. Efficiency of the hepatoprotective effect and risk assessment when using reamberin, remaxol, and ademetionine in patients with respiratory tuberculosis and drug-induced liver injury. Terapevticheskii Arkhiv. 2012;84(11):26–9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit450"><label>450</label><citation-alternatives><mixed-citation xml:lang="ru">Суханов Д.С., Павлова М.В., Виноградова Т.И. Клиническая эффективность инфузионных растворов на основе янтарной кислоты в терапии поражений печени, вызванных противотуберкулезными препаратами. Туберкулез и болезни легких. 2013;90(8):050–6.</mixed-citation><mixed-citation xml:lang="en">Sukhanov D.S., Pavlova M.V., Vinogradova T.I. Clinical efficacy of infusion solutions based on succinic acid in the treatment of liver damage caused by anti-tuberculosis drugs. Tuberculosis and Lung Diseases. 2013;90(8):050–6. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit451"><label>451</label><citation-alternatives><mixed-citation xml:lang="ru">Кляритская И.Л., Максимова Е.В. Тактика ведения пациентов с онкологическими заболеваниями и лекарственными поражениями печени. Крымский терапевтический журнал. 2013;1:71–82.</mixed-citation><mixed-citation xml:lang="en">Klyaritskaya I.L., Maksimova E.V. Tactics of managing patients with oncological diseases and drug-induced liver damage. Crimean Therapeutic Journal. 2013;1:71–82. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit452"><label>452</label><citation-alternatives><mixed-citation xml:lang="ru">Скрипник І.М., Маслова А.С. Вплив S-адеметіоніну на вміст аргініну і його метаболітів у хворих на хронічну лімфоцитарну лейкемію на фоні хіміотерапії. Семейная медицина. 2020;3:20–3. DOI: 10.30841/2307-5112.3.2020.211188</mixed-citation><mixed-citation xml:lang="en">Skripnik I.M., Maslova A.S. Infusion of S-ademetionine instead of arginine and its metabolites in patients with chronic lymphocytic leukemia during chemotherapy. Family Medicine. 2020;3:20–3. (In Ukran.). DOI: 10.30841/2307-5112.3.2020.211188</mixed-citation></citation-alternatives></ref><ref id="cit453"><label>453</label><citation-alternatives><mixed-citation xml:lang="ru">Угрюмова Е.В. Адеметионин в цитостатической терапии псориаза. Вестник дерматологии и венерологии. 2010;2:52–6.</mixed-citation><mixed-citation xml:lang="en">Ugryumova E.V. Ademetionine in cytostatic therapy of psoriasis. Bulletin of Dermatology and Venereology. 2010;2:52–6. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit454"><label>454</label><citation-alternatives><mixed-citation xml:lang="ru">Hisanaga M., Utsumi S., Miyamoto S., Okazaki A., Tsukamoto S. Abnormality of liver function in patients treated with antiepileptic drug and a trial of polyene phosphatidyl choline treatment for these patients. Folia Psychiatr Neurol Jpn. 1980;34(3):318–9. DOI: 10.1111/j.1440-1819.1980.tb01551.x</mixed-citation><mixed-citation xml:lang="en">Hisanaga M., Utsumi S., Miyamoto S., Okazaki A., Tsukamoto S. Abnormality of liver function in patients treated with antiepileptic drug and a trial of polyene phosphatidyl choline treatment for these patients. Folia Psychiatr Neurol Jpn. 1980;34(3):318–9. DOI: 10.1111/j.1440-1819.1980.tb01551.x</mixed-citation></citation-alternatives></ref><ref id="cit455"><label>455</label><citation-alternatives><mixed-citation xml:lang="ru">Слюндин Д.Г., Алехнович А.В., Иванов В.Б., Ливанов А.С., Анучин В.В. Фармакологическая коррекция гипераммониемии при криминальных отравлениях клозапином. Medline. ru. 2010;11:518–25.</mixed-citation><mixed-citation xml:lang="en">Slyundin D.G., Alekhnovich A.V., Ivanov V.B., Livanov A.S., Anuchin V.V. Pharmacological correction of hyperammonemia in criminal poisonings with clozapine. Medline.ru. 2010;11:518–25. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit456"><label>456</label><citation-alternatives><mixed-citation xml:lang="ru">Остапенко Ю.Н., Иванов В.Б., Алехнович А.В., Ливанов А.С. Гипераммониемия при острых отравлениях психотропными средствами и возможность ее коррекции. Consilium Medicum. 2006;8(7):10–3.</mixed-citation><mixed-citation xml:lang="en">Ostapenko Yu.N., Ivanov V.B., Alekhnovich A.V., Livanov A.S. Hyperammonemia in acute poisoning with psychotropic drugs and the possibility of its correction. Consilium Medicum. 2006;8(7):10–3. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit457"><label>457</label><citation-alternatives><mixed-citation xml:lang="ru">Scheller A., Jacob U., Keilhauer R. Verbesserung der Zytostatikatoleranz durch Ornithinaspartat. Der Bayrische Internist. 1998;1:54–60.</mixed-citation><mixed-citation xml:lang="en">Scheller A., Jacob U., Keilhauer R. Verbesserung der Zytostatikatoleranz durch Ornithinaspartat. Der Bayrische Internist. 1998;1:54–60.</mixed-citation></citation-alternatives></ref><ref id="cit458"><label>458</label><citation-alternatives><mixed-citation xml:lang="ru">Солдатова Г.С., Поспелова Т.И., Чечерина А.А. Гипераммониемия у пациентов с лимфопролиферативными заболеваниями. Гематология и трансфузиология. 2022;67(2):300–1.</mixed-citation><mixed-citation xml:lang="en">Soldatova G.S., Pospelova T.I., Checherina A.A. Hyperammonemia in patients with lymphoproliferative diseases. Hematology and Transfusiology. 2022;67(2):300–1. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit459"><label>459</label><citation-alternatives><mixed-citation xml:lang="ru">Мацишевская И.В. Опыт использования ОРНИТОКСА (L-орнитин-L-аспартата) в практике отделения химиотерапии Винницкого областного клинического онкологического диспансера для оптимизации проведения химиотерапии. Клінічна Онкологія. 2011;4(4):1–3.</mixed-citation><mixed-citation xml:lang="en">Matsyshevskaya I.V. Experience of using ORNITOX (L-ornithine-L-aspartate) in the practice of the chemotherapy department of the Vinnytsia Regional Clinical Oncology Dispensary to optimize chemotherapy. Clinical Oncology. 2011;4(4):1–3. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit460"><label>460</label><citation-alternatives><mixed-citation xml:lang="ru">Суханов Д.С., Иванов А.К., Романцов М.Г., Коваленко А.Л. Лечение гепатотоксических осложнений противотуберкулезной терапии сукцинатсодержащими препаратами. РМЖ. 2009;6:22–5.</mixed-citation><mixed-citation xml:lang="en">Sukhanov D.S., Ivanov A.K., Romantsov M.G., Kovalenko A.L. Treatment of hepatotoxic complications of anti-tuberculosis thera-py with succinate-containing drugs. RMJ. 2009;6:22–5. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit461"><label>461</label><citation-alternatives><mixed-citation xml:lang="ru">Шевырева Е.В., Иванов А.К., Суханов Д.С., Мурзина А.А. Гепатопротекторная терапия ремаксолом у больных туберкулезом и ВИЧ-инфекцией в дневном стационаре противотуберкулезного диспансера. Антибиотики и химиотерапия. 2012;57(7–8):31–7.</mixed-citation><mixed-citation xml:lang="en">Shevyreva E.V., Ivanov A.K., Sukhanov D.S., Murzina A.A. Hepatoprotective therapy with remaxol in patients with tuberculosis and HIV infection in the day hospital of the tuberculosis dispensary. Antibiotics and chemotherapy. 2012;57(7–8): 31–7. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit462"><label>462</label><citation-alternatives><mixed-citation xml:lang="ru">Иванова М.И., Матякин Г.Г., Иванов В.М., Шейкин М.В., Коваленко А.Л., Петров А.Ю. Возможности сопроводительной терапии злокачественных новообразований орофарингеальной области. Онкология. Журнал им. П.А. Герцена. 2023;12(5):34–8. DOI: 10.17116/onkolog20231205134</mixed-citation><mixed-citation xml:lang="en">Ivanova M.I., Matyakin G.G., Ivanov V.M., Sheikin M.V., Kovalenko A.L., Petrov A.Yu. The possibilities of accompanying therapy for malignant oropharyngeal neoplasms. P.A. Herzen Journal of Oncology. 2023;12(5):34–8. (In Russ.). DOI: 10.17116/onkolog20231205134</mixed-citation></citation-alternatives></ref><ref id="cit463"><label>463</label><citation-alternatives><mixed-citation xml:lang="ru">Волчегорский И.А., Новоселов П.Н., Ушкарева Э.В. Влияние ремаксола на эффективность стандартного лечения больных инфильтративным туберкулезом легких. Терапевтический архив. 2016;88(3):73–8. DOI: 10.17116/terarkh201688373-78</mixed-citation><mixed-citation xml:lang="en">Volchegorskii I.A., Novoselov P.N., Ushkareva E.V. Effect of Remaxol on the efficiency of standard treatment for infiltrative pulmonary tuberculosis. Terapevticheskii Arkhiv. 2016;88(3):73–8. (In Russ.). DOI: 10.17116/terarkh201688373-78</mixed-citation></citation-alternatives></ref><ref id="cit464"><label>464</label><citation-alternatives><mixed-citation xml:lang="ru">Матякин Г.Г., Иванов В.М., Иванова О.В., Шейкин М.М. Токсико-модифицирующее действие ремаксола при лечении местно-распространенного рака слизистой полости рта. Стоматология. 2013;92(6):12–5.</mixed-citation><mixed-citation xml:lang="en">Matyakin G.G., Ivanov V.M., Ivanova O.V., Sheikin M.M. Toxic-modifying effect of remaxol in the treatment of locally advanced cancer of the oral mucosa. Stomatologiya. 2013;92(6):12–5. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit465"><label>465</label><citation-alternatives><mixed-citation xml:lang="ru">Шовкун Л.А., Кудлай Д.А., Кампос Е.Д., Николенко Н.Ю., Севостьянова Т.А., Франчук И.М. Терапия предупреждения и купирования гепатотоксических реакций у больных туберкулезом с лекарственной устойчивостью. Туберкулез и болезни легких. 2025;103(2):13–21. DOI: 10.58838/2075-1230-2025-103-2-13-21</mixed-citation><mixed-citation xml:lang="en">Shovkun L.A., Kudlay D.A., Kampos E.D., Nikolenko N.Yu., Sevostyanova T.A., Franchuk I.M. Therapy for prevention and relief of hepatotoxic reactions in patients with drug resistant tuberculosis. Tuberculosis and Lung Diseases. 2025;103(2):13–21. (In Russ.). DOI: 10.58838/2075-1230-2025-103-2-13-21</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
